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Abstract 
TFH cells have been identified as a new T helper subset specialized to regulate the 
development of effector and memory B cells and long-lived plasma cells. The 
interaction between TFH and B cells leads to the activation of B cells and germinal 
centers (GC) formation. Considering the importance of TFH for B cell antibody 
response, novel vaccine adjuvants and intranasal vaccines to boost TFH number or 
function may be an attractive vaccination strategy to enhance vaccine efficacy in 
humans. Adenotonsillar tissues are major parts of nasopharyngeal associated 
lymphoid tissues (NALT) and they are important in response to upper respiratory 
tract pathogens and intranasal vaccination. This PhD project investigated the 
frequencies of TFH in human NALT and PBMC in children and adults. The effects of 
CpG-DNA and live attenuated influenza vaccine (LAIV) on TFH in human NALT 
and the TFH-mediated B cell immunity to influenza virus were studied. The 
importance of the cytokine IL-21 and plasmacytoid dendritic cells (pDC) in TFH cell-
mediated B cell antibody production was also investigated. 
Adenotonsillar MNC and PBMC were isolated from adenotonsillar tissues and 
peripheral blood respectively. TFH (CD4
+
 CXCR5
high
 ICOS
high
) numbers and function 
were analysed by flowcytometry and intracellular cytokine staining. Purified TFH 
(CD4
+ 
CXCR5
hi
) and non-TFH cells (CD4
+ 
CXCR5
-
) were co-cultured with B cells in 
the presence of influenza virus antigen and CpG-DNA or of LAIV. Purified pDC 
were added to the TFH-B cell co-culture to study their importance in TFH -mediated B 
cell antibody production. Haemagglutinin (HA)-specific antibody production was 
analysed by ELISA and ELISpot assay. IL-21 receptor blocking by neutralization 
was used to study the importance of IL-21 in TFH-mediated B cell antibody 
production. 
A prominent number of TFH were found in human NALT which were considerably 
higher than in PBMC. There was an age-associated difference in TFH numbers in 
NALT and BPMC, i.e. the mean TFH number was higher in children than in adults. 
TFH in NALT were shown to express high levels of IL-4, IL-10 and IL-21 and that 
were important for B cell antibody production. A good correlation between the 
numbers of GC B cell and TFH in NALT was seen. Co-culture of purified TFH but not 
non-TFH with B cells promoted antibody production. Stimulation of adenotonsillar 
MNC by CpG-DNA significantly increased TFH number and that was correlated with 
HA-specific antibody production following influenza antigen stimulation. Co-
incubation of TFH-B cell with pDC enhanced the CpG-DNA-mediated antibody 
production. We also found that stimulation with LAIV significantly increased TFH 
number and that was correlated with HA-specific antibody production. Blocking the 
IL-21R significantly reduced the number of TFH that was correlated with a 
significant reduction of HA-specific antibody production. 
Enhancing vaccine immunogenicity through modulation of TFH numbers or function 
in human NALT using immunological adjuvants such as CpG-DNA and through 
intranasal vaccination may be an effective vaccination strategy against respiratory 
pathogens. 
 ii | P a g e  
 
 Index 
 
 
Abstract  
Dedication 
i 
iii 
Declaration  iv 
Acknowledgements  v  
Table of contents  vi-xii  
List of table  xiii 
List of figures  xiii-xv 
Abbreviations  xvi-xix  
Chapter 1: General Introduction  1-43  
Chapter 2: Materials and Methods  44-74  
Chapter 3:  Characterisation of TFH cells in human NALT and PBMC 75-103  
Chapter 4:  CpG-DNA promotes TFH cells in human NALT and PBMC 104-138  
Chapter 5:  Effect of TFH on Live Attenuated Influenza Vaccine (LAIV) 
induced antibody response in NALT 
139-170  
Chapter 6: General Discussions and Conclusions  171-184  
Chapter 7: References  185-217  
Chapter 8: Appendices  218-222  
 iii | P a g e  
 
 
Dedication 
 
 
All my thanks to Allah for helping me bring this work to a successful completion. I 
dedicate this work to my parents and family for supporting me constantly by their 
unlimited care and prayers. A dedication also goes to my beloved wife (Hissah) for 
her patience, support and inspiration through the good and bad times in the past 
four years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv | P a g e  
 
 
Declaration  
No part of the work referred to in this thesis has been submitted in support of an 
application for another degree or qualification at this or any other university, or other 
institution of learning. All laboratory experiments described here have been carried 
out by the author, in the Department of Clinical Infection, Microbiology and 
Immunology, Institute of Infection and Global Health, University of Liverpool. 
 
Abdullah Nasser Aljurayyan 
December 2014
 v | P a g e  
 
Acknowledgements  
I would like to sincerely thank my supervisor Dr Qibo Zhang for giving me the opportunity 
to work in his group and guiding me throughout the course of my study. His constant 
motivation and mentoring invaluably contributed to my graduate experience. I would also 
like to thank my second supervisor Professor Stephen Gordon, for all his help and 
encouragement throughout this project.  
I must thank all past and current members of our research group; Dr Shamsher Ahmed, Dr 
Waleed Mahallawi, Dr Jennifer Mullin, Dr Christian Gray, Ayman Mubarak and Aimee 
Rider for their patience, assistance and support. Thanks also to the other PhD researchers in 
the Immunology group; Dr Suliman Alomar, Dr Ali Alejenef, Wael Alturaiki, Mazen 
Almehmadi and Mustafa Halawi for their friendship and encouragements.  
I am also indebted to Dr Steve Christmas who has been invaluable on both an academic and 
a personal level, for which I am extremely grateful. I would like to express my gratitude to 
Ms Caroline Broughton and Dr Debbie Howarth for providing me the technical support in 
the laboratory. I am also grateful to Ms Helen Nelson for her general advice, support and 
encouragement. I must acknowledge to all other academics, members of the staff and 
researchers in the Department of Clinical Infection, Microbiology and Immunology, in 
Institute of Infection and Global Health, University of Liverpool for being so nice and 
supportive during my course of studies.  
I would like to thank all of the participating patients and all ENT surgeons who provided the 
samples for this study; Dr S Derbyshire, Dr A Kasbekar, Dr S Leong, Dr C Loh and Dr R 
Sharma of Alder Hey Children’s Hospital; and Dr M McCormick and Dr H Beer of Royal 
Liverpool and Broadgreen University Hospitals. Thanks to my sponsorship, King Fahad 
Medical City, Ministry of health, Saudi Arabia, for the financial support to complete this 
project.  
All my successes would not have been possible without the prayers of my parents. May 
Allah bless them and I ask Allah for them the paradise. I am grateful to my brothers and 
sister for supporting and encouraging me all my life. Unlimited thanks go to my lovely wife 
(Hissah) and son who were my source of enthusiasm.  
 
Abdullah Nasser Aljurayyan 
December 2014 
 vi | P a g e  
 
Table of Contents 
 
Chapter 1: General Introduction .............................................................................. 1 
1. Introduction .................................................................................................... 2 
1.1 Vaccines ......................................................................................................... 2 
1.1.1 Live attenuated vaccines ................................................................................ 3 
1.1.2 Killed or inactivated whole cell vaccines ...................................................... 3 
1.1.3 Subunit vaccines ............................................................................................ 4 
1.1.4 DNA vaccines ................................................................................................ 5 
1.2 Mucosal vaccinations ..................................................................................... 5 
1.3 Vaccine Adjuvants ......................................................................................... 6 
1.3.1 Toll like receptor (TLR) agonists as adjuvants ............................................. 7 
1.3.2 Mucosal adjuvants ......................................................................................... 7 
1.4 The Immune System ...................................................................................... 8 
1.5 The Mucosal Immune System in the Upper Respiratory Tract ..................... 9 
1.5.1 Nasopharyngeal Associated Lymphoid Tissues (NALT) ............................ 10 
1.6 CD4
+
 T cell subsets ..................................................................................... 11 
1.6.1 T helper 1 cells (TH1) ................................................................................... 12 
1.6.2 T helper 2 cells (TH2) ................................................................................... 13 
1.6.3 T helper 17 cells (TH17) ............................................................................... 13 
1.6.4 T regulatory cells (Treg) ................................................................................ 14 
1.7 T Follicular Helper cells (TFH cells) ............................................................ 14 
1.7.1 TFH cell characterization .............................................................................. 15 
1.7.2 TFH Cell Differentiation ............................................................................... 16 
1.7.3 Cell markers of TFH cells ............................................................................. 16 
1.7.3.1 CXCR5 and CCR7 ....................................................................................... 17 
1.7.3.2 Inducible co-stimulator molecule (ICOS) .................................................... 18 
1.7.3.3 Programmed cell death 1 (PD-1) ................................................................. 20 
 vii | P a g e  
 
1.7.4 BCL-6 as a Regulator of TFH Differentiation .............................................. 21 
1.7.5 Cytokine profile for TFH cells ...................................................................... 22 
1.7.5.1 IL-21 ............................................................................................................ 23 
1.7.5.2 IL-10 ............................................................................................................ 23 
1.7.5.3 IL-4 .............................................................................................................. 24 
1.7.6 Peripheral TFH cells (pTFH) .......................................................................... 25 
1.8 Germinal Centre B cells .............................................................................. 26 
1.9 TFH cell – B cell Interactions in the GC....................................................... 27 
1.10 The Germinal Centre Response ................................................................... 29 
1.11 Dendritic Cells ............................................................................................. 31 
1.11.1 Plasmacytoid DC (pDC) .............................................................................. 32 
1.12 Pattern Recognition Receptors (PRRs) ....................................................... 33 
1.12.1 The role of Toll-like receptors (TLRs) ........................................................ 34 
1.13 CpG-DNA a TLR-9 Ligand ........................................................................ 35 
1.13.1 CpG-DNA classes ........................................................................................ 36 
1.13.2 CpG-DNA clinical applications ................................................................... 37 
1.14 The Upper Respiratory Tract Infections ...................................................... 38 
1.14.1 Influenza virus ............................................................................................. 39 
1.15 Influenza vaccine types ............................................................................... 41 
1.15.1 Trivalent Inactivated Influenza Vaccine (TIV; intramuscular) ................... 41 
1.15.2 Live Attenuated Influenza Vaccine (LAIV; intranasal) ............................... 41 
1.16 Aims of the Thesis ....................................................................................... 43 
Chapter 2: Materials and Methods ......................................................................... 44 
2.1 Subjects and Samples ................................................................................... 45 
2.1.1 Subjects ....................................................................................................... 45 
2.1.2 Patient Samples ........................................................................................... 45 
2.1.2.1 Adenotonsillar Tissues ................................................................................. 45 
2.1.2.2 Peripheral Blood .......................................................................................... 45 
 viii | P a g e  
 
2.2 Mononuclear Cell Isolation.......................................................................... 46 
2.2.1 Adenotonsillar Mononuclear Cells (MNC) ................................................. 46 
2.2.2 Peripheral Blood Mononuclear Cells (PBMC)............................................ 46 
2.3 Influenza virus antigens and proteins .......................................................... 47 
2.3.1 Seasonal H1N1 (sH1N1) virus antigen ....................................................... 47 
2.3.2 Intranasal Live Attenuated Influenza Vaccine (LAIV) ............................... 47 
2.3.3 Recombinant HA ......................................................................................... 48 
2.3.4 CpG-DNA ................................................................................................... 48 
2.4 Cell culture and stimulation by LAIV, influenza virus antigen and CpG-
DNA for antibody and IL-21 production ................................................................... 49 
2.5 Enzyme-Linked Immunosorbent Assay (ELISA) ........................................ 49 
2.5.1 Measurement of HA specific antibodies from cell culture supernatants ..... 49 
2.5.1.1 Measurement of HA-specific IgG antibody ................................................. 50 
2.5.1.2 Measurement of HA-specific IgM antibody ................................................ 51 
2.5.1.3 Measurement of HA-specific IgA antibody ................................................. 51 
2.5.2 Time-course of HA-specific antibody production ....................................... 51 
2.6 Enzyme Linked Immuno Spot Assay (ELISpot) ......................................... 53 
2.6.1 Principle of the test ...................................................................................... 53 
2.6.2 Culture of adenotonsillar MNC ................................................................... 53 
2.6.3 Antigen coating of ELISpot plate ................................................................ 54 
2.6.4 Incubation of cells in the ELISpot plate ...................................................... 54 
2.6.5 ELISpot assay procedure ............................................................................. 54 
2.6.6 Counting of ELISpots .................................................................................. 55 
2.7 Measurement of IL-21 in cell culture supernatants ..................................... 55 
2.8 Flow Cytometric Analysis of Cells .............................................................. 57 
2.8.1 Principle of the test ...................................................................................... 57 
2.8.2 Cell culture and stimulation by influenza virus antigen, LAIV and CpG-
DNA for FACS analysis ............................................................................................ 58 
 ix | P a g e  
 
2.8.3 Cell staining for surface phenotyping for FACS analysis ........................... 59 
2.9 T cell Proliferation Assay ............................................................................ 61 
2.9.1 Labelling of adenotonsillar MNC with CFSE ............................................. 61 
2.9.2 Staining of the CFSE labelled cells for FACS analysis .............................. 62 
2.10 Intracellular staining for BCL-6, TLR-9 and cytokines............................... 62 
2.10.1 Cell stimulation ........................................................................................... 62 
2.10.2 Intracellular cytokine and BCL-6 staining .................................................. 63 
2.10.3 Intracellular TLR-9 staining ........................................................................ 63 
2.11 Anti-IL-21R blocking experiments .............................................................. 64 
2.12 CD45RO
+
 cell-depleted adenotonsillar MNC ............................................. 65 
2.12.1 Principle of the MACS separation ............................................................... 65 
2.12.2 Magnetic labelling and depletion ................................................................ 65 
2.13 Cell sorting for co‐culture experiments ....................................................... 66 
2.13.1 Isolation of B cells from adenotonsillar MNC ............................................ 66 
2.13.2 Isolation of CD4
+ 
T cells from adenotonsillar MNC ................................... 68 
2.13.3 Isolation of TFH cells (CD4
+ 
CXCR5
hi
)
 
from adenotonsillar MNC ............. 69 
2.13.4 Isolation of Plasmacytoid DC cells (pDC) from adenotonsillar MNC ....... 71 
2.14 B cell help by TFH cells ................................................................................ 73 
2.15 Assessment of effect of pDC ....................................................................... 73 
2.16 Health and safety.......................................................................................... 74 
2.17 Statistical analysis ........................................................................................ 74 
Chapter 3: Characterisation of TFH cells in human NALT and PBMC .............. 75 
3.1 Introduction .................................................................................................. 76 
3.2 Aims of Study .............................................................................................. 78 
3.3 Experimental Design .................................................................................... 79 
3.4 Results .......................................................................................................... 82 
3.4.1 Identification of TFH Cells in Adenotonsillar MNC .................................... 82 
3.4.2 Expression of IL-21 by TFH Cells ................................................................ 85 
 x | P a g e  
 
3.4.3 Expression of IL-10 by TFH Cells ................................................................ 86 
3.4.4 Expression of IL-4 by TFH Cells .................................................................. 87 
3.4.5 Percentage of TFH Cells in Adenotonsillar Tissues in Children and Adults 88 
3.4.6 Number of GC B Cells in Children and Adults ........................................... 91 
3.4.7 Correlation between percentage of TFH Cells and GC B Cells.................... 92 
3.4.8 Identification of Peripheral TFH Cells (pTFH) in PBMC .............................. 93 
3.4.9 Percentage of pTFH Cells in Children and Adults........................................ 94 
3.5 Discussion .................................................................................................... 97 
Chapter 4: CpG-DNA promotes TFH cells in human NALT and PBMC .......... 104 
4.1 Introduction ................................................................................................ 105 
4.2 Aims of Study ............................................................................................ 107 
4.3 Experimental Design .................................................................................. 108 
4.4 Results ........................................................................................................ 115 
4.4.1 CpG-DNA Promotes TFH Cells in Adenotonsillar Cells ........................... 115 
4.4.2 Effect of CpG-DNA on IL-21 Production in Relation to TFH in NALT ... 117 
4.4.3 Effect of CpG-DNA as an Adjuvant on B cell Antibody Production in 
Relation to TFH Cells ................................................................................................ 118 
4.4.4 Effect of CpG-DNA and Influenza Antigen on TFH Cell Proliferation in 
Adenotonsillar MNC ................................................................................................ 124 
4.4.5 Effect of Plasmacytoid DC on TFH-mediated Help for B cell Antibody 
Production ................................................................................................................ 125 
4.4.6 Detection of Antibody Secreting Cells (ASC) Following Stimulation by 
CpG-DNA and Influenza Virus Antigen in Adenotonsillar cells ............................ 126 
4.4.7 IL-21 is Important in TFH cell-mediated B cell Antibody Production in 
Adenotonsillar cells .................................................................................................. 127 
4.4.8 TLR-9 Expression on Purified TFH cells, non-TFH cells, B cells and pDC 128 
4.4.9 Effect of CpG-DNA on pTFH cells in PBMC ............................................ 129 
4.4.10 Induction of IL-21 in PBMC with Influenza antigen and CpG-DNA ....... 130 
4.5 Discussion .................................................................................................. 131 
 xi | P a g e  
 
Chapter 5: Effect of TFH on Live Attenuated Influenza Vaccine (LAIV)-induced 
antibody response in NALT .................................................................................. 139 
5.1 Introduction ................................................................................................ 140 
5.2 Aims of Study ............................................................................................ 143 
5.3 Experimental Design .................................................................................. 143 
5.4 Results ........................................................................................................ 150 
5.4.1 Optimisation of LAIV concentration for TFH cell stimulation in 
adenotonsillar MNC ................................................................................................. 150 
5.4.2 LAIV can promote TFH cells in adenotonsillar cells ................................. 151 
5.4.3 Induction of CD4
+
 BCL-6
+
 cells in adenotonsillar cells by LAIV ............ 153 
5.4.4 Effect of LAIV on TFH cell proliferation in adenotonsillar MNC ............. 154 
5.4.5 Induction of anti-sH1N1 HA antibodies in adenotonsillar cells by LAIV 155 
5.4.6 Detection of ASC following stimulation by LAIV in adenotonsillar cells158 
5.4.7 Effect of LAIV on Human adenotonsillar GC B cells .............................. 159 
5.4.8 Induction of CD4
+
 IL-21
+
 cells in adenotonsillar cells by LAIV .............. 160 
5.4.9 IL-21 is important in TFH cell-mediated B cell antibody production in 
adenotonsillar cells ................................................................................................... 162 
5.4.10 LAIV promotes pTFH, anti-sH1N1-HA antibodies and IL-21 in PBMC .. 163 
5.5 Discussion .................................................................................................. 166 
Chapter 6: General Discussion and Conclusion .................................................. 171 
6.1 Discussion .................................................................................................. 172 
6.1.1 Characterisation of TFH cells in human NALT .......................................... 172 
6.1.2 CpG-DNA promotes TFH cells in human NALT ....................................... 173 
6.1.3 LAIV promotes TFH cells in human NALT ............................................... 174 
6.1.4 Effect of CpG-DNA and LAIV on TFH proliferation in human NALT..... 175 
6.1.5 GC B cells strongly correlate with TFH cells ............................................. 176 
6.1.6 Effect of CpG-DNA and LAIV on B cell antibody production in relation to 
TFH cells ...................................................................................................................176 
6.1.7 Effect of pDC on TFH-mediated help for B cell antibody production ....... 177 
 xii | P a g e  
 
6.1.8 TLR-9 expression in TFH, non-TFH, B cells and pDC ................................ 178 
6.1.9 IL-21 is important in TFH-mediated B cell antibody production in NALT179 
6.1.10 pTFH found in PBMC ................................................................................. 180 
6.2 Conclusion ................................................................................................. 182 
6.3 Future directions ........................................................................................ 183 
Chapter 7: References ............................................................................................ 185 
Chapter 8: Appendices ........................................................................................... 218 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii | P a g e  
 
List of Table 
Table 2.1. Antibodies used for flow cytometry.......................................................... 60 
 
List of Figures 
Figure 1.1. The Waldeyer’s ring ................................................................................ 11 
Figure 1.2. CD4
+
 T helper subsets ............................................................................. 12 
Figure 1.3. BCL-6 inhibition of other CD4 T cell differentiation pathways ............. 22 
Figure 1.4. Important interactions between TFH and B cells in the GC ..................... 28 
Figure 2.1. Time course of HA-specific sH1N1 IgG, IgM and IgA production ........ 52 
Figure 2.2. Flow cytometric purity analysis of isolated B cells ................................. 67 
Figure 2.3. Flow cytometric purity analysis of isolated adenotonsillar CD4
+
 T cells68 
Figure 2.4. Flow cytometric purity analysis of isolated TFH cells and non-TFH cells 70 
Figure 2.5. Flow cytometric purity analysis of isolated adenotonsillar pDC............. 72 
Figure 3.1. Representative sample analysis showing gating strategy for identification 
of TFH cells (CD4
+
 CXCR5
hi
 ICOS
hi
) in adenotonsillar MNC ........................... 82 
Figure 3.2. TFH cells express high amounts of CXCR5, ICOS, PD-1 and BCL-6 in 
adenotonsillar tissues .......................................................................................... 83 
Figure 3.3. Correlation between levels of expression (MFI) of CXCR5 and ICOS, 
PD-1 and BCL-6 in CD4
+
 T cells ....................................................................... 84 
Figure 3.4. Expression of IL-21 in adenotonsillar TFH cells ...................................... 85 
Figure 3.5. Expression of IL-10 in adenotonsillar TFH cells ...................................... 86 
Figure 3.6. Expression of IL-4 in adenotonsillar TFH cells ........................................ 87 
Figure 3.7. Children have higher percentage of TFH cells in adenotonsillar tissues 
than in adults ....................................................................................................... 88 
Figure 3.8. Percentage of TFH cells at different age groups in adenotonsillar tissue . 89 
Figure 3.9. Relationship between percentage of TFH cells in tonsillar tissue and age90 
Figure 3.10. Number of GC B Cells in Children and Adults ..................................... 91 
Figure 3.11. Correlation between numbers of GC B cells and TFH cells in 
adenotonsillar MNC ............................................................................................ 92 
Figure 3.12. A representative sample analysis showing gating strategy for 
identification of pTFH cells in PBMC ................................................................. 93 
Figure 3.13. Children have higher percentage of pTFH cells in PBMC than in adults
 ............................................................................................................................ 94 
 xiv | P a g e  
 
Figure 3.14. Percentage of pTFH cells at different age groups in PBMC ................... 95 
Figure 3.15. Relationship between percentage of pTFH cells in PBMC and age ....... 96 
Figure 4.1. CpG-DNA promotes TFH cells in adenotonsillar cells ........................... 115 
Figure 4.2. CpG-DNA promotes CD4
+
 CXCR5
hi
 BCL-6
+
 cells in adenotonsillar cells
 .......................................................................................................................... 116 
Figure 4.3. IL-21 concentration increases in the presence of CXCR5
hi
, but not of 
CXCR5
-
 CD4
+
 T cells following stimulation with CpG-DNA ......................... 117 
Figure 4.4. Anti-sH1N1 HA-specific antibody production in adenotonsillar MNC 
following CpG-DNA and influenza antigen stimulations ................................ 118 
Figure 4.5. HA-specific sH1N1 IgG, IgM and IgA titre are produced from B cells co-
cultured with purified TFH cells but not with non-TFH cells ............................. 119 
Figure 4.6. Effect of CpG-DNA on TFH percentage in adenotonsillar MNC in the 
presence of an influenza virus antigen .............................................................. 120 
Figure 4.7. Effect of CpG-DNA on TFH percentage in CD45RO
+
 cell depleted MNC 
in the presence of an influenza virus antigen .................................................... 121 
Figure 4.8. CpG-DNA promotes CD4
+
 CXCR5
hi
 BCL-6
+
 cells in adenotonsillar cells
 .......................................................................................................................... 122 
Figure 4.9. Correlation between HA-specific sH1N1 antibody levels and percentage 
of TFH cell in adenotonsillar MNC .................................................................... 123 
Figure 4.10. Analysis of TFH cell proliferation in the presence of an influenza virus 
antigen and CpG-DNA ..................................................................................... 124 
Figure 4.11. pDC enhances the antibody production when added to purified TFH cells 
co-cultured with purified B cells ...................................................................... 125 
Figure 4.12. ELISpot assay to enumerate antibody secreting B cell response showing 
number of HA-specific ASC ............................................................................ 126 
Figure 4.13. Blocking IL-21R leads to a significant reduction in percentage of TFH 
cells and antibody production in human adenotonsillar tissue ......................... 127 
Figure 4.14. TLR-9 expression in TFH, non-TFH, B cells and pDC .......................... 128 
Figure 4.15. CpG-DNA can promote pTFH cells in PBMC ..................................... 129 
Figure 4.16. IL-21 Levels increases after stimulation with CpG-DNA in PBMC ... 130 
Figure 5.1. Dose-response curve for TFH cell induction by stimulation with LAIV 150 
Figure 5.2. LAIV can promote TFH cells in adenotonsillar cells .............................. 151 
Figure 5.3. LAIV induced TFH cells in CD45RO
+
 depleted adenotonsillar MNC ... 152 
Figure 5.4. CD4
+
 BCL-6
+
 cells induction by LAIV ................................................. 153 
 xv | P a g e  
 
Figure 5.5. TFH cell proliferative response in adenotonsillar MNC after stimulation 
with LAIV ......................................................................................................... 154 
Figure 5.6. Optimisation of LAIV concentration for in vitro stimulation of 
adenotonsillar MNC for specific antibody response ......................................... 155 
Figure 5.7. LAIV induces HA-specific anti-sH1N1 IgG, IgM and IgA in 
adenotonsillar MNC .......................................................................................... 156 
Figure 5.8. LAIV induces HA-specific sH1N1 IgG, IgM and IgA from B cells co-
cultured with purified TFH cells but not with non-TFH cells ............................. 157 
Figure 5.9. ELISpot assay to enumerate IgG ASC to sH1N1-HA ........................... 158 
Figure 5.10. Effect of LAIV on adenotonsillar GC B cells ..................................... 159 
Figure 5.11. Induction of CD4
+
 IL-21
+
 cells in adenotonsillar cells by LAIV ........ 160 
Figure 5.12. IL-21 concentration increases in the presence of TFH cells, but not with 
non-TFH cells following stimulation with LAIV ............................................... 161 
Figure 5.13. Blocking IL-21R leads to a significant reduction in percentage of TFH 
cells and antibody production in human adenotonsillar tissue ......................... 162 
Figure 5.14. LAIV can promote pTFH cells in PBMC ............................................. 163 
Figure 5.15. LAIV induces HA-specific anti-sH1N1 IgG, IgM and IgA in PBMC 164 
Figure 5. 16. IL-21 Levels increases after stimulation with LAIV in PBMC .......... 165 
Figure 8.1. Dose-response curve for TFH cell induction by stimulation with LAIV 219 
  
 xvi | P a g e  
 
 
 
 
 
AID 
ANOVA 
Anti-HA   
 
 
          List of Abbreviations 
 
Activation-Induced Cytidine Deaminase  
Analysis of variance 
Anti-haemagglutinin 
AP  Alkaline Phosphatase  
APC  Antigen Presenting Cell  
ASC  
BALT 
BCL-6 
BCR 
BDCA 
Antibody Secreting Cell  
Bronchus-Associated Lymphoid Tissue  
B Cell Lymphoma 6  
B Cell Receptor  
Human blood dendritic cell antigen  
BSA 
BTLA 
CCL19 
CCL21 
CCR7 
Bovine Serum Albumin  
B and T lymphocyte attenuator  
Chemokine (C-C motif) ligand 19 
Chemokine (C-C motif) ligand 21 
C-C chemokine receptor type 7 
CD  Cluster of Differentiation  
CDC  Centres for Disease Control and Prevention  
CFSE  
CMV 
5-(6) Carboxyfluorescein diacetate succinimidyl ester  
Cytomegalovirus  
CO2 
CpG-DNA  
CT 
CVID 
CXCL13 
CXCR5 
Carbon dioxide  
CpG oligodeoxynucleotides 
Cholera Toxin  
Common Variable Immunodeficiency  
C-X-C motif chemokine 13 
C-X-C chemokine receptor type 5  
DC  Dendritic Cell  
DNA  Deoxyribonucleic acid  
EDTA  Ethylene Diamine Tetra Acetate  
ELISA  Enzyme linked immunosorbent assay  
 xvii | P a g e  
 
ELISpot  Enzyme linked immunosorbent spot  
FACS  Fluorescence activated cell sorting  
FBS 
FDC 
Foxp3 
Foetal Bovine Serum 
Follicular dendritic cell 
Forkhead box P3  
FITC  Fluorescein isothiocyanate  
FSC  Forward scatter  
g  
GALT 
GATA-3 
Centrifugal force  
Gut Associated Lymphoid Tissues  
Trans-acting T-cell-specific transcription factor  
GC  Germinal Centre  
HA 
HAI 
Haemagglutinin protein 
Haemagglutination Inhibition  
H2O2  Hydrogen peroxide  
H2SO4  Sulphuric acid  
HRP  
IFA 
IFN-α 
Horseradish peroxidase  
incomplete Freund’s adjuvant 
Interferon alpha 
IFN-γ  Interferon gamma  
IgA  
IgD 
IgE 
Immunoglobulin A  
Immunoglobulin D 
Immunoglobulin E 
IgG  
IgM 
Immunoglobulin G  
Immunoglobulin M 
IL  
IL-21R 
ILT7  
KLH 
Interleukin  
Interleukin-21 Receptor 
Immunoglobulin like transcript 7 
Keyhole Limpet Hemocyanin  
l  
LAIV 
LN 
Litre  
Live Attenuated Influenza Vaccine 
Lymph Node 
LPS  Lipopolysaccharide  
M  Molar  
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Secretory Immunoglobulin A  
seasonal H1N1 influenza 
SSC  
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T-box transcription factor  
TCR  
TFH  
T-cell receptor  
T Follicular helper cells 
TH  T helper  
TH1  T helper 1 cell  
TH17  T helper 17 cell  
TH2  
TIV 
T helper 2 cell  
Intramuscular Trivalent Inactivated Influenza Vaccine 
TLR  Toll like receptor  
TNF-α  
Treg 
Tumour necrosis factor alpha  
T regulatory cells  
U  
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Upper Respiratory Tract  
Upper Respiratory Tract Infection  
WHO  
α-IL-21R 
World Health Organization 
Human anti-IL-21R Fc blocking antibody  
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1. Introduction 
It is known that T cell help to B cells is an essential process for T cell-dependent 
antibody responses. Recently, a new T helper subset has been identified, named as T 
follicular helper cells (TFH). Within secondary lymphoid organs, TFH cells are 
specialized to regulate the development of effector and memory B cells and long-
lived plasma cells. The interaction between TFH cells and B cells leads to the 
development of B cells and germinal centre (GC) formation. Considering the 
importance of TFH cells for B cell antibody response, novel vaccine adjuvants and 
intranasal vaccines to boost TFH number or function may be an attractive vaccination 
strategy to enhance vaccine efficacy in young children. 
1.1 Vaccines 
After Edward Jenner’s discovery of the smallpox vaccine in 1798, a great interest in 
vaccine development has occurred in vaccinology. Vaccines are one of the most 
successful and cost-effective public health and medical achievements. Worldwide, it 
is estimated that over 3 million lives are saved each year because of successful 
vaccination programs (Shaw & Feinberg 2008). The global eradication of smallpox 
is a great example of how vaccinations are very effective. Similarly, efforts to 
eliminate other diseases including poliomyelitis, measles and others have made 
tremendous progress due to vaccination programs (Mak & Saunders 2006). Progress 
in the development of new vaccines significantly increased in the past 10 years by 
developing new vaccines against emerging diseases as well improving existing 
vaccines for better efficiency. Still, the need for new and improved vaccines is 
constantly present. 
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The major types of vaccines presently licensed and under development include: (i) 
live attenuated vaccines, (ii) killed or inactivated whole cell vaccines, (iii) subunit 
vaccines consisting of purified components of an organism, and (iv) DNA and vector 
vaccines (Mak & Saunders 2006). 
 
1.1.1 Live attenuated vaccines 
The main concept of live attenuated vaccines is to mimic the natural infection for an 
effective host immune response. A live attenuated vaccine includes live, whole viral 
particles or bacterial cells that are handled in a way that they lost their virulence 
within the host but maintain their ability to initiate an immune response (He et al. 
2006). This type of vaccine has been used to develop vaccines against number of 
viral and bacterial infections including measles, mumps, rubella, varicella-zoster, 
yellow fever, polio, influenza and tuberculosis vaccine (Shaw & Feinberg 2008). 
This type of vaccine has proven to be highly effective and protection is often long 
lasting. Live attenuated vaccines can induce CD4
+
 and CD8
+
 T cell responses, as 
well as specific neutralizing antibodies and memory B cell responses. However, 
there is always a risk that the attenuated pathogen gains its virulence, as has been 
reported with the oral polio vaccine (Plotkin 2008). 
 
1.1.2 Killed or inactivated whole cell vaccines 
In a killed vaccine, a whole organism is involved but remains harmless due to assault 
by physical or chemical methods to kill it or otherwise inactivate the pathogenic 
organism. In most cases, the organism is treated with chemical agents such as β-
propiolactone and formaldehyde to eliminate the pathogen infectivity. This only 
works with organisms that do not contain toxic substances. Killed bacterial vaccines 
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including, Yersinia pestis (plague) and Vibrio. cholerae (cholera) and killed viral 
vaccines for polio, rabies and influenza are successfully in use (Girard et al. 2005). 
Killed or inactivated vaccines have been shown to generate memory B cells and 
pathogen-neutralizing antibodies, likely in concert with memory CD4
+
 T cell; 
however, they do not typically induce CD8
+
 T cell responses (Plotkin 2008). In 
addition, killed vaccines are generally less immunogenic than live attenuated 
vaccines, thus, they are commonly administered with an adjuvant (Mak & Saunders 
2006; Shaw & Feinberg 2008).  
 
1.1.3 Subunit vaccines 
Using a purified subunit antigen from a pathogen in designing a vaccine is a method 
to avoid unwanted side effects and problems of reversion associated with using 
whole bacterial cells or viral particles. The principle is to use a component that is 
able to induce an immune response that protect against the whole pathogen. A lot of 
interest in vaccine design is now using purified subunit antigens, including, toxoids, 
recombinant proteins, and purified lipopolysaccharides (LPS) (Shaw & Feinberg 
2008). Examples of subunit vaccines are the acellular pertussis vaccine, toxoid 
vaccines against diphtheria and tetanus, carbohydrate vaccine against pneumococcus 
(Takahashi et al. 2009). These subunit antigens benefit from being safe and specific, 
but they usually have a low immunogenicity. Consequently, most subunit vaccines 
contain immune enhancing agents such as adjuvants and may also require specific 
delivery systems (McKee et al. 2010). 
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1.1.4 DNA vaccines 
The recombinant DNA technologies provided great advances in vaccine 
development. No antigens are found in vaccines based on DNA, instead they provide 
the genetic material for antigen production by the host cell. These types of vaccines 
mimic a viral infection by inducing antigen presenting cells (APC) to ensure optimal 
MHC class I presentation and CD8
+
 T cells response. DNA vaccines has also been 
reported to induce antibody response against expressed antigens (Donnelly, Wahren 
& Liu 2005). In order to improve delivery to target cells and recruitment of APC, 
these types of vaccines have been mixed with different components such as, lipid 
complexes, microparticulates and adjuvants (Ferraro et al. 2011).   
 
1.2 Mucosal vaccinations 
The first interaction between pathogens and the human host commonly occurs within 
the mucosal surfaces, specifically, the nasal, oropharyngeal, respiratory, 
gastrointestinal and genitourinary mucosa. In the past few years, major developments 
in the production of mucosal vaccines have occurred. Examples for licensed mucosal 
vaccines includes, the intranasal influenza vaccine (FluMist) (Belshe 2004), the 
Cholera vaccine (Dukoral) (Jelinek & Kollaritsch 2008), Rotavirus vaccine 
(RotaTeq) (Plosker 2010) and the oral Polio vaccine (OPV) (WHO 2014). Mucosal 
vaccines offer a number of potential advantages over systemic vaccines including, 1) 
promoting both mucosal and systemic immunity, 2) increased stability, 3) increased 
shelf life, and 4) no need for needles or trained healthcare specialists to administer 
vaccines. A major limiting factor for the development of mucosal vaccines is the 
availability of a safe and an effective adjuvant that functions in the mucosa (Freytag 
& Clements 2005). Mucosal immunizations are characterized by inducing antigen 
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specific secretory IgA (S-IgA) antibodies directed against specific pathogens of 
mucosal surfaces. These S-IgA may block the attachment of pathogens by 
neutralizing their toxins, and they also inactivate invading viruses inside epithelial 
cells (Eriksson & Holmgren 2002). The immune responses induced by mucosal 
immunization are initiated in specific mucosal-associated lymphoid tissue (MALT) 
structures such as the tonsils and adenoids in the nasal cavity in response to 
intranasal vaccination (Lycke 2012).  
1.3 Vaccine Adjuvants 
The word ‘adjuvant’ (derived from the Latin adjuvare, to help) refers to any element 
added to a vaccine formula that improves both the quality and durability of the 
immunological response to an antigen (Shaw & Feinberg 2008). Until recently, the 
exact mechanisms of how these adjuvants improve immune responses were 
unknown. Recent advances in understanding the mechanisms of how dendritic cells 
(DC) recognizes foreign antigens, have led to massive improvements in adjuvant 
discovery and optimization. These advances in understanding adjuvants mechanisms 
helped to shape a better quantity, quality, and durability of host cellular and humoral 
immune responses. A better quality, and durability response is meant by a more 
specific antibody response that lasts for a longer period.  Several substances have 
been identified as potent adjuvants including, Alum, Oil-in-water emulsions (like 
MF59) (Ott, Barchfeld & Van Nest 1995) and TLR agonists (Weeratna et al. 2005). 
Alum is the most commonly used adjuvant in vaccine formulations worldwide 
(Clements & Griffiths 2002; Kool, Fierens & Lambrecht 2012). 
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1.3.1 Toll like receptor (TLR) agonists as adjuvants 
TLR ligands/agonists activate innate immune response through TLR and have been 
studied as immunological adjuvants. Currently, many efforts for developing novel 
adjuvants are focused on the activation of TLRs that are expressed on innate immune 
cells and they are crucial for the initiation of innate and adaptive immune responses. 
A number of ligands for TLR have been identified including, double-stranded RNA 
(recognized by TLR-3), lipopolysaccharide (LPS) from bacterial cell walls 
(recognized by TLR-4), flagellin (recognized by TLR-5), single-stranded RNA 
(recognized by TLR-7) and CpG-DNA (recognized by TLR-9). Of the defined TLR 
agonists being explored as vaccine adjuvants, CpG-DNA, which activate TLR-9, are 
being evaluated in clinical studies (Halperin et al. 2003; Klinman 2006; McCluskie 
& Davis 1999). 
 
1.3.2 Mucosal adjuvants 
The adjuvant to be selected for a mucosal vaccine is perhaps as important as the 
selection of the vaccine antigen. The initiation of an immune response following a 
mucosal immunization usually relies on the co-administration of an adjuvant which 
induces and supports the transition from innate to adaptive immunity. The most 
studied mucosal adjuvants include, the ADP-ribosylating enterotoxins, cholera toxin 
(CT) and E. coli heat-labile enterotoxin (LT) (Freytag & Clements 2005; Lycke 
2012).  However, unwanted side effects of these mucosal adjuvants have been 
reported (Fujihashi et al. 2002; Mutsch et al. 2004). Among all adjuvants, TLR 
agonists constitute a major category of candidate mucosal adjuvants. For example, 
CpG-DNA, a TLR-9 ligand, have been tested in experimental vaccine studies and in 
clinical trials (Blaas et al. 2009; McCluskie & Davis 1999). Other TLR ligands 
 8 | P a g e  
 
including monophosphoryl lipid A (MPL) (Childers et al. 2000) and flagellin (Bates 
et al. 2008) (TLR-4 and 5 ligands respectively) have also been tested as mucosal 
adjuvants. CpG-DNA as an immunological adjuvant will be discussed in further 
detail later in this chapter. 
 
1.4  The Immune System 
Every day, people are challenged by millions of pathogenic agents such as 
microorganisms that try to invade our bodies. The main function of our immune 
system is to eliminate and protect us from these invading pathogens including 
influenza virus. Importantly, the distinction between self and non-self is an essential 
component of immune activation (Chi & Flavell 2008). Cells specialised in immuno-
surveillance monitor the body for pathogens, and transport fragments of any foreign 
material they encounter back to lymphoid organs. This function needs highly 
complex mechanisms which can be done by both the innate immune system (non-
specific) and the adaptive immune system (specific).  
 
Innate immunity represents the first line of our immunological defence against 
invading pathogens including influenza virus through its ability to distinguish 
between what is non-self and self.
 
This function by the innate immune system 
requires special tools such as phagocytes, complements and pattern recognition 
receptors (PRRs) that have the ability to recognize conserved pathogen associated 
molecular patterns (PAMPs) which are able to distinguish self/non-self cells 
(Khalturin & Bosch 2007; Tosi 2005).  
 
Unlike innate responses, adaptive immunity are slower to respond and require the 
recognition of a specific antigen. The adaptive immunity requires the involvement of 
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T and B lymphocytes and is characterized by immunological memory and antibody 
responses. Pathogens taken up by APC including DC are fragmented then presented 
as antigens on MHC molecules. Priming of naïve T cells takes place in the T cell 
zone of lymphoid organs, in close proximity to the B cell follicles. Activated CD8
+
 
and some CD4
+
 T cells exit the lymphoid organs into the peripheral blood. Activated 
CD4
+
 T cells that remain in the lymph node (LN) may become TFH cells that migrate 
towards the B cell follicle, where they help B cells in forming GC (Victora & 
Nussenzweig 2012).  
 
1.5 The Mucosal Immune System in the Upper Respiratory Tract  
Most viral and bacterial infections gain entry via mucosal surfaces (respiratory tract, 
gastrointestinal tract and genital epithelium). The mucosal immune system, known 
as mucosa-associated lymphoid tissue (MALT), is composed of lymphoid tissues 
inhabiting the internal lining of our bodies. This mucosal immune system includes: 
the upper respiratory tract immune system named as nasopharyngeal-associated 
lymphoid tissues (NALTs), the lower respiratory tract immune system known as the 
bronchus-associated lymphoid tissue (BALT) and the gastrointestinal immune 
system named as gut-associated lymphoid tissues (GALTs) (van Kempen, Rijkers & 
Van Cauwenberge 2000).  
The mucosal respiratory tract (epithelial-cell surfaces) has a large interface with the 
external environment ranging from the oral and nasal cavities to the alveoli in the 
lungs, with an estimated surface area of 70 m
2
 in human adults (Holt et al. 2008). 
The upper respiratory tract mucosal immunity is a vital component of the body 
functioning as a first line of physical and immunological defence against invading 
pathogens such as bacteria, viruses, fungi, etc., dietary proteins and other 
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environmental molecules. This immune system has a highly complicated function of 
distinguishing harmful (invading pathogens) from non-harmful (commensal 
microorganisms) using its unique innate and acquired immune mechanisms (Nochi 
& Kiyono 2006).    
The Waldeyer’s ring of lymphoid tissues in the oropharynx including tonsils and 
adenoids that form NALT, and Peyer’s patches, one of the well-characterized GALT 
elements, are two of the main components of MALT.  These tissues (NALT and 
GALT) have been shown to be important inductive sites for the generation of 
antigen-specific immune responses including IgA isotype switching, generation of 
IgA
+
 memory B cells and the induction of Ag-specific cytotoxic T lymphocytes 
(CTL), in diffuse mucosal effector sites (such as the lamina propria of the intestinal 
and respiratory tracts, and glandular tissues) (Fujihashi & Kiyono 2009; Kiyono & 
Fukuyama 2004).  
In general, the MALT can be functionally classified in two main types of tissues:  
i. Inductive sites: where naive B and T cells are activated and clonally selected 
and expanded upon antigens contact. 
ii. Effector sites: where activated B and T cells relocate after antigen priming in 
inductive sites to express their effector functions (Zuercher et al. 2002). 
 
1.5.1 Nasopharyngeal Associated Lymphoid Tissues (NALT) 
NALT is a major front line of immune defence against inhaled pathogens. The 
Waldeyer’s ring is considered as the inductive site of NALT to generate antigen 
specific immune responses. The Waldeyer’s ring anatomically is especially arranged 
around the wall of the throat and consists of the palatine tonsil, adenoid 
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(nasopharyngeal tonsil) and lingual tonsils as major parts of the Waldeyer’s ring.  
The lateral pharyngeal bands and tubal tonsils are less prominent components of the 
Waldeyer’s ring (Hellings, Jorissen & Ceuppens 2000; van Kempen, Rijkers & Van 
Cauwenberge 2000) (Figure 1.1). Reticular crypt epithelium, the extrafollicular area, 
the mantle zones of lymphoid follicles and the follicular GC are all special lymphoid 
elements that have major roles in the immune responses in NALTs, particularly in 
tonsils and adenoids (Brandtzaeg 2003).  
 
Figure 1.1. The Waldeyer’s ring 
The Waldeyer’s ring is formed by the adenoid, tubal tonsils, palatine tonsils and lingual 
tonsil. Adapted from (Perry & Whyte 1998).  
 
1.6 CD4+ T cell subsets 
Upon activation by APC, naïve CD4
+
 T cells (TH0) can develop into one of many 
functionally distinct effector CD4
+
 T subsets. Some of the major types of CD4
+
 T 
cell subsets include T helper 1 (TH1), T helper 2 (TH2), T helper 17 (TH17), T 
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regulatory (Treg) cells, and the more recently discovered T follicular helper cells 
(TFH) (Figure 1.2). CD4
+
 T cell subsets are classified based on cytokines produced, 
transcription factors and cell surface markers expressed. The differentiation of a 
naïve T cell into a specific subset depends on the type of cytokines found in the 
microenvironment at the time of T cell activation (Chaplin 2010; Zhu, Yamane & 
Paul 2010).  
 
Figure 1.2. CD4
+
 T helper subsets 
CD4
+
 T cells can differentiate into different subsets depending on the cytokine milieu 
present during T cell activation. Adapted from (Crotty 2011) 
 
1.6.1 T helper 1 cells (TH1) 
TH1 are characterized by the expression of T-box transcription factor (T-bet) and 
production of pro-inflammatory cytokines, particularly, interferon gamma (IFN-γ), 
tumor necrosis factor alpha (TNF-α) and IL-2 (Szabo et al. 2000). IL-12 and IFN-γ 
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induce the TH1 differentiation by up regulating the expression of STAT-1 and 
STAT-4 leading to the expression of T-bet (Anne & Arai 2000). TH1 functions 
during intracellular bacterial and viral infections and their cytokines are important 
for macrophage activation by enhancing the phagocyte-mediated defence (Chaplin 
2010; Li, Zhang & Sun 2011).  
 
1.6.2 T helper 2 cells (TH2) 
TH2 are regulated by the Trans-acting T-cell-specific transcription factor (GATA-3) 
and secrete a range of cytokines, predominantly, IL-4, IL-5 and IL-13. IL-4 induces 
the TH2 cell differentiation by up regulating the expression of the transcription factor 
STAT-6 leading to the expression of GATA-3 (Anne & Arai 2000; Li, Zhang & Sun 
2011). TH2 cells are important in the protection against helminth and parasite 
infections (Pearce et al. 2004) and allergens (Maezawa et al. 2003). In allergy, a 
dysfunctional TH2 regulation results in an IgE and eosinophil/mast cell mediated 
immune responses and a release of histamine in the affected tissue (Licona-Limon et 
al. 2013).  
 
TH2 cells have long been viewed as the main T helper subset supporting B cells for 
antibody production. Recently, a new T helper subset named as TFH cells have been  
identified as a subset distinct from TH1 or TH2 cells (Chtanova et al. 2004). TFH cells 
are discussed in further detail later in this chapter. 
 
1.6.3 T helper 17 cells (TH17) 
A third T helper cell termed TH17 cells are characterised by secreting large amounts 
of IL-17 (A and F) and IL-22. TH17 cells have also been reported to secrete IL-21 in 
an autocrine manner for TH17 cells development (Wei et al. 2007). These cells 
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express high levels of the transcription factors retinoid-related orphan receptor γt 
(RORγt). TH17 cells differentiate in response to transforming growth factor-β (TGF-
β) together with IL-6 and IL-1, while IL-23 may also be involved in their generation 
and or maintenance (Korn et al. 2009; Stockinger & Veldhoen 2007). TH17 cells have 
major roles in the recruitment, activation and migration of neutrophils. TH17 cells are 
important in immune responses to extracellular bacteria and fungi and are also potent 
inducers of autoimmunity and tissue inflammation (Korn et al. 2009; Kurts 2008). 
 
1.6.4 T regulatory cells (Treg)  
Tregs are CD4
+
 T cells that highly express CD25 (also known as IL-2Rα), the 
transcription factor forkhead box protein P3 (FoxP3) and TGF-β. Two types of this 
subset have been described, the naturally occurring Tregs population that develops in 
the thymus, and IL-10 producing regulatory T cells known as the inducible subtype 
(iTregs) (Ito et al. 2008). Unlike natural Tregs, iTregs differentiate from naïve CD4
+
 T 
cells in the periphery in a TGF-β dependent manner. Tregs has a critical role in 
controlling the immune system against inflammation, autoimmunity and allergy via 
suppressing effector T cells (Zheng & Rudensky 2007).  
1.7 T Follicular Helper cells (TFH cells)  
In the last decade, T Follicular helper CD4 (TFH) cells in humans have been 
identified as a new T helper subset. Within secondary lymphoid organs, TFH cells are 
specialized to regulate the development of effector and memory B cells and long-
lived plasma cells. These cells were first described by several research groups which 
reported a unique CD4 T cell phenotype expressing high levels of C-X-C chemokine 
receptor type 5 (CXCR5) in tonsils (Breitfeld et al. 2000; Kim et al. 2001).  Loss of 
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the chemokine receptor CCR7 and high expression of CXCR5 is a major player to 
drive TFH cells migration into B cells follicles in secondary lymphoid tissue, using a 
CXCL13-dependent manner (Choi et al. 2011; Fazilleau et al. 2009).  
 
It is generally considered that T cell help to B cells is an essential process for 
adaptive immunity. The first interaction between TFH cells and B cells happens at the 
T cell-B cell border leading to B cells differentiation and GC formation within the 
follicle (Choi et al. 2011). In secondary lymphoid tissue, high expression of the 
costimulatory molecules including: CD40L, OX40 and inducible T-cell co-
stimulator (ICOS), as well as the inhibitory molecule Programmed Death 1 (PD-1) 
are major players in modifying antigen specific contact of TFH cells to B cells 
expressing peptide major histo-compatibility complex class II (pMHC-II), CD40, 
OX40L, ICOSL and PDL-1 (Fazilleau et al. 2009; Kassiotis & O'Garra 2009).  
 
1.7.1 TFH cell characterization    
TFH cells have been established as a distinct T helper subset based on characteristic 
cell surface markers expressed and cytokine profile. In addition to CD4 and CXCR5 
(CD185), TFH cells are identified by expressing high levels of ICOS (CD278), PD-1 
(CD279), the transcriptional repressor B cell lymphoma 6 (BCL-6), IL-21R, OX40 
(CD134), CD40L (CD154) and GL7 (Kerfoot et al. 2011; King 2009; Laurent, 
Fazilleau & Brousset 2010). Elevated expression of signalling lymphocytic 
activation molecule-associated protein (SAP), B and T lymphocyte attenuator 
(BTLA) and CD200 have been reported (Crotty 2011). Other markers have also been 
reported in humans including, CD25 (IL-2Rα), CD69, CD95 and CD57 (Laurent, 
Fazilleau & Brousset 2010).  
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1.7.2 TFH Cell Differentiation 
Where and when a naïve T cell becomes a TFH cell is controversial and remains to be 
defined. At present, four models for TFH cell differentiation have been suggested: 
Model 1: direct TFH differentiation via cytokine (IL-6 or IL-21); Model 2: B cell–
dependent direct TFH differentiation; Model 3: a non-distinct subset differentiated 
from TH1/TH2/TH17 cells (secondary program); Model 4: TFH differentiation is 
initially induced by DC and maintained by cognate interaction with B cells (Crotty 
2011; Deenick et al. 2011).  
 
In support of the first model, studies have shown the development of TFH cells as a 
distinct and independent subset after exposing purified CD4 T cells (TH0) to IL-6 or 
IL-21 (Dienz et al. 2009; Nurieva et al. 2008; Nurieva et al. 2009; Suto et al. 2008). 
A second model of TFH development has suggested that TFH cells are a distinct CD4 
T cell subset and they are directly differentiated in a B cell-dependent interaction.  It 
was shown that in the absence of B cells, TFH cells were not observed after viral 
infection (Johnston et al. 2009), and protein immunization (Haynes et al. 2007). In 
support of the third model (secondary program), a study has shown TFH cells to 
develop from another TH subset under certain conditions (Zaretsky et al. 2009).  The 
fourth model of TFH differentiation is based on more recent findings which suggest 
prolonged antigen presentation by DC is critical in the generation of TFH cells 
(Chakarov & Fazilleau 2014; Deenick et al. 2011; Goenka et al. 2011).  
 
1.7.3 Cell markers of TFH cells 
In addition to CD4 and CXCR5, several other molecules have been associated with 
TFH cells. These markers include, ICOS, PD-1, BCL-6 and IL-21. 
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1.7.3.1 CXCR5 and CCR7 
CXCR5 was the first (and most widely used) cell surface marker to identify TFH cells 
discovered in 2000 (Breitfeld, Ohl et al. 2000). CXCR5 is a G protein-coupled seven 
transmembrane chemokine receptor, which specifically allows migration of cells 
towards the follicular chemokine ligand CXCL13 (Forster et al. 1994). In the 
activation process of naïve TH cells when interacted with APC, CXCR5 expression is 
upregulated which then binds to its receptor CXCL13, a chemokine responsible for 
TFH and B cells entry into follicles produced mainly by follicular dendritic cells 
(FDC) (Laurent, Fazilleau & Brousset 2010).  However, the CXCR5 upregulation is 
not applied on all activated T cells and only a part of CXCR5
+
 CCR7
low
 cells 
migrates towards the follicle following an antigen exposure by APC (Yu & Vinuesa 
2010a). 
 
By down-regulation of CCR7, these activated TH cells become less reactive to both 
CCL19 (also known as Epstein-Barr virus-induced receptor ligand chemokine 
(ELC)) and CCL21 (also known as secondary lymphoid tissue chemokine (SLC)) 
which are main T-zone chemokines (Haynes 2008).  Together, the CXCR5-CXCL13 
interaction and down-regulation of CCR7 expression levels are responsible for TFH 
cells follicular homing. This leads to regulation of antigen-specific B-cell responses 
using co-stimulatory molecules including ICOS, CD28 and OX40 (Gómez-Martín et 
al. 2010; Laurent, Fazilleau & Brousset 2010).  
 
It has been reported that a subset of human peripheral blood memory CD4
+
 T cells, 
but not naïve CD4
+ 
T cells, TH1 cells and TH2 cells, are CXCR5
+ 
(Morita et al. 
2011). A small proportion (<2%) of blood memory cytotoxic CD8
+
 T cells has also 
been reported to express CXCR5 (Moser, Schaerli & Loetscher 2002). CD25
+
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Foxp3
+
 cells that localize in the follicles has also been shown to express high levels 
of CXCR5 in addition to ICOS and PD-1 and they have recently been termed as 
follicular Treg (Wollenberg et al. 2011).  
 
In a murine study, Haynes and Allen et al. showed that overexpression of CXCR5 is 
not enough for T cells access to follicles unless the CCR7 expression is down 
regulated. The absence of CXCR5 in T cells resulted in impairment of T cells entry 
into B cells follicles leading to a reduction of 2-fold in GC response (Haynes et al. 
2007). Arnold and Campbell et al. reported that GC B cells response is significantly 
impaired in CXCR5 deficient T cells in mice (Arnold et al. 2007). 
 
1.7.3.2 Inducible co-stimulator molecule (ICOS) 
Inducible co-stimulator molecule (ICOS, also called CD278) is a homodimeric 
protein of relative molecular mass 55,000-60,000 (Mr 55K-60K). ICOS has been 
identified as a member of the CD28 receptor family of co-stimulatory molecules that 
regulates T cell activation and function expressed primarily on activated human T 
cells. As a member of CD28 family, ICOS induces T cell proliferation, 
differentiation, cytokine secretion (such as IL-2, IL-4 and especially IL-10 and IL-
21), upregulates cell-cell interaction molecules and offers effective help to B cells 
for antibody production (Hutloff et al. 1999; Simpson, Quezada & Allison 2010).   
In addition to CXCR5, ICOS has commonly been used to identify TFH cells in 
humans (Yu & Vinuesa 2010a). Highest expression of ICOS is found on TFH cells. 
Recent studies show that following T cell activation, ICOS is upregulated leading to 
T cell proliferation and promotion of either TH1, TH2, TH17 or TFH cells response 
depending on the type of inflammation. These activation effects are controlled by the 
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interaction of ICOS molecules with its specific ligand, ICOS-L (also named as: 
LICOS, B7RP-1, B7h, B7-H2 and GL50) and expressed on B cells as well as antigen 
presenting cells including DC and macrophages (Haynes 2008; Simpson, Quezada & 
Allison 2010). Studies have shown that ICOS are expressed in the apical light zone 
of GC in human tonsillar tissues (Shilling, Bandukwala & Sperling 2006).  
Both murine and human studies have shown the importance of ICOS in the 
development and function of TFH cells. It has recently been reported that ICOS or 
ICOS-L deficiency is correlated with fewer TFH cells and a decrease in GC formation 
suggesting a major role of ICOS in TFH cell differentiation (Laurent, Fazilleau & 
Brousset 2010). Bauquet et al reported that ICOS is a major player in TFH cells 
development by enhancing the transcription factor c-MAF expression on TFH cells. 
On the other hand, ICOS-deficient mice had significantly less c-MAF expression 
resulting in fewer TFH cells. c-MAF also controls IL-21 production which 
consequently regulates TFH cell development (Bauquet et al. 2009).  
Reports show that ICOS deficiency in humans is related with different 
immunodeficiency syndromes including late-onset common variable 
immunodeficiency (CVID) resulting in impaired B cells memory and major defects 
in immunoglobulin class switching (Grimbacher et al. 2003; Haynes 2008). These 
ICOS or ICOS-L deficiencies resulted in reduction of serum IgG production in 
particular IgG1 levels in a T-dependent pathway; whereas, the antibody levels were 
normal against T-independent antigens (Akiba et al. 2005). Studies suggested a 
crucial role of ICOS/ICOS-L interaction in regulating the formation of GC and 
development of effector and memory B cells and long-lived plasma cells, although 
the mechanism controlling this interaction remains unclear (Akiba et al. 2005). 
Akiba et al reported an essential role of ICOS/B7RP-1 interaction for the up-
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regulation of CXCR5 expression on CD4
+
 cells in LN and spleen for the 
development of CXCR5
+
 TFH cell in vivo (Akiba et al. 2005). 
 
1.7.3.3 Programmed cell death 1 (PD-1) 
The receptor ‘programmed cell death 1’ (PD-1; also called CD279), a member of the 
CD28 family and a potent inhibitory receptor, is an important molecule for T cell 
tolerance. PD-1 is induced on activated CD4
+
 T cells, CD8
+
 T cells, natural killer T 
cells, B cells, myeloid cells and activated monocytes (Iwai et al. 2002; Sharpe et al. 
2007). PD-1 is highly expressed on TFH cells and has been used as an identification 
marker for TFH cells (Haynes et al. 2007; Xu et al. 2014).  PD-1 is suggested to 
contribute to GC B cell survival and the formation and affinity of long-lived plasma 
cells through interaction with its ligands PD-L1 (also called CD274 or B7-H1) and 
PD-L2 (also called CD273 or B7-DC) which are members of the B7 (CD28 ligand) 
family. These PD-L1 and PD-L2 are highly expressed on GC B cells (Good-
Jacobson et al. 2010).   
 
PD-1 provide an inhibitory signal to GC TFH cells to prevent excess proliferation of 
CD4 T cells in GCs (Crotty 2011). The extended TCR signalling from B cells that 
occur in the GC induces the PD-1 expression on TFH cells (Crotty 2011).  Haynes 
and colleagues have shown that within CXCR5
high 
CCR7
low
 population the PD-1 
expression levels and the abundance of IL-4 transcripts were the highest (Haynes et 
al. 2007). A study with human tonsillar tissue by immunohistochemistry has shown 
that PD-1
+
 T cells are highly enriched within the GC light zone (Iwai et al. 2002). 
PD-1 has been reported to increase during viral infections to prevent activated T 
cells of becoming autoreactive or causing immunopathology (Sang-Jun et al. 2008; 
Sharpe et al. 2007). Recent studies have reported alterations in TFH subsets including 
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reduced IL-4 and IL-21 production in the absence of PD-1(Good-Jacobson et al. 
2010).    
 
1.7.4 BCL-6 as a Regulator of TFH Differentiation 
Master regulatory transcription factors control CD4 T cell differentiation. TH1 cells 
express T-bet (Szabo et al. 2000), TH2 cells express GATA-3 (Zheng & Flavell 
1997), TH17 cells express RORt (Kurts 2008) and Treg express Foxp3 (Zheng & 
Rudensky 2007).  
 
Most recently, BCL-6 has been identified as the master regulatory transcription 
factor which controls TFH cell differentiation program (Johnston et al. 2009; Nurieva 
et al. 2009; Yu et al. 2009b). Up-regulation process of BCL-6 by TFH cells leads to 
down-regulation and blocking for TH1, TH2 and TH17 cells proliferation by 
suppressing their transcription factors (See Figure 1.3) (Laurent, Fazilleau & 
Brousset 2010; Yu et al. 2009b). Over-expression of BCL-6 in activated T helper 
cells has been reported to stimulate IL-6 receptor and IL-21 receptor expression and 
they are both necessary for TFH cells differentiation (Laurent, Fazilleau & Brousset 
2010). However, the expression of BCL-6 by TFH cells is heterogeneous and around 
10-15% of TFH cells in GC have detectable BCL-6 protein (Vinuesa et al. 2005). 
Thanks to gene expression profiling, TFH cells has been distinguished from TH1, TH2, 
TH17 and iTreg gene expression profiles (Choi et al. 2011). Recent studies have 
shown that TFH differentiation does not occur in vivo in the absence of BCL-6 (Bcl6
-
/
-
). However, the differentiation of other CD4 T cell subsets is relatively unaffected 
by the lack of BCL-6 (Johnston et al. 2009; Nurieva et al. 2009; Yu et al. 2009b). 
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Figure 1.3. BCL-6 inhibition of other CD4 T cell differentiation pathways 
BCL-6 can cause a generalized inhibition of other CD4 T cell differentiation pathways by 
blocking Blimp-1 expression. Taken from (Crotty 2011).  
 
BCL-6 is an antagonist of Blimp-1 and Blimp-1 is an antagonist of BCL-6. BCL-6 is 
highly expressed on TFH cells and Blimp-1 is highly expressed on non-TFH cells, i.e., 
TH1, TH2, TH17, or other subsets (Crotty, Johnston & Schoenberger 2010; Johnston 
et al. 2009). BCL-6 can limit all non-TFH differentiation by repressing Blimp-1. 
Recent studies have reported that BCL-6 can inhibit transcription factors important 
for TH1 cells (Nurieva et al. 2009; Yu et al. 2009b), TH2 cells (Kusam et al. 2003; 
Nurieva et al. 2009), or TH17 cells  (Mondal, Sawant & Dent 2010) differentiation. 
Other transcription factors such as c-Maf, Batf, and BCL-6-binding partners also 
play essential roles in the development and function of TFH cells (Crotty 2011). 
However, more studies are needed to fully understand the mechanisms by how BCL-
6 controls TFH cell differentiation. 
 
1.7.5 Cytokine profile for TFH cells 
It is clear that TFH cells can produce many cytokines in biologically relevant 
quantities in particular, IL-21, IL-10 and IL-4 which are all important for B cell 
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development and proliferation (Eto et al. 2011; Leddon & Sant 2012; Luthje et al. 
2012; Reinhardt, Liang & Locksley 2009; Yusuf et al. 2010). Interferon- (INF-), 
IL-4 and IL-17 which are usually related to TH1, TH2 and TH17 cells, respectively, 
has also been reported to be produced by TFH cells (Yu et al. 2009a).  
 
1.7.5.1 IL-21 
IL-21 influences the function of T cells, NK cells, and B cells. In humans, IL-21 is 
mainly produced by TFH cells (Eto et al. 2011; Nurieva & Dong 2009; Reinhardt, 
Liang & Locksley 2009) although not exclusively expressed by TFH cells (Suto et al. 
2008; Wei et al. 2007). IL-21 has been reported to play a role in TFH cell formation 
and it is crucial in stimulating the differentiation of human B cells (Ettinger et al. 
2005; Linterman et al. 2010). Major defects in IgG1 production following antigen 
priming, has been reported in IL-21R-deficient mice (Ozaki et al. 2002). Recent 
studies have also shown that IL-21 is important for optimal GC B cell proliferation. 
Impaired affinity maturation and reduction in the proportion of IgG1
+
 GC B cells 
was seen in IL-21 deficiency. However, the formation of early memory B cells was 
not affected by the lack of IL-21. A reduction of BCL-6 expression on GC B cells 
has been reported in absence of IL-21 (Linterman et al. 2010; Zotos et al. 2010).   
 
1.7.5.2 IL-10 
IL-10 is known to act as a survival, proliferation, and differentiation factor for B 
cells and is more efficiently provided by TFH cells than other T cells (Kim et al. 
2001). Chevalier et al. reported that CXCR5
+
 T cells expressed significantly higher 
levels of IL-10 as compared with CXCR5
-
 T cells in human blood. This study also 
showed that plasma cell differentiation and immunoglobulin secretion were 
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significantly increased when B cells were cultured with CXCR5
+
 T cells compared 
with CXCR5
-
 T cells (Chevalier et al. 2011). Using an IL-21 reporter mouse Luthje 
and co-workers reported that the expression of  IL-10 mRNA was restricted to IL-
21
+
 TFH cells (Luthje et al. 2012). Kim et al. reported in human tonsillar tissues that 
GC-TFH cells (CXCR5
+
 CD57
+
) are more efficient in production of  IL-4 and IL-10 
as evidenced by intracellular staining and ELISA compared to CXCR5
+
 CD57
- 
cells 
( non- GC-TFH cells),  naive or CXCR5
-
 T cells (Kim et al. 2001).  
 
1.7.5.3 IL-4 
IL-4 is widely recognized as the main marker for TH2 polarized CD4
+
 T cells and as 
a B cell survival and differentiation factor. TFH cells have frequently been reported to 
produce IL-4 (Fazilleau et al. 2009; King & Mohrs 2009; Reinhardt, Liang & 
Locksley 2009). TFH cells are the major producers of IL-4 in secondary lymphoid 
tissues where humoral immune responses develop. Production of IL-4 by GC TFH 
cells is required for optimal B cell help (Vijayanand et al. 2012). Using a IL-4 GFP 
reporter mice, Yusuf et al. demonstrated that IL-4 production was observed by GC-
TFH cells (GL7
+ 
CXCR5
+
 CD4 T cells) but not CXCR5
-/low
 virus-specific CD4 T 
cells. The majority of the IL-4 was produced by the highest CXCR5 expressing cells, 
even within the TFH population and no IL-4 was made by non-TFH CD4 T cells. The 
IL-4 expression by the GC TFH population was independent of TH2 differentiation, 
because the expression of GATA3 was not increased above basal levels in any virus-
specific CD4 T cells (Yusuf et al. 2010).  
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1.7.6 Peripheral TFH cells (pTFH) 
Recent studies in humans have also shown a circulating CD4
+
 T cell population 
characterized by high CXCR5 expression in peripheral blood (Chevalier et al. 2011; 
Ma & Deenick 2014; Morita et al. 2011; Simpson et al. 2010). These circulating 
cells, termed ‘‘peripheral TFH’’ (pTFH) share similar functional characteristics to TFH 
cells found in human secondary lymphoid tissues by expressing higher levels of PD-
1 and IL-21 compared to CD4
+
 CXCR5
-
 T cells (Ma & Deenick 2014). However, a 
main difference between TFH cells found in secondary lymphoid organs and pTFH 
cells is the lack of expression of the transcription factor BCL-6 and much lower 
expression of ICOS by pTFH cells (Chevalier et al. 2011; Morita et al. 2011; Simpson 
et al. 2010). 
 
Humans who show severely impaired GC formation through deficiency of CD40-
ligand or ICOS show significantly less circulating CD4
+ 
CXCR5
+
 T cells (Bossaller 
et al. 2006). A study by Morita et al. has shown the ability of these CXCR5
+
 pTFH 
cells in providing better help to B cells to differentiate and proliferate compared to 
their CD4
+
 CXCR5
-
 counterparts. This study also showed that CD4
+ 
CXCR5
-
 
express higher Blimp-1 mRNA than their CD4
+ 
CXCR5
+
 cell (pTFH) counterparts 
(Morita et al. 2011). These pTFH cells have been suggested to represent the memory 
counterparts of TFH cells outside the lymphoid organs, although it remains unknown 
whether there is a direct relationship between pTFH cells and TFH cells found in 
secondary lymphoid tissue (Morita et al. 2011; Simpson et al. 2010; Vinuesa & Cook 
2011).  
 
In concordance with TFH cells found in secondary lymphoid tissue, blood CD4
+
 
CXCR5
+
 T cells (pTFH) was found to support naïve and memory B cells to become 
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antibody-producing cells via IL-21, IL-10, ICOS, and secrete CXCL13. In contrast 
with TFH cells found in NALT, pTFH cells express less CD69, ICOS, and PD-1 
suggesting that they are in a resting state and express CCR7 and CD62L, suggesting 
their capacity to migrate into secondary lymphoid organs (Kim et al. 2001; Ma et al. 
2009; Simpson et al. 2010). Whether pTFH originate from cells that migrated out of 
GCs, TFH precursors, is an important question, although it remains unclear in 
humans. 
 
1.8 Germinal Centre B cells 
B cells are found circulating in the peripheral blood. However, within special 
follicles in secondary lymphoid tissues including tonsils and adenoids, B cells are 
most abundant. B cells activation needs either a soluble antigen or an antigen 
delivered on DC, macrophages or FDC through BCR stimulation. B cells can be 
activated by either a T cell-independent or a T cell-dependent manner (Jeurissen & 
Bossuyt 2004). In a T cell-independent response, the crosslinking in BCRs by 
repeated antigenic or multiple polyclonal epitopes can provide enough stimuli for B 
cells to be activated. Neutralizing antibodies can be generated within 2-3 days in T 
cell-independent responses, although without affinity maturation or memory B cell 
responses (Shih, Roederer & Nussenzweig 2002). In T cell-dependent responses, the 
initiation of the interaction between B and T cells requires antigen presentation by B 
cells via MHC class II, the binding of antigen specific T cells, and the formation of 
an immunological synapse between the two cells (Parker 1993).  
 
The up-regulation of CCR7 and down-regulation of CXCR5, initiates the B cell 
migration towards the boundary of the T/B cell zones. The subsequent TFH cell 
interaction initiates proliferation and formation of GCs (Cyster 2010; Victora & 
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Nussenzweig 2012). After interaction with TFH cells, B cells can either be 
programmed to become memory B cells, or plasma cells producing high affinity 
antibodies.  
 
In addition to its importance for TFH cell differentiation, BCL-6 is also an important 
regulator for GC B cells. BCL-6 is able to block Blimp-1, the transcription factor 
regulating differentiation of plasma cells, to keep B cells in the GC response (Shaffer 
et al. 2000). Up-regulation of the transcription factor Blimp-1, which is accompanied 
by the down-regulation of BCL-6, drives GC B cells to become either short lived 
plasma cells that reside in secondary lymphoid tissue or long-lived plasma cells 
found in the bone marrow (Shapiro-Shelef & Calame 2005). CXCL13 is mainly 
expressed by FDCs, retaining B cells and attracting TFH cells expressing high levels 
of CXCR5 to the GC (Laurent, Fazilleau & Brousset 2010). These processes leads to 
the formation of memory B cells and plasma cells producing high affinity antibodies, 
which is the goal of most vaccinations, although the exact signals that determine GC 
B cells differentiation into memory cells or plasma cells are unknown (Klein & 
Dalla-Favera 2008). 
 
1.9 TFH cell – B cell Interactions in the GC 
Specific antigen activated T cells which were primed on DC in the T cell zone, 
upregulate the expression of CXCR5, ICOS and PD-1, and downregulate CCR7 
allowing them to migrate to the B cell follicles (Yu & Vinuesa 2010b). These 
activated T cells mature into TFH cells after interacting with follicular B cells. 
Antigen activated follicular B cells migrate towards the T cell zone boundary. Some 
of these B cells differentiate into either extrafollicular plasmablasts or become early 
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memory B cells, however, most of them return to the follicle and initiate massive 
proliferations to form a GC (Nutt & Tarlinton 2010). (See Figure.1.4) 
 
 Antigen activated follicular B cells require a cognate interaction with TFH cells 
which takes place at the B-T cell boundary, to initiate the B cell differentiation 
process towards forming GCs. Before these interactions happen, activated follicular 
B cells and T cells adjust their chemokine receptor expression allowing them to 
relocate. Activated B cells upregulate CCR7 expression and migrate to the T cell 
zone (Reif et al. 2002), while activated T cells upregulate CXCR5 expression 
allowing them to  migrate towards the follicle (Fillatreau & Gray 2003).  
 
 
 
 
 
Figure 1.4. Important interactions between TFH and B cells in the GC 
In the GC, TFH cells interact with GC B cells through an array of molecular pairings leading 
to the secretion of cytokines by TFH cells, particularly IL-4, IL-10 and IL-21, which are 
received by B cells for optimal GC function. Taken from (Nutt & Tarlinton 2010). 
 29 | P a g e  
 
TFH and GC B cell interactions are crucial in GC response. In the GC, TFH cells 
interact with GC B cells via a range of molecular pairings, including those between 
T cell antigen receptor and CD4 with major histocompatibility complex class II 
(TCR-MHC-II); CD28-B7 family members; ICOS and its ligand ICOSL (ICOS-
ICOS-L); CD40 and its ligand CD40L (CD40-CD40L); PD-1 and its ligand PDL-1 
(PD1-PDL-1); IL-21 and its receptor IL-21R (IL-21-IL-21R) and signaling 
lymphocytic-activation molecule family members (SLAMF) on both cell types. 
These interactions leads to the secretion of IL-4, IL-10 and IL-21 by TFH which are 
received by GC B cells for optimal GC function by forming high affinity memory B 
cells and long-lived plasma cells (Nutt & Tarlinton 2011). (See Figure 1.4) 
 
These interactions, which occur in the GC, have been intensively examined. Major 
defects in the immune response that developed in the absence of one of these specific 
molecules from either TFH cells or B cells have been documented. For example, a 
significant reduction in long-lived plasma cells was seen in the absence of PD-1 or 
its ligands (Good-Jacobson et al. 2010). ICOS or ICOS-L deficiency was correlated 
with fewer TFH cell numbers and major defects in GC formation (Laurent, Fazilleau 
& Brousset 2010). Significant reduction in both GC B cells and antibody levels was 
also reported in the absence of IL-21 or its receptor (Linterman et al. 2010; Ozaki et 
al. 2002; Zotos et al. 2010).   
 
1.10 The Germinal Centre Response 
The GC is a distinct microanatomical region of secondary lymphoid organs. GCs 
have a dynamic microenvironment where antigen activated B cells go through 
various essential modification including, clonal expansion, somatic hypermutation, 
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selection of high-affinity B cells and class-switch recombination (Klein & Dalla-
Favera 2008). During T-cell-dependent antibody responses to exogenous antigen, 
GCs have been shown to initiate after around 6 days of a primary immunization, 
when foci of rapidly proliferating B cells begin to appear within the B cell follicles 
of secondary lymphoid organs including tonsils. The size of these foci increase 
rapidly and within a few days of their formation they differentiate into a mature GC 
reaction (Victora & Nussenzweig 2012). 
 
The GC contains two major zones known as the light zone, proximal to the LN 
capsule or the spleen marginal zone, and the dark zone, proximal to the T cell zone. 
The dark zone is consists almost entirely with rapidly proliferating GC B cells with a 
high nucleus-to-cytoplasm ratio, consequently appearing “dark” by light microscopy. 
In the light zone GC B cells are intermixed with a network of FDCs which give this 
zone a “light” appearance (van Nierop & de Groot 2002). The light zone also 
contains a large number of TFH cells (Crotty 2011; Nutt & Tarlinton 2011) as well as 
a small number of DCs (Grouard et al. 1996). Tingible body macrophages, a 
specialized group of phagocytes that engulf dying B cells that develop during GC 
selection, are found throughout the GC (Smith et al. 1998; Victora & Nussenzweig 
2012). These two areas have separate functions. The dark zone is where GC B cells 
proliferate and go through the process of somatic hypermutation and class switch 
recombination. Whereas the light zone is the site for clonal selection through 
recognition of antigen-bearing FDCs and interactions with TFH cells (Victora & 
Nussenzweig 2012). 
 
To increase antibody diversity and affinity, activated B cells undergo somatic hyper 
mutation and then alter antibody affinity and undergo class-switch recombination. 
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Class-switch recombination changes the constant region of the Ig heavy chain from 
IgD or IgM to IgG, IgA, or IgE which is an essential stage in humoral immunity 
(isotype-switching) (Xu et al. 2012). Somatic hyper mutation and class-switch 
recombination require the presence of the enzyme activation-induced cytidine 
deaminase (AID) which initiates DNA strand-breaks in the V(D)J section of the Ig 
variable regions and is expressed by proliferating B cells (Klein & Dalla-Favera 
2008; Vinuesa, Sanz & Cook 2009).  
 
1.11 Dendritic Cells 
DCs are considered to be the most effective APCs and provide an important link 
between the innate and adaptive immunity (Stockwin et al. 2000).  DCs are usually 
found where pathogens are most likely to first be encountered, for example, dermal 
tissues, mucosal surfaces of the nasal cavity, lungs and intestine (Stockwin et al. 
2000). Upon antigen encounter, DCs migrates to the draining LNs via lymphatic 
vessels where they interact with T cells. Following degrading of antigens by DCs, 
immuno-peptides (epitopes) are presented by MHC class I or II molecules. The 
presentation of MHC class I by DC is recognized by specific CD8
+
 cytotoxic T cells 
(CTL), and MHC class II is recognized by CD4
+
 T helper cells. Driving the 
differentiation of naïve T cells into a certain T helper subset can be the difference 
between inflammation and tolerance responses (Merad et al. 2013). The common 
property of several agents with adjuvant activity, including, CpG-DNA, is that they 
stimulate immune responses by inducing the maturation of DCs (Ramírez-Pineda et 
al. 2004). 
 
Currently, many subtypes of DCs have been identified including conventional DCs 
(cDC), plasmacytoid DCs (pDC), monocyte-derived DCs and the epidermal 
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Langerhans cells.  DCs are derived from blood-circulating precursors, originating 
from the bone marrow, and differentiate in peripheral tissues including lymphoid 
organs (Geissmann et al. 2010). Immature DC are characterized by low surface 
MHC and co-stimulatory molecules expression, however, they are highly phagocytic 
and have a large range of PRRs (Banchereau & Steinman 1998).  
 
The initiation of the maturation process starts after the encountered antigens are 
engulfed by endocytosis. These internalized antigens are then degraded in lysosomes 
to be loaded on MHC molecules and transported to the cell surface to be recognized 
by T cells (Banchereau & Steinman 1998). Another feature of DC maturation is the 
expression of co-stimulatory molecules CD80 and CD86. Mature DC also express 
CCR7 to enable a gradient-dependent migration to the T cell zone of lymphoid 
tissues, which are rich in the chemokines CCL21 and CCL19 (Weber et al. 2013). 
 
Recently, it has been reported that antigen presentation by DC is necessary to initiate 
TFH cell development (Choi et al. 2011; Goenka et al. 2011), despite the fact that in 
most cases, antigen presentation by B cells is ultimately responsible for promoting 
the full differentiation program of TFH cells (Ballesteros-Tato & Randall 2014; 
Johnston et al. 2009; Nurieva et al. 2009).  
 
1.11.1 Plasmacytoid DC (pDC) 
Plasmacytoid DC differs from classical DC morphologically as pDC are more 
spherically formed and classical DC have extending dendrites. pDC represents a 
small subset of DC and can be found in the bone marrow, blood and all lymphoid 
organs (including tonsils) (Polak et al. 2008; Rescigno 2013) and enter the LN via 
the blood circulation (Merad et al. 2013). pDC have been previously described in the 
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T-cell area of human mucosa, especially in tonsils (Polak et al. 2008; Rescigno 
2013) 
 
They are characterized with rapid production of type I interferons (IFN-α/β) in 
response to viral infections. They also can act as APC and control T cell responses 
(Geissmann et al. 2010). Several relatively pDC specific surface markers have been 
established for pDC identification, including, ILT7 (immunoglobulin like transcript 
7) (also known as CD85g), human blood dendritic cell antigen (BDCA)-2, BDCA-4 
and CD123 (known as human IL-3Rα) (Reizis 2010; Reizis et al. 2011). At the same 
time, pDC lack the expression of CD11b and only express low levels of CD11c. In 
humans, pDC uniquely express both TLR-7 and TLR-9 which are not found on other 
DC types (Fuchsberger, Hochrein & O'Keeffe 2005; Hornung et al. 2002).  
 
 
1.12 Pattern Recognition Receptors (PRRs) 
The innate immune system has the ability to recognize different microorganisms and 
distinguish them from self cells by several phylogenetically germ line encoded 
Pattern Recognition Receptors or PRRs. These PRRs are considered to act as a key 
component of the innate immunity and are expressed in cells of innate system, 
including mononuclear phagocytes, such as circulating monocytes and tissue 
macrophages, DCs, mucosal epithelial cells, and lymphocytes (Akira, Uematsu & 
Takeuchi 2006; Tosi 2005). PRRs can identify specific microbial structures known 
as pathogen associated molecular patterns (PAMPs), which are important microbial 
molecules for pathogens to survive and they are unique to each microorganism that 
are not found in the host body.  
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In addition, it's unlikely for these infectious agents to change these molecules as any 
major changes will lead to disadvantages to the invader (Chi & Flavell 2008). 
Several bacterial components are included such as, lipopolysaccharide (LPS) and 
peptidoglycans (PGNs), bacterial DNA and viral RNA in case of a virus infection 
(Martinon & Tschopp 2005). Although PAMPs are important to trigger an innate 
immune response, there are other elements that can be detected to initiate the innate 
immunity such as abnormal self cells or danger signals like DNA, RNA or even uric 
acid that normally should not be outside cells or at certain areas inside the cell 
(Martinon & Tschopp 2005). 
 
Additionally, there are several types of PRRs in the innate immune system including 
members of the Toll-like receptors (TLRs) family which are found to be expressed at 
the cell surface or monitor endosomal compartments (Lotz, Ménard & Hornef 2007). 
Furthermore, each of these PRRs acts in response to specific PAMPs that will 
activate specific signaling pathways resulting in distinct anti-pathogen responses 
(Akira, Uematsu & Takeuchi 2006). 
 
1.12.1 The role of Toll-like receptors (TLRs) 
The first human TLR was identified by Medzhitov et al. (Medzhitov, Preston-
Hurlburt & Janeway 1997). However, the Toll gene was originally discovered in the 
fruit fly Drosophila long time earlier. TLRs are conserved transmembrane signaling 
receptors of the innate immune system characterized by an extracellular domain 
including leucine-rich repeats (Abrahams & Mor 2005; Takeda & Akira 2005) and 
an intracellular domain which shows homology with the interleukin-1 receptor (IL-
1R) that forms the TOLL/IL-1R (TIR) family. In addition, TLRs are considered the 
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first line of defence against bacteria, fungi and some viruses (Janeway & Medzhitov 
2002; Papadimitraki, Bertsias & Boumpas 2007).  
 
Furthermore, several types of TLRs have been identified in humans and each one of 
them has the ability to recognize some unique PAMPs (Medzhitov & Janeway 
2002). For example, TLR-4 has the ability to recognize LPS of Gram-negative 
bacteria and the F protein of the respiratory syncytial virus (RSV). Whereas TLR-2 
has the ability to recognize several groups of components derived from pathogens 
such as lipopeptides from Gram-positive and Gram-negative bacteria, mycobacteria 
and some parasites, while TLR-3, -7, -8 and -9 are able to recognize nucleic acids of 
some pathogens (Suzuki, Chow & Downey 2008; Takeda & Akira 2005). Bacterial 
DNA is highly rich in unmethylated CpG motifs and they are detected by TLR-9. 
Exposure to unmethylated CpG-DNA released during an infection provides a 
‘‘danger signal’’ to the innate immune system, triggering a protective immune 
response that improves the host’s capacity to eliminate the pathogen. Synthetic 
ODNs expressing CpG motifs similar to those found in bacterial DNA stimulate a 
similar response (Klinman 2006). 
 
1.13 CpG-DNA a TLR-9 Ligand 
CpG oligodeoxynucleotides (CpG-DNA) are short single-stranded synthetic 
oligonucleotides containing unmethylated Cytosine-Guanine (CpG, where the p 
indicates the phosphodiester bond) dinucleotides known as CpG motifs. CpG-DNA 
is recognized as PAMPs due to their abundance in bacterial DNA compared to 
mammalian DNA. CpG-DNA mimic the immunostimulatory activity of bacterial 
DNA and are recognized by the Toll-like receptor 9 (TLR-9) leading to strong 
immunostimulatory effects. Three types of stimulatory CpG-DNA have been 
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suggested based on their immunostimulatory activities named as CpG-DNA type A, 
B and C (Klinman 2006; McCluskie & Davis 1999).  
 
1.13.1 CpG-DNA classes  
Three major classes of immune stimulatory CpG-DNA has been described, with 
distinct structural and biological characteristics; CpG-DNA class A (also known as 
type D), CpG-DNA class B (also known as type K) and CpG-DNA class C. One of 
the first class A CpG-DNA was described in 2001 by Krug et al. (Krug et al. 2001a). 
This class is characterized by its strong stimulatory effect on pDC to produce high 
quantities of IFN-α, induces APC maturation and through IFN-α (indirectly) 
activates natural killer (NK) cells. In addition, CpG-DNA class A have a weak effect 
on B cell activation compared to CpG-DNA type B (Krug et al. 2001a; Vollmer et al. 
2004).  
 
On the other hand, CpG-DNA type B is the strongest B cell stimulatory class. CpG-
DNA class B was first identified in 1995 by Krieg and colleges (Krieg et al. 1995). 
Members of this class of CpG-DNA mainly induce B cell proliferation, 
differentiation and immunoglobulin and cytokine secretion. They induce pDC 
expression of costimulatory molecules, including CD86, CD54, MHC II and CD40. 
Class B CpG-DNA was also reported to activate NK cells but stimulate little IFN-α 
secretion (Hartmann & Krieg 2000; Krieg & Yi 2000; Krieg et al. 1995).  
 
Class C CpG-DNA, which was firstly identified by Marshall et al., combines the 
properties of both class A and B CpG-DNA by being potent stimulators of pDC IFN-
α production, APC activation and maturation, indirect NK cell activation, and direct 
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B cell stimulation and proliferation, but to a lower extent than class A or B alone 
(Marshall et al. 2003; Vollmer et al. 2004).  
 
Recently a new CpG-DNA was identified, called the P-class CpG-DNA. This new 
class combines the preferred properties of the other CpG-DNA classes.  It is able to 
induce the strongest type I IFN secretion by pDC, compared to the other classes, and 
induces superior stimulation of cytokine production in vivo (Samulowitz et al. 2010).  
 
1.13.2 CpG-DNA clinical applications 
In recent years, novel adjuvants and vaccine delivery systems aimed to enhance 
vaccine immunogenicity have been under study (Spensieri et al. 2013). CpG-DNA is 
a TLR-9 ligand and has several potential therapeutic uses such as treatment for 
allergic disorders (Kitagaki, Businga & Kline 2006), immunotherapy for cancer 
(Mason et al. 2005; Mason et al. 2006) and as immune stimulants to improve host 
resistance to infection (Klinman 2006). CpG-DNA were also suggested previously as 
a candidate vaccine adjuvant capable of enhancing antibody responses when 
combined to antigens (Klinman 2006; McCluskie & Davis 1999; Weeratna et al. 
2000).  However, it remains unclear whether such effect was mediated by the 
induction of higher numbers of TFH or through direct effect on B cells via TLR 
activation (Mastelic et al. 2012).  
 
CpG-DNA has strong TLR-9 mediated immunomodulatory effects developing 
antigen specific humoral and cellular responses and is currently undergoing clinical 
trials (Halperin et al. 2003; Krieg et al. 1995; Sagara et al. 2009). Several 
mechanisms are involved in the B cell stimulatory effects of CpG-DNA, including 
the cross-linking between TLR-9 and B cell antigen receptor (BCR) signaling, 
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rescuing B cells from apoptosis (Krieg & Yi 2000).  CpG-DNA was also reported to 
enhance the T cell–mediated help through DC maturation and differentiation (Krieg 
2002). Therefore, CpG-DNA may have a dual effect on TFH and B cell activation 
allowing GC B cells to provide a feedback loop signal to TFH cells. Subsequently, the 
TFH will help and enhance GC B cell responses. (Mastelic et al. 2012). 
 
Accordingly, for working with TFH cells and B cells, CpG-DNA class B was chosen 
to be examined as a candidate adjuvant. The member of this class that has been  used 
in this project is CpG 2006 (5’- TCG TCG TTT TGT CGT TTT GTC GTT -3’ (24 
mer)) which was first identified by Hartmann and Krieg (Hartmann & Krieg 2000). 
Since then, this member of B-class CpG-DNA has become the most widely studied 
B-class member. 
 
1.14 The Upper Respiratory Tract Infections   
According to WHO, acute respiratory tract infections are shown to be the leading 
cause of the global burden of disease worldwide particularly in low-income 
countries. It is estimated that more than 4 million deaths yearly; 50% of them 
children under five years, are due to respiratory tract infections (WHO 2004). Large 
numbers of infectious agents gain entry into the human host through the upper 
respiratory tract (URT).  
 
Respiratory tract infections can be classified into two main groups: the upper 
respiratory tract infection (URTI), and the lower respiratory tract infection (LRTI). 
The URTI includes sinusitis, pharyngitis, tonsillitis, middle ear infections and 
rhinitis (Elwood & Bailey 2005; Heikkinen & Ruuskanen 2006). On the other hand, 
pneumonia and bronchiolitis are the main LRTIs (Chang et al. 2009). The highest 
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rates for developing a fatal respiratory infection can be seen in young children <5 
years, elderly people >65 years and in immune-compromised patients. The main 
pathogens responsible for respiratory tract infections include viruses such as 
influenza virus, RSV (Nair et al. 2010) and parainfluenza virus type 3 (PIV-3) 
(Hsieh et al. 2010). In addition, several bacteria have also been known to cause acute 
respiratory tract infections including Streptococcus pneumoniae (Barnett & Klein 
2011; Klugman & Feldman 2011) and Haemophilus influenza (Nicholson et al. 
2002).  
1.14.1 Influenza virus 
Influenza virus is a major cause of respiratory tract infection and responsible for 3–5 
million clinical infections and 250,000–500,000 fatal cases annually worldwide 
(Stöhr 2002). Influenza virus infection induces host immune responses that help to 
reduce virus replication and prevent further spread. Protection against influenza virus 
is mediated by neutralizing antibodies, and their induction at high and sustained 
titres is essential for successful vaccination (Spensieri et al. 2013). Immunological 
memory induced by an infection may offer protection against subsequent influenza 
virus infection of the same subtype, but may offer limited protection against other 
subtypes (Kreijtz, Fouchier & Rimmelzwaan 2011).  
 
There are three types of influenza viruses, type A, B and C, and all have many 
biological properties in common (Taubenberger & Morens 2008). A key difference 
between these types is their host range, influenza A viruses have been isolated from 
many animal species, including humans, pigs, horses, marine mammals, and a wide 
range of domestic and wild birds (Taubenberger & Kash 2010), whereas influenza 
viruses of types B and C are predominantly human pathogens although have 
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sporadically been isolated from seals and pigs (Osterhaus et al. 2000). 
 
Influenza virus is highly contagious and it is transmitted through airborne droplets 
and via the nasal mucosa. The virus infects by binding their surface glycoprotein 
haemagglutinin (HA) to sialic acid receptors on the host epithelia cell surface 
(Barbey-Martin et al. 2002). Intranasal vaccination has been proposed for a more 
effective and biologically relevant way of immunization against influenza. Intranasal 
vaccination essentially depends on the local mucosal immune tissue. Mucosal 
immunity in the upper respiratory tract is considered the first line of defence against 
a number of pathogens of both bacterial and viral origin. Human adenoids and tonsils 
are major components of the NALT and known to be main induction sites for both 
mucosal and systemic immunity against upper respiratory tract pathogens including 
influenza infection (Kiyono & Fukuyama 2004; Tamura & Kurata 2004; Wu & 
Russell 1997; Zuercher et al. 2002).  
 
In the 1940s, inactivated influenza vaccines were first presented and they are still 
considered the main formulation of influenza vaccine. The aim of influenza 
vaccination is to offer an immunological memory protection against influenza 
infection. Protection following natural infection with influenza is primarily mediated 
by anti-HA specific antibodies in serum and mucosa, and T-cell responses associated 
with reduced disease severity (Brokstad et al. 2001). However, influenza vaccination 
is the main method of preventing influenza infection and its associated complications 
(Brokstad et al. 2001; Cox & Subbarao 1999).  
 
The surface HA glycoprotein of influenza virus is a major target for antiviral activity 
as immune response to HA offer neutralizing antibodies following vaccination or 
natural infection (Wilks et al. 2012).  As HA is a major virulence factor and essential 
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for influenza virus - host cells binding process, HA-specific neutralizing antibodies 
are important to prevent the virus attachment to host cell thus prevent infection 
(Wang et al. 2011). 
1.15 Influenza vaccine types 
1.15.1 Trivalent Inactivated Influenza Vaccine (TIV; intramuscular) 
The current inactivated influenza vaccine contains three strains of influenza viruses: 
one influenza A (H1N1) virus, one influenza A virus (H3N2), and one influenza B 
virus (WHO). It is given as an injection subcutaneously or intramuscularly. In 
primed individuals it will induce a quick systemic humoral immune response in the 
blood. In serum, the influenza specific IgG antibody response is predominant after 
vaccination (Belshe et al. 2004; Cox & Subbarao 1999). Wrammert et al. reported 
that the majority of antibody secreting cells (ASC) produced in blood are IgG 
positive, with minor IgA and IgM positive cells in vaccinated individuals 
(Wrammert et al. 2008).  
 
1.15.2 Live Attenuated Influenza Vaccine (LAIV; intranasal) 
Intranasal Live Attenuated Influenza Vaccine (LAIV) is a live, trivalent intranasal 
spray vaccine that produces the HA and NA surface antigens from a number of 
influenza viruses including seasonal strains such as A/Brisbane/59/2007 (H1N1), 
A/Brisbane/10/2007 (H3N2) and B influenza strains. Studies have reported using 
LAIV vaccines delivered intranasally was able to induce strong immune response 
including induction of mucosal IgA and IgG, and serum IgG and enhanced local 
cytokine responses, which may provide better protection. LAIV vaccines also shown 
to stimulate stronger cellular immune response by inducing influenza specific 
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memory T cells and B cells (De Filette et al. 2006; Vajdy et al. 2007). Intranasal 
vaccination may offer certain advantages over intramuscular vaccination by inducing 
a protective local immunity preventing local spread and transmission of the virus. 
Intranasal vaccination with LAIV has been used successfully in several countries 
including USA and Canada (under the commercial name FluMist
®
) with good 
efficacy (Belshe 2004). Most recently, LAIV Intranasal vaccination has also been 
licensed in Europe including the UK (under the commercial name Fluenz
™
).  
 
Both live attenuated vaccine and inactivated vaccines are currently in use. At 
present, seasonal influenza vaccination are recommended to be taken every year 
using TIV for all individuals in particular, children aged 6 months or older, those 
with a diversity of chronic illnesses and health care workers.  In addition to TIV, 
LAIV is also recommended for healthy non-pregnant people aged 2-49 years 
(Osterholm et al. 2012).  
 
Although it has been shown to be safe and effective in humans, not much research 
has been done to evaluate the local mucosal immunity induced by these LAIV 
intranasal vaccines. As these vaccines contain live attenuated viruses and 
administered through the nasal mucosa mimicking natural infection, it may induce an 
immune response resembling natural immunity. NALT components, including 
adenotonsillar tissues are local mucosal immune organs in the upper respiratory tract, 
therefore, intranasal vaccines are likely to depend on these immune tissues to induce 
specific immune responses. 
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1.16 Aims of the Thesis 
The aims of this PhD project include: 
1. To characterise TFH cells in human NALT in children and adults, 
2. To investigate the effect of CpG-DNA on TFH cells and the adjuvant effect on 
B cell antibody response to influenza antigen, 
3. To determine the effect of TFH cells in LAIV-induced immune response to 
influenza virus antigen, 
4. To study the effects of IL-21 and plasmacytoid DC on TFH cell mediated B 
cell antibody production. 
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Chapter 2 
 
 
Materials and Methods 
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2.1 Subjects and Samples 
2.1.1 Subjects 
Samples used in this study were collected from children and adult patients 
undergoing adenoidectomy and/or tonsillectomy due to upper airway obstruction or 
tonsillitis, attending Alder Hey Children’s Hospital and Royal Liverpool and 
Broadgreen University Hospitals. Patients previously vaccinated against influenza or 
who had any known immunodeficiency were excluded from the study. The study 
was approved by the local ethics committee (Liverpool Paediatric Research Ethics 
Committee) and written informed consent was obtained from each patient or their 
legal guardians as appropriate. 
2.1.2 Patient Samples  
2.1.2.1 Adenotonsillar Tissues 
In sterile conditions, adenoids and tonsils were kept in a 25ml universal tube, 
containing 5ml HANK’S balanced salt solution (Sigma Aldrich, UK) supplemented 
with 1% L-glutamine, streptomycin (50μg/ml) and penicillin (50U/ml) (Sigma-
Aldrich). The adenotonsillar tissues were then transported to the laboratory 
immediately.  
 
2.1.2.2 Peripheral Blood  
Peripheral blood samples (obtained from the patients by venous puncture) were 
collected into a 25ml universal tube containing Heparin as an anti-coagulant 
(Heparin 100μl, LEO Pharma, UK). These blood samples were then transported to 
the laboratory immediately. 
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2.2 Mononuclear Cell Isolation 
2.2.1 Adenotonsillar Mononuclear Cells (MNC) 
All cell separation procedures were processed within a class-II Bio-safety cabinet 
and under a negative pressure situation to avoid any probable contamination. 
Mononuclear cells were freshly isolated from adenoids and/or tonsils. To remove 
any blood, adenotonsillar tissues were rinsed with 10 ml HANK’S medium before 
being placed into a sterile Petri-dish. Using a sterile forceps, the tissues were minced 
by a scalpel to release cells into the medium. Then the cell suspension was filtered 
through a 70μm cell strainer (BD biosciences, USA) using a sterile Pasteur pipette. 
The cells were then carefully layered onto 15 ml Ficoll-Paque™ PREMIUM (GE 
Healthcare Life Sciences, UK) and spun at 400g for 30 min at room temperature 
with no brake. After centrifugation, the cloudy layer of mononuclear cells formed at 
the sample/Ficoll-Paque™ interface were carefully harvested using a Pasteur pipette. 
Then MNC were washed twice with sterile PBS solution (Sigma, UK), at 400g for 
10 min with the brake. The pellet was re-suspended in 5 ml RPMI-1640 culture 
medium with HEPES (Sigma-Aldrich, UK) supplemented with 10% heat inactivated 
Foetal Bovine Serum (FBS) (Sigma), 1% L-glutamine (Sigma), streptomycin 
(50μg/ml) and penicillin (50U/ml) (Sigma-Aldrich); and counted in an automated 
cell counter (BioRad, UK). After counting, each cell suspension was adjusted to 
contain 4x10
6
 cells/ml concentrations.  
 
2.2.2 Peripheral Blood Mononuclear Cells (PBMC) 
Peripheral blood mononuclear cells (PBMC) were isolated from sample blood by 
density gradient centrifugation using Ficoll-Paque™ PREMIUM (GE Healthcare 
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Life Sciences, UK). Peripheral blood was carefully layered onto 10 ml Ficoll-
Paque™ PREMIUM (GE Healthcare Life Sciences, UK) and spun at 400g  for 30 
min at room temperature with no brake. After centrifugation, the cloudy layer of 
mononuclear cells formed at the sample/Ficoll-Paque™ interface were carefully 
harvested using a Pasteur pipette. Then PBMC were washed twice with sterile PBS 
solution (Sigma, UK), at 400g for 10 min with the brake. The pellet was re-
suspended in 1 ml RPMI-1640 culture medium with HEPES (Sigma-Aldrich, UK) 
supplemented with 10% heat inactivated FBS (Sigma), 1% L-glutamine (Sigma), 
streptomycin (50μg/ml) and penicillin (50U/ml) (Sigma-Aldrich); and counted in an 
automated cell counter (BioRad, UK). Then further re suspended in culture medium 
and adjusted to 4x10
6
 cells/ml concentrations. 
2.3 Influenza virus antigens and proteins 
2.3.1 Seasonal H1N1 (sH1N1) virus antigen 
The sH1N1 virus antigen used in this study for cell stimulation experiments was 
derived from a seasonal H1N1 (A/Brisbane/59/2007) strain. This influenza antigen 
was β-propiolactone inactivated, partially purified A/Brisbane/59/2007 virus antigen 
containing HA (83µg/ml) from National Institute for Biological Standards and 
Control (NIBSC, UK).  
 
2.3.2 Intranasal Live Attenuated Influenza Vaccine (LAIV)  
Intranasal LAIV (FluMist formula 2009-10) is a live, trivalent intranasal spray 
vaccine that produces the Hemagglutinin (HA) and Neuraminidase (NA) surface 
antigens from a number of influenza viruses including A/Brisbane/59/2007 (H1N1), 
A/Brisbane/10/2007 (H3N2) and B influenza strains. The vaccine viruses are 
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characterized being temperature sensitive, cold adapted and attenuated viruses 
(FluMist, BEI resources ATCC).  
2.3.3 Recombinant HA 
The recombinant HA from a seasonal H1N1 influenza virus (A/Brisbane/59/2007) 
(sH1N1), contains an N-terminal part of HA with histidine Tag and produced in Sf9 
insect cells using a baculovirus expression vector system. This HA was purified from 
cell culture supernatant by conventional chromatographic techniques (Biodefense 
and Emerging Infections Research Resources Repository, BEI Resources, ATCC, 
Manassas VA, USA).  
 
2.3.4 CpG-DNA 
CpG oligodeoxynucleotides (CpG-DNA) are short single-stranded synthetic 
oligonucleotides containing unmethylated Cytosine-Guanine (CpG, where the p 
indicates the phosphodiester bond) dinucleotides also known as CpG motifs. CpG-
DNA is recognized as PAMPs due to their abundance in bacterial DNA compared to 
mammalian DNA. CpG-DNA are recognized by TLR-9 leading to 
immunostimulatory effects. Three types of stimulatory CpG-DNA have been 
suggested based on their immunostimulatory activities named as CpG-DNA type A, 
B and C (Klinman 2006; McCluskie & Davis 1999). In this study type B CpG-DNA 
(5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’ (24 mer) (CpG 2006, InvivoGen, 
USA) was chosen to be examined as a candidate adjuvant. CpG-DNA class B was 
first identified in 1995 by Krieg and colleges (Krieg et al. 1995).  
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2.4 Cell culture and stimulation by LAIV, influenza virus antigen and CpG-
DNA for antibody and IL-21 production 
Adenotonsillar MNC were isolated from adenotonsillar tissues and PBMC were 
isolated from blood as described earlier. The cell suspension was adjusted to contain 
4x10
6
 cells/ml concentrations in RPMI-1640 culture medium with HEPES (Sigma-
Aldrich, UK) supplemented with 10% heat inactivated FBS (Sigma), 1% L-
glutamine (Sigma), streptomycin (50μg/ml) and penicillin (50U/ml) (Sigma-
Aldrich). 500 μl/well of cells were cultured in 48-well flat bottom culture plates 
(Corning Inc., USA) in the presence or absence of different stimulants.  
 
These cells were stimulated with (1μg/ml) sH1N1 antigen alone or in combination 
with (0.1μg/ml) CpG-DNA (InvivoGen, USA) or CpG-DNA alone. Samples were 
also stimulated with (2μl/ml) of LAIV alone. An unstimulated (RPMI culture 
medium) control was included in each experiment. To prevent fungal contamination, 
all cultures and medium used for antibody production throughout was treated with 
2.5μl/ml amphotericin B (Sigma). Cells then were cultured for 24 hours for cytokine 
production and for 14 days for antibody production in a CO2 incubator at 37°C, 5% 
CO2. After that, cell culture supernatants were collected from each well and stored at 
-80°C until further analysis by ELISA. 
2.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
2.5.1 Measurement of HA specific antibodies from cell culture supernatants 
ELISA assay in this study was designed and developed to detect specific HA of 
sH1N1 IgG, IgM and IgA antibodies production in cell culture supernatants using 
the following protocol. Coating solution (2μg/ml) of HA/H1N1 recombinant purified 
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proteins (ATTC) was prepared by adding 20μl of stock HA antigen into 10ml of 
PBS. The HA recombinant purified proteins were tested and optimized to reach 
optimal coating concentration. 
 
2.5.1.1 Measurement of HA-specific IgG antibody 
Using a 96-well flat-bottom, high binding Costar EIA plate (Corning Inc., USA) 
100μl of coating solution was added per well and covered by adhesive seal then 
incubated overnight in 4°C. The following day, plates were washed 5 times with 
PBS containing 0.05% Tween-20 (Sigma-Aldrich) then plates were blotted on a 
paper towel. The plates were then blocked with 150μl/well blocking buffer (10% 
FBS in PBS) for 1 hour at room temperature. In the meantime, samples were 
prepared by diluting them (1:5) in blocking buffer.  Diluted samples (50 μl/well) 
were then added in duplicate to the plate and incubated for 2 hours in room 
temperature.  
 
Plates were then washed 5 times with PBS containing 0.05% Tween-20 and blotted 
on a paper towel. Followed by the addition of 50μl/well of alkaline phosphatase-
conjugated mouse anti-human IgG (1:2000 diluted in blocking buffer) (Sigma). After 
2 hours, plates were washed 5 times with PBS containing 0.05% Tween-20 and then 
blotted on a paper towel. By the end of the last washing cycle, the substrate was 
prepared by dissolving one PNitrophenyl Phosphate (PNPP)  (5mg) tablet into 5ml 
of substrate buffer and then 50μl substrate were added to each well. Then the plates 
were incubated at room temperature and in dark protecting it from direct light for 30 
min. Finally, the Optical Density (OD) at 405 nm was measured using a microtiter 
plate reader (Opsys MR, Thermo labsystems, UK) and data were analysed using 
DeltaSoft software (BioMetallics Inc, NJ). 
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2.5.1.2 Measurement of HA-specific IgM antibody  
Specific HA of H1N1 IgM in cell culture supernatants were also measured by 
ELISA following a procedure similar to specific HA of H1N1 IgG measurement, 
except alkaline phosphatase-conjugated mouse anti-human IgM (1:1000 dilution) 
(Sigma) was used as conjugate.  
 
2.5.1.3 Measurement of HA-specific IgA antibody 
Specific HA of H1N1 IgA in cell culture supernatants were also measured by ELISA 
following a procedure similar to specific HA of H1N1 IgG measurement, except 
alkaline phosphatase-conjugated mouse anti-human IgA (1:1000 dilution) (Sigma) 
was used as conjugate.  
 
2.5.2 Time-course of HA-specific antibody production  
Time-course of antibody production for HA-specific antibodies to sH1N1 in 
adenotonsillar MNC following sH1N1 virus antigen and CpG-DNA stimulation was 
determined. MNC culture supernatants were collected at different time points (1, 4, 
7, 10 and 14 days) following stimulation with sH1N1 virus antigen with or without 
CpG-DNA in 5 patients. Production of HA-specific sH1N1 IgG, IgM and IgA was 
seen to rise 4 days after stimulation with sH1N1 antigen combined with CpG-DNA. 
The time-course of antibody production was shown in (Figure 2.1). The highest level 
of HA-specific sH1N1 IgG, IgM and IgA was observed at day 14 samples. In 
subsequent experiments, cell culture supernatants were collected at day 14 of 
stimulation for measurement of specific HA-specific sH1N1 antibody production by 
ELISA. 
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Figure 2.1. Time course of HA-specific sH1N1 IgG, IgM and IgA production 
Adenotonsillar MNC were stimulated with sH1N1 virus antigen with or without CpG-DNA 
and CpG-DNA alone. Cell culture supernatants were collected at 1, 4, 7, 10 and 14 days and 
analysed for anti-sH1N1 HA IgG (A), IgM (B) and IgA (C) antibody production using 
ELISA. The value represents the mean OD read at 405 nm ± SEM of 5 patient samples. 
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2.6 Enzyme Linked Immuno Spot Assay (ELISpot)  
2.6.1 Principle of the test  
ELISpot assay is a sensitive immunoassay which measures the frequency of 
Antibody Secreting Cells (ASC) at a single-cell level. In this assay, adenotonsillar 
MNC cells were cultured on a solid surface lined with a polyvinylidene difluoride 
(PVDF) and pre-coated with a specific antigen of interest. Secreted antibodies which 
are produced by B lymphocytes will be captured by the specific antigen on the 
surface. These secreted antibodies are detected using a similar procedure like ELISA 
by using a secondary antibody-enzyme conjugate and its reaction with the substrate, 
resulting in the development of visible spots on the surface where each spot 
represents an ASC. In this study, ELISpot assay was used to measure the frequencies 
of antibody-producing cells specific to HA of sH1N1 (A/Brisbane/59/2007).   
 
2.6.2 Culture of adenotonsillar MNC  
Adenotonsillar MNC cells were resuspended in RPMI-1640 medium (4x10
6
/ml) and 
stimulated with (1μg/ml) sH1N1 (A/Brisbane/59/2007) (NIBSC, UK) antigen alone 
or in combination with (0.1μg/ml) CpG-DNA (InvivoGen, USA) and CpG-DNA 
alone. Samples were also stimulated with (2μl/ml) of LAIV alone. An unstimulated 
control (RPMI culture medium) was included in each experiment. The cells were 
incubated in a 24-well cell culture plate (Corning Inc., USA) at 37°C, in 5% CO2 for 
5 days. Thereafter, the cells were harvested and washed with sterile PBS with 1% 
BSA followed by centrifugation at 400xg for 10 min. The pellets were then 
resuspended in RPMI-1640 medium to a final cell concentration of 4x10
6
/ml. 
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2.6.3 Antigen coating of ELISpot plate 
A filtered 96-well ELISpot plate (Millipore, UK) was coated on the day before cell 
harvesting. Immediately before coating, the wells were pre-wetted with 15μl of 35% 
ethanol for 1 min, then washed 3 times with 150μl of PBS containing 0.05% Tween-
20. For detecting sH1N1-HA specific memory B cells, the ELISpot plate was coated 
with (2μg/ml) of HA/sH1N1 (A/Brisbane/59/2007) recombinant purified proteins 
(ATTC, Manassas VA, USA) and incubated overnight at 4°C. For enumeration of 
total IgG spots as positive controls, some wells were also coated with a Fab specific 
anti-human IgG (Sigma) antibody in 1:1000 dilutions.  
 
2.6.4 Incubation of cells in the ELISpot plate  
On the following morning, the plate was washed 3 times with PBS containing 0.05% 
Tween-20. Then the plate was blocked with 150μl of RPMI-1640 media 
supplemented with 10% FBS for an hour at room temperature. In the meantime, 
adenotonsillar MNC were harvested from the incubation as described earlier. 100μl 
of cell suspension was added into each of the designated wells in triplicate. Cell 
concentration used for different antigens were: 4x10
6
/ml for antigen and 4x10
5
/ml 
for total IgG. RPMI-1640 media with no cells was added into the wells designated as 
negative controls (at least one well for each antigen). The plate was then incubated 
overnight at 37°C in 5% CO2 incubator. 
 
2.6.5 ELISpot assay procedure  
The following day, the plate was washed 3 times with PBS containing 0.05% 
Tween-20 and 50μl of goat anti-human IgG (H+L) biotin (1:2,000 dilutions) 
(Invitrogen, USA) was added to the appropriate wells. After 30 min incubation in 
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room temperature, the plate was washed 3 times with PBS containing 0.05% Tween-
20, followed by the addition of 50μl of Horseradish peroxidase Avidin D conjugate 
(1:10,000 dilutions) (Vector laboratories Inc., USA). After 30 min incubation in 
room temperature, the plate was washed 3 times with PBS containing 0.05% Tween-
20. During the last washing cycle, the substrate was prepared by adding 0.5 ml 3-
amino-9 ethylcarbazole into 9.5 ml acetate buffer and addition of 25μl H2O2 
immediately before use (Sigma-Aldrich). After adding freshly prepared AEC 
substrate (50μl/well), the plate was incubated in dark for 15-20 min at room 
temperature. The reaction was stopped by washing the plate with running cold tap 
water. Finally, the plate was blotted gently with adsorbent paper to remove the 
excess water and allowed to dry for 2-3 hours in room temperature.  
 
2.6.6 Counting of ELISpots  
The spots were imaged by Chemi-doc XRS system, and analysed with NIST’s 
Integrated Colony Enumerator software (Version 1.2.1, National Institute of 
Standards and Technology, USA). The result was expressed as number of 
ASC/million of lymphocytes. For antigen-specific HA/sH1N1 ASC, the average spot 
counts were multiplied by 2.5 to get this result. This calculation was obtained by 
dividing 1x10
6
 (one million) by 4x10
5
 that was the number of cells in 100μl of 
(4x10
6
) cell suspension, which was put into each well. For total IgG, the result was 
obtained by multiplying the spot counts with 50. 
2.7 Measurement of IL-21 in cell culture supernatants 
In vitro IL-21 production in adenotonsillar MNC and PBMC cultures was measured 
with human IL-21 ELISA Ready-Set-Go® set (eBioscience, UK), following 
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manufacturer’s instructions. 96-well flat-bottom, high binding Costar EIA plate 
(Corning Inc., USA) were coated with the capture antibody which was prepared by 
adding 48μl of purified anti-human IL-21 into 12ml coating buffer (1:250 dilutions). 
100μl of the capture antibody solution was added into each well of the plates and 
incubated overnight at 4°C. In the following day, the plate was washed 5 times with 
PBS containing 0.05% Tween-20 (Sigma-Aldrich) then blotted on a paper towel.  
 
The plate was then blocked with 1x assay diluent (200μl/well) for 1 hour at room 
temperature. Then the plate was washed 5 times with PBS containing 0.05% Tween-
20.  In the meantime, standards and samples were prepared by diluting them in 1x 
assay diluent. For standards, the top concentration (1000pg/ml) was prepared by 
adding 10μl of human IL-21 recombinant protein into 10ml of 1x assay diluent. The 
samples from cell culture supernatants were prepared by diluting them 1:10 in 1x 
assay diluent. Then, 100μl/well of standards and samples were added to the 
appropriate wells. A total of 8 standards were prepared by 2-fold serial dilutions 
from the top standard (1000pg/ml). For maximal sensitivity, the plates were then 
incubated overnight at 4°C.  
 
In the following morning, the plate was washed 5 times with PBS containing 0.05% 
Tween-20. In the meantime, detection antibody was prepared by adding 48μl of 
purified anti-human IL-21 Biotin into 12ml 1x assay diluent (1:250 dilutions). After 
that, 100μl of detection antibody was added to each well. Following 1 hour 
incubation in room temperature, the plate was washed 5 times with PBS containing 
0.05% Tween-20. Thereafter, 100μl of Avidin-HRP (diluted 1:250) was added to 
each well; and incubated at for 30 min at room temperature. After washing 7 times 
with PBS containing 0.05% Tween-20, 100μl of TMB substrate solution was added 
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to each well, and incubated for 15 min at room temperature in dark. The reaction was 
then stopped by adding 50μl of stop solution (1M H2SO4) to each well. Finally, the 
plate was read at 450nm, and the concentration (pg/ml) of each sample was 
calculated against the standard curve, with the help of DeltaSoft software 
(BioMetallics Inc, NJ). 
2.8 Flow Cytometric Analysis of Cells  
2.8.1 Principle of the test  
Flow cytometry is widely used as an important tool in both diagnostic and research 
laboratories. This device is able to analyse the physical and optical features of the 
fluorochrome-labelled cells passing through a focused laser beam. In this process, 
cells passing through the laser beam will scatter light; resulting in what is known as 
forward scatter (FSC) and side scatter (SSC). FSC is usually used as an indicator of 
the cell size allowing the differentiation of different cell types such as erythrocytes 
from lymphocytes and monocytes. The FSC is also been used to distinguish dead 
cells with low FSC distribution from the viable cells.  
 
On the other hand, SSC is an indicator of cells density and internal complexity or 
granularity, distributing the more granular cells to be more scattered. A combination 
of FSC and SSC characteristically distribute different subsets of cells in sample 
containing a mixed population such as blood, bone marrow, spleen, adenotonsillar, 
and LN single cell preparations. 
  
In this study, a BD FACS Calibur (BD Biosciences) has been used to carry out flow 
cytometry analyses. Different lymphocyte subsets were defined and characterized 
using multiple parameters, including FSC and SSC based gating. Fluorescence 
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emissions of different fluorochromes were measured at different wavelengths; FL1 
was used for FITC and Alexafluor488 at 519nm, FL2 for PE at 578nm, FL3 for 
PerCPCy5.5, PECy5 and PECy7 at 695nm and FL4 for APC at 660nm. The data 
were acquired using Cell Quest software (BD Biosciences) and analysed with 
WinMDI 2.9 software.  
 
2.8.2 Cell culture and stimulation by influenza virus antigen, LAIV and CpG-
DNA for FACS analysis 
Adenotonsillar MNC were isolated from adenotonsillar tissues and PBMC were 
isolated from blood as described earlier. The cell suspension was adjusted to contain 
4x10
6
 cells/ml concentrations in RPMI-1640 culture medium with HEPES (Sigma-
Aldrich, UK) supplemented with 10% heat inactivated FBS (Sigma), 1% L-
glutamine (Sigma), streptomycin (50μg/ml) and penicillin (50U/ml) (Sigma-
Aldrich). 500 μl/well of cells were cultured in 48-well flat bottom culture plates 
(Corning Inc., USA) in the presence or absence of different stimulants. These cells 
were stimulated with (1μg/ml) sH1N1 antigen alone or in combination with 
(0.1μg/ml) CpG-DNA (InvivoGen, USA) and CpG-DNA alone. Samples were also 
stimulated with (2μl/ml) of LAIV alone. An unstimulated (RPMI culture medium) 
control was included in each experiment. Unfractionated adenotonsillar MNC were 
cultured for 3 days and CD45RO
+
 cell-depleted adenotonsillar MNC were cultured 
for 7 days in a CO2 incubator at 37°C, 5% CO2. After that, cells were harvested for 
staining.  
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2.8.3 Cell staining for surface phenotyping for FACS analysis 
Adenotonsillar MNC and PBMC were harvested and washed twice with 0.02% 
BSA-PBS buffer (Sigma-Aldrich), by centrifuging at 400xg for 5 min. The pellets 
were resuspended in 50μl of 0.02% BSA-PBS and fluorochrome-labelled anti-human 
antibodies were added depending on the phenotype. Anti-human antibodies used for 
flow cytometric analysis are described in the table below (Table 2.1). For TFH cell 
identification, adenotonsillar MNC and PBMC were stained with anti-human-CD3, -
CD4, -CXCR5 and -ICOS antibodies. In some samples, PD-1 and CCR7 were also 
stained to confirm the TFH cell phenotype. For GC B cells identification, 
adenotonsillar MNC were stained with anti-human-CD19, -CD38 and -IgD 
antibodies. For pDC staining, purified pDC were stained with anti-human-CD123 
and -CD85g (ILT7), a unique marker for pDC and not found on other DC types (Cho 
et al. 2008). All cell staining was performed in Falcon 5ml round bottom tubes (BD 
bioscience). Cells were kept at room temperature for 30 minutes in the dark then 
washed twice with 2ml of 0.02% BSA-PBS (500xg for 8 min) to remove unbound 
antibodies. Finally, the pellets were resuspended in 300μl of 0.02% BSA-PBS; and 
immediately acquired/analysed in the BD FACS Calibur (BD bioscience) or fixed 
and permeabilized if needed for intracellular staining. 
 
 
 
 
 
 
 
 60 | P a g e  
 
 
 
 
Antibody Fluorochrome Clone Species and 
Isotype 
Company 
CD3 APC HIT3a Mouse IgG2a BD Biosciences 
CD4 PE RPA-T4 Mouse IgG1 BD Bioscience 
CD4 PE-Cy5 RPA-T4 Mouse IgG1 BD Bioscience 
CD4 PE-Cy7 SK3 Mouse IgG1 BD Bioscience 
CD19 PE HIB19 Mouse IgG1 BD Bioscience 
CD19 FITC HIB19 Mouse IgG1 BD Bioscience 
CD38 PE H1T2 Mouse IgG1 BD Bioscience 
CD45RO FITC UCHL1  Mouse IgG2a BD Bioscience 
CD45RA PE HI100  Mouse IgG2b BD Bioscience 
CD85g (ILT7) PE 17G10.2 Mouse IgG1 eBioscience 
CD123 PE-Cy5 9F5 Mouse IgG1 BD Bioscience 
CXCR5 Alexa Fluor® 488 RF8B2 Rat IgG2b BD Bioscience 
CXCR5 PE MU5UBEE Mouse IgG2a eBioscience 
CXCR5 Biotin RF8B2 Rat IgG2b BD Bioscience 
CXCR5 FITC 51505 Mouse IgG2b R&D Systems 
PD1 PE MIH4 Mouse IgG1 BD Bioscience 
ICOS APC ISA-3 Mouse IgG1 eBioscience 
ICOS PE DX29 Mouse IgG1 BD Bioscience 
BCL6 PE K112-91 Mouse IgG1 BD Bioscience 
IL-4 PE 8D4-8  Mouse IgG1 BD Bioscience 
IL-10 PE JES3-9D7 Rat IgG1 eBioscience 
IL-21 APC 3A3-N2 Mouse IgG1 Biolegend 
IL-21 PE 3A3-N2 Mouse IgG1 eBioscience 
IgD PE-Cy7 IA6-2 Mouse IgG2a BD Bioscience 
TLR9 PE Eb72-1665 Rat IgG2a eBioscience 
CCR7 FITC 3D12 Rat IgG2a BD Biosciences 
Table 2.1. Antibodies used for flow cytometry 
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2.9 T cell Proliferation Assay  
2.9.1 Labelling of adenotonsillar MNC with CFSE  
Adenotonsillar MNC were washed with PBS and pelleted at 400xg for 10 min and 
the cell pellet was dissolved in 3ml sterile PBS. Just before use, a working 
concentration of CFSE was prepared by adding 5μl of CFSE stock solution (5μM, 
stored at -20°C) to 10ml of sterile PBS. Next, 3 ml of this CFSE solution (50μM) 
was added to the cell suspension and mixed by vortexing thoroughly. After 
incubating for 8 min at 37°C, 15ml of ice-cold RPMI-1640 media was added. Then, 
cells were spun at 400xg for 10 min; and the pellet was dissolved in RPMI-1640 
culture medium with HEPES (Sigma-Aldrich, UK) supplemented with 10% heat 
inactivated FBS (Sigma), 1% L-glutamine (Sigma), streptomycin (50μg/ml) and 
penicillin (50U/ml) (Sigma-Aldrich).   
 
Cells were then adjusted to 4x10
6
cells/ml suspensions. 500μl of these cell 
suspensions was stimulated with (1μg/ml) sH1N1 antigen alone or in combination 
with (0.1μg/ml) CpG-DNA (InvivoGen, USA) and CpG-DNA alone. Samples were 
also stimulated with (2μl/ml) of LAIV alone. An unstimulated (RPMI culture 
medium) control was included in each experiment and a positive control stimulated 
with 0.1μg/ml Staphylococcal enterotoxin B (SEB) (Sigma). The cells were then 
added into a 96-well cell culture plate (Corning); and incubated at 37°C in 5% CO2 
for 5 days. After incubation, cells were harvested for T cell proliferation assay and 
analysed by flow cytometry using a BD FACS Calibur (BD bioscience). 
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2.9.2 Staining of the CFSE labelled cells for FACS analysis  
At the end of incubation, the cells were harvested and washed with 0.02% BSA-PBS 
buffer (Sigma-Aldrich), by centrifuging at 500xg for 8 min. The pellets were 
resuspended in 50μl of 0.02% BSA-PBS and anti-Human CD4-PE-Cy5 (BD 
bioscience), anti-Human CXCR5-PE (eBbioscience) and anti-Human ICOS-APC 
(eBbioscience) were added to stain CD4
+
 CXCR5
hi
 ICOS
hi
 cells (TFH cells). After 
incubated in dark at 4°C for 30 min, the tubes were washed (500xg for 8 min) with 
1ml of 0.02% BSA-PBS. The pellets were resuspended in 300μl of 0.02% BSA-
PBS; and immediately acquired/analysed in the BD FACS Calibur (BD bioscience). 
TFH cell proliferation index was examined by gating from TFH cells (CXCR5
hi
 
ICOS
hi
 cells).  
2.10 Intracellular staining for BCL-6, TLR-9 and cytokines 
2.10.1 Cell stimulation  
Cell suspension (4x10
6
/ml) were cultured in 48-well flat bottom culture plates (500 
μl/well) (Corning Inc., USA) in the presence or absence of different stimulants. 
These cells were stimulated with (1μg/ml) sH1N1 antigen alone or in combination 
with (0.1μg/ml) CpG-DNA (InvivoGen, USA) and CpG-DNA alone. Samples were 
also stimulated with (2μl/ml) of LAIV alone. For cytokine analysis, stimulated cells 
were incubated for overnight; thereafter, 10µg/ml brefeldin A (Sigma) was added to 
each well and further incubated for 4 hours at 37°C in 5% CO2. Cells in one well 
was also stimulated with Ionomycin (1μg/ml) and PMA (20ng/ml) for the last 4 
hours as a positive control.  After that, cells were harvested for staining and cell 
culture supernatants were collected from each well and stored at -80°C until further 
analysis by ELISA.  
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2.10.2 Intracellular cytokine and BCL-6 staining  
For BCL-6 analysis, either freshly isolated cells or stimulated cells incubated for 3 
days (unfractionated) and 7 days (for CD45RO
+
 cell-depleted adenotonsillar MNC) 
were used for staining. For cytokine analysis, either freshly isolated cells or 
stimulated cells incubated for overnight were used for staining. Cells were harvested 
and washed twice with FACS staining buffer (0.02% PBS-BSA) (500xg for 5 min). 
Firstly, cells were stained for surface markers such as CD4, CXCR5 and ICOS in a 
same procedure described earlier. Thereafter, cells were washed (500xg for 5 min) 
and the pellets were resuspended and fixed with 100µl intracellular fixation buffer 
(eBioscience). After incubation in dark at room temperature for 20 min, cells were 
washed twice with 2 ml 1x permeambilization buffer (eBioscience) (500xg for 5 
min); and the pellets were resuspended with 100µl of 1x permeambilization buffer 
(eBioscience). Then the proper amount of fluorochrome-labeled antibody (see Table 
2.1) was added to each samples; and incubated in the dark at room temperature for 
30 min. After that, 2ml of 1x permeambilization buffer was added to each tube. After 
washing twice (500xg for 5 min), the stained cells were resuspended in 400μl of 
FACS staining buffer; and immediately acquired/analysed by flow cytometry. 
 
2.10.3 Intracellular TLR-9 staining  
Freshly purified TFH cells, non-TFH cells, B cells and pDC were harvested and 
washed twice with FACS staining buffer (0.02% PBS-BSA) by centrifugation 
(500xg for 5 min). Cells were then stained for surface staining markers in a same 
procedure described earlier. Thereafter, the cells were washed (500xg for 5 min) and 
the pellets were resuspended and fixed with 100µl intracellular fixation buffer 
(eBioscience). After incubation in dark at room temperature for 20 min, cells were 
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washed twice with 2 ml 1x permeabilization buffer (eBioscience) (500xg for 5 min); 
and the pellets were resuspended with 100µl of 1x permeambilization buffer 
(eBioscience). Then 2µg/ml of anti-human-TLR9-PE (eBioscience) was added to 
each samples; and incubated in the dark at room temperature for 30 min. After that, 
2ml of 1x permeabilization buffer was added to each tube. After washing twice 
(500xg for 5 min), the stained cells were resuspended in 400μl of FACS staining 
buffer; and immediately analysed by flow cytometry. 
2.11 Anti-IL-21R blocking experiments  
Adenotonsillar MNC were isolated from adenotonsillar tissues as described earlier. 
The cell suspension was adjusted to contain 4x10
5
 cells/ml concentrations 
supplemented with 10% heat inactivated FBS (Sigma), 1% L-glutamine (Sigma), 
streptomycin (50μg/ml) and penicillin (50U/ml). Cells were cultured (250 μl/well) in 
96-well round bottom plate (Corning Inc., USA) in the presence or absence of 
different stimulants with or without the recombinant human anti-IL-21R Fc blocking 
antibody (α-IL-21R) (R&D systems, UK). Firstly, 10μg/ml α-IL-21R was added to 
the allocated wells and incubated for 1 hour at 37°C in a 5% CO2 incubator.  These 
cells were then stimulated with (0.5μg/ml) sH1N1 antigen in combination with 
(0.05μg/ml) CpG-DNA (InvivoGen, USA). In some experiments, cells were also 
stimulated with (0.5μl/ml) of LAIV. An unstimulated medium control was included 
in each experiment. Cells were then cultured at 37°C, 5% CO2, for 3 days for TFH cell 
measurement by FACS and 10 days for antibody production. After 3 days, cells were 
harvested and washed twice with FACS staining buffer (0.02% PBS-BSA) by 
centrifugation (500xg for 5 min). Next, cells were stained for surface staining 
markers such as CD4, CXCR5 and ICOS in a same procedure described earlier. 
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Furthermore, after 10 days incubation, cell culture supernatants were collected from 
each well and stored at -80°C until further analysis by ELISA to measure the HA-
specific IgM and IgA antibodies to sH1N1 virus. 
2.12 CD45RO+ cell-depleted adenotonsillar MNC 
To evaluate the proliferative and cytokine production response of CD45RO
-
 naïve T 
cells, effector and memory (CD45RO
+
) T cells were depleted from the adenotonsillar 
MNC with the help of magnetic beads (Miltenyi Biotech, Germany), magnetic 
column (Miltenyi Biotech), and a MACS magnet (Miltenyi Biotech).  
 
2.12.1 Principle of the MACS separation  
Firstly, the cells to be depleted (CD45RO
+
) are labelled with the specific magnetic 
micro-beads labelled with anti-CD45RO antibody. Thereafter, the cell suspension is 
allowed to pass through a MACS LD column, placed within the magnetic field of a 
MACS separator. The magnetically labelled cells (CD45RO
+ 
cells) are retained 
within the column, and the unlabelled cells (CD45RO
- 
cells) pass through the 
column and collected in a tube placed underneath it. This process is known as 
negative selection.  
 
2.12.2 Magnetic labelling and depletion  
Approximately, 50x10
6
 cells/ml adenotonsillar MNC were resuspended in 400μl 
(80μl/107cells) of cold MACS depletion buffer (0.5% BSA in PBS); and 100μl 
(20μl/107cells) of CD45RO magnetic beads (Miltenyi Biotech) was added into them. 
After incubation for 15 min at 4˚C, cells were washed with 10ml of MACS depletion 
buffer (400xg for 10 min). The cell pellet was resuspended in 250μl (50μl/107cells) 
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of MACS depletion buffer; and magnetic separation was carried out in a class-II bio-
safety cabinet. The MACS LD column (Miltenyi Biotech) was placed in the 
magnetic field of MACS Separator and rinsed with 3 ml of MACS depletion buffer. 
Then the cell suspension was added to the column and allowed to pass through. The 
naive (CD45RO
+
 depleted) T cells obtained by this process were collected in a new 
tube (purity >98%) then resuspended into RPMI medium to a concentration of 
4x10
6
cells/ml. The depletion of CD45RO
+
 cells in adenotonsillar MNC removed the 
majority of TFH cells. 
2.13 Cell sorting for co‐culture experiments 
For co-culture experiments, cells were isolated by magnetic cell sorting using 
EasySep™ magnetic technology (STEMCELL Technologies Inc.). Adenotonsillar B 
cells were purified by negative selection using EasySep™ human B cell enrichment 
kit (purity 99%). Adenotonsillar CD4
+
 T cells were also purified by negative 
selection using EasySep™ human CD4+ T cell enrichment kit (purity >98%) 
followed by the isolation of CD4
+
 CXCR5
hi
 cells by positive selection using biotin 
anti-human CXCR5 antibody (BD bioscience) and EasySep™ biotin selection kit 
(STEMCELL Technologies Inc.) (purity >90%). Adenotonsillar Plasmacytoid DC 
(pDC) were also negatively selected using EasySep™ human plasmacytoid DC 
enrichment kit (purity 96%) as described below.  
 
2.13.1 Isolation of B cells from adenotonsillar MNC 
Using sterile 5ml round bottom tubes (BD bioscience), 50x10
6
 cells/ml of freshly 
isolated adenotonsillar MNC were resuspended in 1ml of EasySep™ buffer 
(STEMCELL Technologies Inc.). Then, 50μl/ml of EasySep™ human B cell 
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enrichment cocktail were added to the cells. After incubating for 10 min in room 
temperature, 75μl/ml of EasySep™ D magnetic particles were added to the mixture 
and incubated for 5 min at room temperature. To ensure that the magnetic particles 
were in a uniform suspension with no visible aggregates they were vortexed for 30 
seconds. After that, 1ml of EasySep™ buffer was added to the tube and gently mixed 
by pipetting up and down 2-3 times. The tube was then placed into the EasySep™ 
magnet (STEMCELL Technologies Inc.) and incubated for 5 min in room 
temperature. Finally, the EasySep™ magnet with the tube inserted in it was picked 
up carefully and in one continuous motion inverted to pour off the desired fraction of 
B cells into a new 5ml round bottom tube (BD bioscience). The isolated B cells 
(99% purity) in the new tube are now ready to be used for the co-culture experiments 
and the magnetically labelled unwanted cells remained bounded inside the original 
tube, held by the magnetic field from the EasySep™ magnet. (Figure 2.2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Flow cytometric purity analysis of isolated B cells 
B cells were purified from freshly isolated adenotonsillar MNC using the EasySep™ 
magnetic cell sorting system resulting in 99% purity. 
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2.13.2 Isolation of CD4+ T cells from adenotonsillar MNC  
Using sterile 5ml round bottom tubes, 50x10
6
 cells/ml of freshly isolated 
adenotonsillar MNC were resuspended in 1ml of EasySep™ buffer. Then, 50μl/ml of 
EasySep™ human CD4+ T cell enrichment cocktail were added to the cells. After 
incubating for 10 min in room temperature, 100μl/ml of EasySep™ D magnetic 
particles were added to the mixture and incubated for 5 min at room temperature. To 
ensure that the magnetic particles were in a uniform suspension with no visible 
aggregates they were vortexed for 30 seconds. After that, 1ml of EasySep™ buffer 
was added to the tube and gently mixed by pipetting up and down 2-3 times. The 
tube was then placed into the EasySep™ magnet and incubated for 5 min in room 
temperature. Finally, the EasySep™ magnet with the tube inserted in it was picked 
up carefully and in one continuous motion inverted to pour off the desired fraction of 
CD4
+
 T cells into a new 5ml round bottom tube. The isolated CD4
+ 
T cells (98.5% 
purity) in the new tube are now ready for the CXCR5 isolation and the magnetically 
labelled unwanted cells remained bounded inside the original tube, held by the 
magnetic field from the EasySep™ magnet. (Figure 2.3) 
 
 
 
 
 
 
 
 
Figure 2.3. Flow cytometric purity analysis of isolated adenotonsillar CD4
+
 T cells 
CD4
+
 T cells were purified from freshly isolated adenotonsillar MNC using the EasySep™ 
magnetic cell sorting system resulting in 98.5% purity.  
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2.13.3 Isolation of TFH cells (CD4
+ 
CXCR5
hi
)
 
from adenotonsillar MNC  
Using sterile 5ml round bottom tubes (BD bioscience), 50x10
6
 cells/ml of purified 
CD4
+
 T cells were resuspended in 400μl of EasySep™ buffer. For TFH cells (CD4
+ 
CXCR5
hi
) purification, CD4
+
 T cells were first labelled with biotin anti-human 
CXCR5 antibody (10μl/106) by incubation at room temperature for 30 min. The cells 
were washed with 2ml EasySep™ buffer and pelleted by 500xg for 5 min. Cell pellet 
was then resuspended in 1ml EasySep™ buffer and 50μl/ml of EasySep™ biotin 
selection cocktail were added to the cells. After incubating for 15 min in room 
temperature, 50μl/ml of EasySep™ magnetic nanoparticles were added to the 
mixture and incubated for 10 min at room temperature. After that, 2ml of EasySep™ 
buffer was added to the tube and gently mixed by pipetting up and down 2-3 times. 
The tube was then placed into the EasySep™ magnet and incubated for 5 min in 
room temperature. Then, the EasySep™ magnet with the tube inserted in it was 
picked up carefully and in one continuous motion inverted to pour off the negative 
unwanted cells. The isolated CD4
+
 CXCR5
hi
 T cells (TFH cells) are the magnetically 
labelled cells and remained bound inside the original tube, held by the magnetic field 
from the EasySep™ magnet. To increase the purity of TFH cells, the final step was 
repeated three more times by adding 2 ml EasySep™ buffer to the tube and placing 
them in the EasySep™ magnet for 5 min and discarding the unwanted fraction. For 
non-TFH cells (CD4
+ 
CXCR5
-
 T cells) purification, the same procedure was used, 
however, higher concentration of biotin anti-human CXCR5 antibody (20μl/106), 
biotin selection cocktail (100μl/ml) and magnetic nanoparticles (100μl/ml) were used 
to remove all CXCR5
+
 cells (CXCR5
int.
 and CXCR5
hi
).  Finally, the negatively 
selected cells (CD4
+ 
CXCR5
-
 T cells) were collected into a new 5ml round bottom 
tube.  (Figure 2.4) 
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Figure 2.4. Flow cytometric purity analysis of isolated TFH cells and non-TFH cells 
TFH cells (CD4
+
CXCR5
hi
 T cells) and non-TFH cells (CD4
+
CXCR5
-
 T cells) were purified from 
freshly isolated CD4
+
 T cell population using the EasySep™ magnetic cell sorting system. 
CXCR5
hi
 TFH cells (A) were positively selected using optimised amount of magnetic beads 
(>90% purity).  CXCR5
-
 Non-TFH cells (B) were negatively selected using optimised quantity of 
magnetic beads (98.5% purity). (C) Representative phenotypic histogram analysis of purified TFH 
cells (red line) and non-TFH cells (blue line), showing the difference in expression of TFH cells 
associated markers: CXCR5, ICOS, PD-1, BCL-6 and CCR7.  
 
 
C 
A 
B 
 71 | P a g e  
 
2.13.4 Isolation of Plasmacytoid DC cells (pDC) from adenotonsillar MNC  
Using sterile 5ml round bottom tubes (BD bioscience), 50x10
6
 cells/ml of freshly 
isolated adenotonsillar MNC were resuspended in 1ml of EasySep™ buffer 
(STEMCELL Technologies Inc.). Then, 50μl/ml of EasySep™ human Plasmacytoid 
DC enrichment cocktail (STEMCELL Technologies Inc.) were added to the cells and 
incubated for 30 min in room temperature. Next, 200μl/ml of EasySep™ D magnetic 
particles (STEMCELL Technologies Inc.) were added to the mixture and incubated 
for 10 min at room temperature. To ensure that the magnetic particles were in a 
uniform suspension with no visible aggregates they were vortexed for 30 seconds. 
After that, 1ml of EasySep™ buffer was added to the tube and gently mixed by 
pipetting up and down 2-3 times. The tube was then placed into the EasySep™ 
magnet (STEMCELL Technologies Inc.) and incubated for 5 min in room 
temperature. Then, the EasySep™ magnet with the tube inserted in it was picked up 
carefully and in one continuous motion inverted to pour off the desired fraction of 
pDC into a new 5ml tube (BD bioscience).   
 
To increase pDC purity, the new 5ml tube containing the negatively selected pDC 
was placed in the EasySep™ magnet once more after adding 2ml of EasySep™ 
buffer then incubated for 5 min. Finally, the purified pDC was poured from the tube 
by picking up the EasySep™ magnet and inverting it in a new 5ml tube (BD 
bioscience). The isolated pDCs in the new tube are now ready for use and the 
magnetically labelled unwanted cells remained bounded inside the original tube, held 
by the magnetic field from the EasySep™ magnet. (Figure 2.5) 
 
 72 | P a g e  
 
  
Figure 2.5. Flow cytometric purity analysis of isolated adenotonsillar pDC 
Purity of pDC preparations as determined by flow cytometry. Representative density plot for 
freshly isolated adenotonsillar MNC before and after sorting purified pDC. pDC were 
purified from freshly isolated adenotonsillar MNC using the EasySep™ magnetic cell 
sorting system resulting in 96% purity. CD123 and CD85g (ILT7) were used to identify 
pDC.  
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2.14 B cell help by TFH cells  
The ability of adenotonsillar TFH cells to help B cell antibody production was studied 
using an autologous cell culture system as follows. Adenotonsillar MNC were 
isolated from adenotonsillar tissues. All three cell types B cells, TFH cells and non-
TFH cells were purified from adenotonsillar MNC of the same donor as described 
earlier. In co-culture experiments, B cells were cultured with an equal number of 
either TFH cells or non-TFH cells at a ratio of 1:1 using a cell concentration of 5x10
5
 
cells/ml. B:T co-culture cells (250 μl/well) were cultured in 96-well round bottom 
plate (Corning Inc., USA) in the presence or absence of different stimulants. These 
cells were stimulated with (0.5μg/ml) sH1N1 antigen in combination with 
(0.05μg/ml) CpG-DNA or stimulated with (0.5μl/ml) of LAIV. An unstimulated 
medium control was included in each experiment. To prevent fungal contamination, 
all cultures and medium used throughout was treated with 2.5μl/ml amphotericin B 
(Sigma). Cells were then cultured at 37°C, 5% CO2, for 1 day for cytokine 
measurement and 10 days for antibody production. After incubation, cell culture 
supernatants were collected from each well and stored at -80°C until further analysis 
by ELISA.  
2.15 Assessment of effect of pDC   
B cells, TFH cells and pDC were purified from adenotonsillar MNC of the same 
donor as described earlier. In co-culture experiments, B cells were cultured with an 
equal number of TFH cells at a ratio of 1:1 using a cell concentration of 5x10
5
 
cells/ml with or without purified pDC. Purified pDC were then added to this mixture 
using a concentration of 5x10
4
 cells/ml. B cells + TFH cells + pDC co-culture cells 
(250 μl/well) were cultured in 96-well round bottom plate (Corning Inc., USA) in 
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medium alone or in the presence or absence of different stimulants. These cells 
where stimulated with (0.5μg/ml) sH1N1 antigen in combination with (0.05μg/ml) 
CpG-DNA (InvivoGen, USA). An unstimulated medium control was included in 
each experiment. To prevent fungal contamination, all cultures and medium used 
throughout was treated with 2.5μl/ml amphotericin B (Sigma). Cells were then 
cultured at 37°C, 5% CO2, for 10 days for antibody production. After incubation, cell 
culture supernatants were collected from each well and stored at -80°C until further 
analysis by ELISA. 
2.16 Health and safety 
All practical work was undertaken in Liverpool University laboratories. All 
chemicals and reagents used were COSHH assessed. Reagents were prepared, stored 
and disposed correctly according to the departmental policy and appropriate 
protective clothing was worn.  
2.17 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5 software (GraphPad 
Software, San Diego, CA, USA). Firstly, data were analysed using the normality test 
to assess if distribution of data points was normal.  Differences between two groups 
(i.e., children and adults) were analysed by two-tailed un-paired Student’s t test 
(parametric). Differences between stimulated and unstimulated samples in the same 
group of subjects were analysed by paired t test (parametric). Correlation between 
two factors was analysed by Pearson’s (parametric) correlation test. Throughout the 
thesis, * indicates a P-value between 0.01-0.05, ** indicates a P-value between 
0.001-0.01 and *** indicates a P-value <0.001.  
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Chapter 3 
 
 
Characterisation of TFH cells in 
human NALT and PBMC 
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3.1 Introduction 
TFH cells in humans have recently been identified as a new T helper subset. Within 
secondary lymphoid organs, TFH cells are specialized to regulate the development of 
effector and memory B cells and long-lived plasma cells. These cells were first 
described by several research groups as a unique CD4 T cell phenotype expressing 
high levels of CXCR5 in tonsils (Breitfeld et al. 2000; Kim et al. 2001).  Loss of 
chemokine receptor CCR7 and high expression of CXCR5 play a major role to drive 
TFH cells migration into B cell follicles in secondary lymphoid tissue, in a CXCL13-
dependent manner (Choi et al. 2011; Fazilleau et al. 2009).  
 
It is known that T cell help to B cells is an essential process for antibody-mediated 
adaptive immunity. The first interaction between TFH cells and B cells happens at the 
T-B cell border leading to B cell differentiation and GC formation within the follicle 
(Choi et al. 2011). In secondary lymphoid tissue, high expression of the 
costimulatory molecules including: CD40L, OX40 and ICOS, as well as the 
inhibitory molecule PD-1 are major players in modifying antigen specific contact of 
TFH cells to B cells expressing peptide MHC-II, CD40, OX40L, ICOSL and PDL-1 
(Fazilleau et al. 2009; Kassiotis & O'Garra 2009).  
 
TFH cells have been established as a distinct T helper subset based on a set of cell 
surface markers and cytokine profile. In addition to CD4 and CXCR5, TFH cells 
express high levels of ICOS, PD-1, BCL-6, IL-21R, OX40, CD40L and GL7 
(Kerfoot et al. 2011; King 2009; Laurent, Fazilleau & Brousset 2010). Other markers 
have also been reported in humans including CD25, CD69, CD95 and CD57 
(Laurent, Fazilleau & Brousset 2010).  
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A number of cytokines are produced by TFH cells that have major roles in B cell 
function and antibody production, such as IL-4, IL-10 and IL-21 (King 2009). Most 
recently, BCL-6 has been identified as the master regulatory transcription factor 
which controls TFH cell differentiation. The up-regulation of BCL-6 in TFH cell leads 
to the down-regulation and blocking of TH1, TH2 and TH17 cell proliferation by 
suppressing their transcription factors (Figure 1.3) (Laurent, Fazilleau & Brousset 
2010; Yu et al. 2009b). Over-expression of BCL-6 in activated T helper cells has 
been reported to stimulate IL-6 receptor and IL-21 receptor expression and they are 
both necessary for TFH cell differentiation (Laurent, Fazilleau & Brousset 2010).  
 
Recent studies in humans have also shown a circulating CD4 T cell population 
characterized by high CXCR5 expression in peripheral blood (Chevalier et al. 2011; 
Ma & Deenick 2014; Morita et al. 2011; Simpson et al. 2010). These circulating 
cells, termed ‘‘peripheral TFH’’ (pTFH) share similar functional characteristics to TFH 
cells found in human secondary lymphoid tissues by expressing higher levels of PD-
1 and IL-21 compared to CD4
+
 CXCR5
-
  T cells (Ma & Deenick 2014). However, a 
main difference between TFH cells found in secondary lymphoid organs and pTFH 
cells is the lack of expression of the transcription factor BCL-6 and much lower 
expression of ICOS by pTFH cells (Chevalier et al. 2011; Morita et al. 2011; Simpson 
et al. 2010). 
 
A study by Morita et al. has shown the ability of these CXCR5+ pTFH cells in 
providing better help to B cells to differentiate and proliferate compared to their 
CD4
+
 CXCR5
-
 counterparts. It also showed that CD4+ CXCR5- cells express higher 
Blimp-1 mRNA than their CD4
+ 
CXCR5
+
 cell (pTFH) counterparts (Morita et al. 
2011). These pTFH cells have been suggested to represent the memory counterparts 
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of TFH cells outside the lymphoid organs, although it remains unknown whether there 
is a direct relationship between pTFH cells in peripheral blood and TFH cells in GC 
(Morita et al. 2011; Simpson et al. 2010; Vinuesa & Cook 2011).  
3.2 Aims of Study 
The aims of this study were to: 
 Characterize TFH cells found in NALT and PBMC. 
 Analyse the frequencies of TFH cells in NALT and PBMC in children and adults. 
 Analyse the correlation between frequencies of GC B cells and TFH cells in 
NALT. 
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3.3 Experimental Design 
To identify TFH cells (CD4
+
 CXCR5
high
 ICOS
high
), freshly isolated MNC were 
stained using a combination of CD4, CXCR5 and ICOS antibodies then analyzed by 
flow cytometry. For further characterization, adenotonsillar MNC were stained 
intracellularly for the transcription factor BCL-6 and cytokines IL-4, IL-10 and IL-
21. The frequencies of TFH cells in NALT and PBMC in children and adults was 
compared. The relationship between frequencies of TFH cells and age was analysed. 
The correlation between numbers of TFH cells and GC B cells in NALT was also 
analysed.  
3.3.1 Patients and Samples  
Surgically removed adenotonsillar tissues were obtained from both children and 
adults (1.5–36 years). Peripheral blood samples were also obtained on the day of 
operation. Patients who had any known immunodeficiency or were previously 
vaccinated against influenza were excluded from the study. The study was approved 
by the local ethics committee (Liverpool Paediatric Research Ethics Committee) and 
written informed consent was obtained from each patient or their legal guardians as 
appropriate. 
3.3.2 Mononuclear Cell Separation 
Adenotonsillar MNC and PBMC were isolated from adenotonsillar tissues and 
peripheral blood respectively. These mononuclear cells were isolated using Ficoll 
density centrifugation following methods described previously in the materials and 
methods chapter 2. Briefly, adenotonsillar tissues samples were minced by a scalpel 
to release cells into the medium. Then the cell suspension was filtered through a 
70μm cell strainer (BD biosciences, USA). The adenotonsillar cells and peripheral 
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blood were carefully layered onto 15 ml Ficoll-Paque™ PREMIUM (GE Healthcare 
Life Sciences, UK) and spun at 400g for 30 min at room temperature. The cloudy 
layer of mononuclear cells was carefully harvested. MNC were washed twice with 
sterile PBS solution (Sigma, UK), then the pellet was re-suspended in 5 ml RPMI-
1640 culture medium with HEPES (Sigma-Aldrich, UK) supplemented with 10% 
heat inactivated FBS (Sigma), 1% L-glutamine (Sigma), streptomycin (50μg/ml) and 
penicillin (50U/ml) (Sigma-Aldrich).  After counting, each cell suspension was 
adjusted to contain 4x10
6
 cells/ml concentrations. 
3.3.3 Flow Cytometric Analysis of Cells  
3.3.3.1 Cell Staining for Phenotyping for FACS Analysis 
Anti-human antibodies used for flow cytometric analysis are described in (Table 
2.1). For TFH cell identification, adenotonsillar MNC and PBMC were stained with 
anti-human-CD3, -CD4, -CXCR5 and -ICOS antibodies. In some samples, PD-1 and 
CCR7 were also stained to confirm the TFH cell phenotype. For GC B cells 
identification, adenotonsillar MNC were stained with anti-human -CD19, -CD38 and 
-IgD antibodies.  All cell staining was performed in Falcon 5ml round bottom tubes 
(BD bioscience) as described earlier. Immediately after staining, cells were 
acquired/analysed using a BD FACS Calibur (BD bioscience) or fixed and 
permeabilized if needed for intracellular staining. 
 
3.3.3.2 Intracellular Staining for BCL-6 and Cytokines 
Adenotonsillar MNC or PBMC (4x10
6
/ml) were incubated at 37°C in 5% CO2. After 
overnight incubation, 10µg/ml brefeldin A (Sigma) was added to each sample and 
further incubated for 4 hours at 37°C in 5% CO2. Cells were then harvested and 
washed twice with FACS staining buffer (500xg for 5 min). Firstly, cells were 
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stained for surface staining markers such as CD4, CXCR5 and ICOS (for TFH cells 
identification) in a same procedure described earlier. Next, the pellets were 
resuspended and fixed with 100µl intracellular fixation buffer (eBioscience) for 20 
min then washed twice with 2 ml 1x permeambilization buffer (500xg for 5 min). 
Then the proper amount of intracellular fluorochrome-labeled antibody (see Table 
2.1) was added to each sample; and incubated for 30 min. After that, cells were 
washed twice with 1x permeambilization buffer (500xg for 5 min), the stained cells 
were resuspended in 400μl of FACS staining buffer; and immediately 
acquired/analysed using the BD FACS Calibur (BD bioscience) and analysed with 
WinMDI 2.9 software.  
 
3.3.4 Statistical Analysis  
Statistical analysis was performed using GraphPad Prism 5 software (GraphPad 
Software, San Diego, CA, USA). Differences between two groups (i.e., children and 
adults) were analysed by two-tailed un-paired Student’s t test (parametric). 
Differences between samples in the same group of subjects were analysed by paired t 
test (parametric). Correlation between two factors was analysed by Pearson’s 
(parametric) correlation test. Throughout the thesis, * indicates a P-value between 
0.01-0.05, ** indicates a P-value between 0.001-0.01 and *** indicates a P-value 
<0.001. 
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3.4 Results 
3.4.1 Identification of TFH Cells in Adenotonsillar MNC 
In order to identify TFH cells in adenotonsillar MNC, a combination of fluorescence-
labelled anti-human CD4, CXCR5 and ICOS antibodies were used to stain the cells 
before flowcytometry. After gating on CD3
+
 CD4
+
 T cells, three populations were 
observed: CD4
+
 CXCR5
high
 ICOS
high
 (TFH cells) (Red) CD4
+ 
CXCR5
int
 ICOS
int
 
(Blue) and CD4
+
 CXCR5
low/-
 ICOS
low/- 
(Green) populations (Figure 3.1). In addition 
to CXCR5 (Figure 3.2.A), TFH cells are characterized by expressing high levels of 
ICOS (Figure 3.2.B), PD-1 (Figure 3.2.C) and BCL-6 (Figure 3.2.D). In contrast, as 
seen in figure 3.2.E, TFH cells express very low levels of the chemokine receptor 
CCR7 compared to CXCR5
low/-
 ICOS
low/- 
cells that express high levels of CCR7.  
Figure 3.1. Representative sample analysis showing gating strategy for identification of 
TFH cells (CD4
+
 CXCR5
hi
 ICOS
hi
) in adenotonsillar MNC 
Adenotonsillar MNC were stained by anti-CD3, -CD4, -CXCR5 and -ICOS antibodies 
followed by flowcytometry. Lymphocytes were defined by typical FSC and SSC (R1) (A).  
CD4
+
 T cells were identified by positive staining of CD3
+
 and CD4
+
 cells (R2) (B).  TFH cells 
were identified by gating on CD3
+
 CD4
+
 T cells (R2), and positive staining of CXCR5
high
 
ICOS
high
 (TFH cells) (R3) CXCR5
int
 ICOS
int
 (R4) and CXCR5
low/-
 ICOS
low/-
 (R5) populations 
(C). 
 
 
A B C 
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Figure 3.2. TFH cells express high amounts of CXCR5, ICOS, PD-1 and BCL-6 in 
adenotonsillar tissues 
A representative FACS histogram of CXCR5 (A), ICOS (B), PD-1(C), BCL-6 (D) and 
CCR7 (E) expression in tonsillar CD4
+
 T cells. Human tonsil cells were gated on CD4
+
 T 
cells and subsequently divided into CXCR5
high
 ICOS
high
 (TFH cells) (red line) CXCR5
int
 
ICOS
int
 (blue line) and CXCR5
low/-
 ICOS
low/-
 (green line). The bar graph represent MFIs of 
CXCR5, ICOS, PD-1, BCL-6 and CCR7 expression in three CD4
+
 T cell populations 
analysed by flowcytometry. Data shown as mean ± SEM from 12 individual donors. p-
value derived from Student’s t test. ***P < 0.001 and **P < 0.01. 
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 The correlation of CXCR5 MFI with ICOS, PD-1 and BCL-6 MFI from CD4
+
 T 
cells was also analysed. As shown in figure 3.3, CXCR5 was correlated with ICOS 
(A) (r =0.76, P<0.001, n=20), PD-1 (B) (r =0.8, P<0.001, n=16), and BCL-6 (C) (r 
=0.85, P<0.001, n=15).  
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Figure 3.3. Correlation between levels of expression (MFI) of CXCR5 and ICOS, PD-1 
and BCL-6 in CD4
+
 T cells 
Correlations between MFIs of CXCR5 and ICOS (A, r = 0.76, P< 0.001, n=20), MFIs of 
CXCR5 and PD-1 (B, r = 0.8, P< 0.001, n=16), and MFIs of CXCR5 and BCL-6 (C, r = 
0.85 P< 0.001, n=15) from CD4
+
 T cells in adenotonsillar tissue.  
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3.4.2 Expression of IL-21 by TFH Cells  
Intracellular cytokine staining for IL-21 was performed to determine the difference 
in IL-21 expression in three CD4
+
 T cell subsets: CXCR5
high 
ICOS
high
 (Red), 
CXCR5
int. 
ICOS
int.
 (Blue) and CXCR5
-/low  
ICOS
-/low
 (Green).  As shown in figure 3.4 
TFH cells expressed the highest level of IL-21 (mean MFI ± SEM, 30.9 ± 2.9) 
compared to (mean MFI ± SEM, 15.6 ± 1.3) produced by CXCR5
int. 
ICOS
int
 cells 
and (mean MFI ± SEM, 7.5 ± 0.6) produced by CXCR5
-/low  
ICOS
-/low 
cells.  
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Figure 3.4. Expression of IL-21 in adenotonsillar TFH cells 
Adenotonsillar MNC were gated on CD4
+
 T cells and subsequently divided into 
CXCR5
high
 ICOS
high
 (TFH cells) (Red line) CXCR5
int
 ICOS
int
 (Blue line) and CXCR5
low/-
 
ICOS
low/- 
cells (Green line). (A) A representative FACS histogram showing IL-21 
expression in tonsillar CD4
+
 T cells. (B) MFI of IL-21 expression in three different CD4
+
 
T cell subsets analysed by flowcytometry. Data shown as mean MFI ± SEM from 15 
individual donors. p-value derived from Paired two-tailed t test. ***P < 0.001. 
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3.4.3 Expression of IL-10 by TFH Cells  
Intracellular cytokine staining for IL-10 was performed to determine the differences 
in IL-10 expression in three CD4
+
 T cell subsets: CXCR5
high 
ICOS
high
 (Red), 
CXCR5
int. 
ICOS
int.
 (Blue) and CXCR5
-/low  
ICOS
-/low
 (Green).  As shown in figure 
3.5, TFH cells express the highest level of IL-10 (mean MFI ± SEM, 55.1 ± 3.7) 
compared to (mean MFI ± SEM, 40.5 ± 3.6) produced by CXCR5
int. 
ICOS
int.
 cells 
and (mean MFI ± SEM, 12.1 ± 1.4) produced by CXCR5
-/low  
ICOS
-/low 
cells. 
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Figure 3.5. Expression of IL-10 in adenotonsillar TFH cells 
Adenotonsillar MNC were gated on CD4
+
 T cells and subsequently divided into 
CXCR5
high
 ICOS
high
 (TFH cells) (Red line) CXCR5
int
 ICOS
int
 (Blue line) and CXCR5
low/-
 
ICOS
low/- 
(Green line). (A) A representative FACS histogram of IL-10 expression in 
tonsillar CD4
+
 T cells. (B) MFI of IL-10 expression in three different CD4
+
 T cells 
analysed by flowcytometry. Data shown as mean ± SEM from 10 individual donors. p-
value derived from Paired two-tailed t test. ***P < 0.001. 
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3.4.4 Expression of IL-4 by TFH Cells  
Intracellular cytokine staining for IL-4 was done to determine the differences in IL-4 
expression in three CD4
+
 T cells: CXCR5
high 
ICOS
high
 (Red), CXCR5
int. 
ICOS
int.
 
(Blue) and CXCR5
-/low  
ICOS
-/low
 (Green). As shown in figure 3.6, TFH cells produces 
the highest amount of IL-4 (mean MFI ± SEM, 106.6 ± 12.2) compared to (mean 
MFI ± SEM, 76.6 ± 10.2) produced by CXCR5
int. 
ICOS
int.
 cells and (mean MFI ± 
SEM, 51.3 ± 10.6) produced by CXCR5
-/low  
ICOS
-/low 
cells.  
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Figure 3.6. Expression of IL-4 in adenotonsillar TFH cells 
Adenotonsillar MNC were gated on CD4
+
 T cells and subsequently divided into 
CXCR5
high
 ICOS
high
 (TFH cells) (Red line) CXCR5
int
 ICOS
int
 (Blue line) and CXCR5
low/-
 
ICOS
low/- 
(Green line). (A) A representative FACS histogram of IL-4 expression in tonsillar 
CD4
+
 T cells. (B) MFI of IL-4 expression in three different CD4
+
 T cells analysed by 
flowcytometry. Data shown as mean ± SEM from 10 individual donors. p-value derived 
from Paired two-tailed t test. ***P < 0.001 and **P < 0.01. 
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3.4.5 Percentage of TFH Cells in Adenotonsillar Tissues in Children and Adults  
To investigate if there is any association between TFH cells and age, freshly isolated 
adenotonsillar MNC from 82 children and 40 adults were stained for TFH cell 
markers and assessed by flow-cytometry. As shown in figure 3.7.A, higher 
percentage of TFH cells (CD4
+
 CXCR5
hi
 ICOS
hi
 cells) was shown in children (mean 
± SEM, 24.9% ± 1.1) compared to that in adults (mean ± SEM, 13.4% ± 1.2). 
Number of CXCR5
int
 ICOS
int
 cells was also shown higher in children (mean ± SEM, 
45.2% ± 2.3) compared to that in adults (mean ± SEM, 39.6% ± 1.7) (Figure 3.7.B).  
However, number of CXCR5
low/-
 ICOS
low/-
 cells was lower in children than in adults 
(mean ± SEM, 24.7% ± 1.2 versus 35.9% ± 1.8, p<0.0001) (Figure 3.7.C).  
  
Figure 3.7. Children have higher percentage of TFH cells in adenotonsillar tissues than 
in adults 
Comparisons of percentage of TFH cells (represents % of TFH cells within CD4
+
 T cells) 
between children and adults (A), percentage of CD4
+
 CXCR5
int
 ICOS
int 
cells between 
children and adults (B) and percentage of CD4
+
 CXCR5 
low/-
 ICOS 
low/-
 cells between 
children and adults (C). Student t-test, ***P < 0.001 and **P < 0.01. 
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Further analysis showed that there was an age-associated decrease in the percentage of 
TFH cells in adenotonsillar tissue (Figure 3.8). During childhood up to 13 years old, the 
percentage of TFH cells appeared to maintain at a similar level with a mean of around 
24%. However, there appeared to be a decrease in percentage in age groups >13 years. 
A significant decrease in TFH cells percentage was seen in the 14-18 years age group 
compared to 10-13 years age group (p<0.05, 23% versus 14%). A further reduction in 
TFH cell percentage was seen in >25 years age group with around only 8% of TFH cells.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Percentage of TFH cells at different age groups in adenotonsillar tissue 
Percentage of TFH cells at different age groups are shown. A total of 120 samples are 
analysed including: <5 years (n=46), 6-9 years (n=22), 10-13 years (n=16), 14-18 years 
(n=12), 19-25 years (n=14) and >25 years group (n=10). The results are expressed as the 
mean percentage of TFH cells ± SEM. Statistical differences (***P < 0.001, **P < 0.01, and 
*P < 0.05) between different groups were calculated by Student t-test.  
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The age-related decrease of TFH cells is also presented in figure 3.9. As shown in the 
figure, in general, there was an inverse correlation between percentage of TFH cells in 
adenotonsillar tissue and age (n=120, r= -0.62, P< 0.0001).  
  
Figure 3.9. Relationship between percentage of TFH cells in tonsillar tissue and age 
A regression linear plot showing the correlation between percentage of TFH cells in 
adenotonsillar tissue and age. Dots (•) represents the percentage of TFH cells in CD4
+
 T cell 
population in 120 subjects. (r = -0.62, P< 0.0001). 
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3.4.6 Number of GC B Cells in Children and Adults  
To determine whether there is any relationship between TFH and GC B cell subsets in 
adenotonsillar MNC, GC B cell subset was also analysed with a combination of 
CD19, CD38 and IgD fluorescence-labelled anti-human antibodies. After gating on 
CD19
+
 B cells, the following B cell subsets were shown: GC B cells (CD19
+
 CD38
++ 
IgD
-
) R1 (red), pre-GC B cells (CD19
+
 CD38
++ 
IgD
+
) R2 (green) and naïve B cells 
(CD19
+
 CD38
- 
IgD
+
) R3 (Figure 3.10.A). As can be seen from figure 3.10.B, a 
higher number of GC B cells was found in children (mean ± SEM, 9.2% ± 0.6) than 
in adults (mean ± SEM, 4.9% ± 0.7) (p<0.01).  
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Figure 3.10. Number of GC B Cells in Children and Adults 
Flowcytometry analysis of B cell subsets in adenotonsillar tissues. (A) Representative 
FACS dotplot showing B cell subsets including GC B cells (CD19
+
 CD38
++ 
IgD
-
) in 
tonsillar MNC.  (B) Comparison of numbers of GC B cells in tonsillar MNC between 
children (n=10) and adults (n=7), Student t-test, **P < 0.01. 
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3.4.7 Correlation between percentage of TFH Cells and GC B Cells 
To investigate if there is any association between numbers of GC B cells and TFH cells, 
freshly isolated adenotonsillar MNC from 15 tonsillar tissue samples were stained for 
both TFH cells and GC B cells and assessed by flow cytometry. As shown in figure 
3.11, there was a good correlation between numbers of GC B cells and TFH cells (r = 
0.86, P< 0.001).    
Figure 3.11. Correlation between numbers of GC B cells and TFH cells in adenotonsillar 
MNC  
A regression linear plot showing the correlation between percentages of GC B cells and TFH 
cells in adenotonsillar MNC (r = 0.86, P< 0.001, n=15). 
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3.4.8 Identification of Peripheral TFH Cells (pTFH) in PBMC 
In order to identify peripheral TFH cells (pTFH) in PBMC, a combination of CD4, 
CXCR5 and ICOS fluorescence-labelled anti-human antibodies were used. After 
gating on CD3
+
 CD4
+
 T cells, three populations could be seen: CD4
+
 CXCR5
high
 
ICOS
+
 (pTFH cells) (Red) CD4
+ 
CXCR5
int
 ICOS
-
 and CD4
+
 CXCR5
-
 ICOS
-
 
populations (Figure 3.12). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. A representative sample analysis showing gating strategy for 
identification of pTFH cells in PBMC 
PBMC were stained with fluorescence-labelled anti-CD3, -CD4, -CXCR5 and -ICOS 
antibodies followed by flowcytometry. Lymphocytes were gated by typical FSC and SSC 
(R1) (A).  CD4
+
 T cells were identified by positive staining of CD3
+
 and CD4
+
 cells (R2) 
(B). (C) pTFH cells were identified by gating on CD4
+
 T cells, showing CXCR5
hi
 ICOS
+
 
(pTFH cells) (R3).   
 
 
A B C 
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3.4.9 Percentage of pTFH Cells in Children and Adults 
To investigate if there is any association between pTFH cells and age, freshly isolated 
PBMC from 17 children and 14 adults were stained for pTFH cell identification and 
assessed by flow-cytometry. Children were shown to have a higher percentage of 
pTFH cells with a mean ± SEM of (0.96% ± 0.11) compared to adults with a mean ± 
SEM of (0.44% ± 0.08) pTFH cells (Figure 3.13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 3.13. Children have higher percentage of pTFH cells in PBMC than in adults  
Freshly human PBMC were stained with anti-CD4, -CD3, -CXCR5 and -ICOS antibodies. 
Data shows that children had higher number of pTFH cells than in adults pTFH cells. Mean 
percentages ± SEM were shown, n=14 for adults and n=17 for children respectively. 
(Student t-test, **P < 0.01). 
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Further analysis showed that there was an age-associated decrease in the percentage of 
pTFH cells in PBMC (Figure 3.14). A decrease in pTFH cells percentage was seen in the 
14-18 years age group compared to children less than 13 years (p<0.05). A further 
reduction in pTFH cells percentage was seen in >25 years age group with less than 
0.3% of pTFH cells in human PBMC.      
 
  
Figure 3.14. Percentage of pTFH cells at different age groups in PBMC 
Percentage of pTFH cells at different age groups are shown. A total of 31 samples (n=31) 
are analysed including: <5 years (n=9), 6-9 years (n=5), 10-13 years (n=6), 14-18 years 
(n=3), 19-25 years (n=3) and >25 years group (n=5). The results are expressed as the mean 
percentage of pTFH cells ± SEM. Statistical differences (***P < 0.001, **P < 0.01, and *P 
< 0.05) between different groups were analysed using student t-test.  
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The association between percentage of pTFH cells and age is also presented in figure 
3.15. As can be seen, overall, there was a negative correlation between percentage of 
pTFH cell and age in human PBMC (n=31, r = -0.60, P< 0.0001). 
  
Figure 3.15. Relationship between percentage of pTFH cells in PBMC and age 
A regression linear plot showing the correlation between percentages of pTFH cells and 
age in PBMC. (r = -0.60, P< 0.0001, n=31). 
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3.5 Discussion 
Secondary lymphoid organs including tonsillar tissues have been reported to be 
highly enriched with TFH cells (Rasheed et al. 2006; Yu & Vinuesa 2010a). In this 
study, we have observed a prominent percentage of TFH cells in adenotonsillar 
samples from both children and adults, using a combination of surface markers of 
CD4, CXCR5 and ICOS. With these markers, three populations were identified in 
CD4
+
 T lymphocytes: CD4
+
 CXCR5
high
 ICOS
high
 (TFH cells), CD4
+ 
CXCR5
int
 
ICOS
int
 and CD4
+
 CXCR5
low/-
 ICOS
low/-
 populations. The frequencies of TFH as 
expressed as proportions in CD4
+
 T cells range from 12% to 36% (in children) and 
from 5% to 20% (in adults). These results are generally consistent with previous 
reports (Bentebibel et al. 2011; Rasheed et al. 2006; Yu & Vinuesa 2010a).  
In addition to the use of CXCR5 and ICOS markers, additional markers for TFH cells 
were also used to confirm the identification of TFH in this study. These additional 
markers included PD-1, BCL6, CCR7 were used, and we confirmed that the CD4
+
 
CXCR5
high
 ICOS
high
 (TFH) was also expressing PD-1
hi
,
 
BCL-6
hi 
and
 
CCR7
low
. These 
are in agreement with previous reports by other groups (Ma et al. 2009).  
Among these TFH markers, CXCR5 was the first and most widely used cell surface 
marker to identify TFH cells (Breitfeld, Ohl et al. 2000). CXCR5 specifically allows 
migration of TFH cells towards the follicular chemokine ligand CXCL13, a 
chemokine responsible for cell entry into follicle (Laurent, Fazilleau & Brousset 
2010). Together, the CXCR5-CXCL13 interaction and down-regulation of CCR7 
expression are responsible for TFH cells follicular homing. This leads to regulation of 
antigen-specific B-cell responses using co-stimulatory molecules including ICOS, 
CD28 and OX40 (Gómez-Martín et al. 2010; Laurent, Fazilleau & Brousset 2010). 
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ICOS is generally used in combination with CXCR5 to identify TFH. ICOS is co-
stimulatory molecules that regulate T cell activation and function expressed 
primarily on activated human T cells including TFH cells. ICOS regulates TFH control 
of B cell function by inducing cytokine secretion (especially IL-4, IL-10 and IL- 21) 
and up-regulating T-B interaction molecules (Hutloff et al. 1999; Simpson, Quezada 
& Allison 2010). Both murine and human studies have shown the importance of 
ICOS in the development and function of TFH cells. It has recently been reported that 
ICOS or ICOS-L deficiency is correlated with fewer TFH cells and a decrease in GC 
formation suggesting a major role of ICOS in TFH cell differentiation (Akiba et al. 
2005; Bauquet et al. 2009; Laurent, Fazilleau & Brousset 2010).  
PD-1 was also shown to be highly expressed on the TFH cells identified in 
adenotonsillar cells in this study. This is consistent with previous reports (Xu et al. 
2014). PD-1 is an important molecule for T cell tolerance (Haynes et al. 2007; Iwai 
et al. 2002).  PD-1 provide an inhibitory signal to GC TFH cells to prevent excess 
proliferation of CD4 T cells in GCs (Crotty 2011). PD-1 is suggested to contribute to 
GC B cell survival and the formation and affinity of long-lived plasma cells through 
interaction with its ligands PD-L1 and PD-L2 which are highly expressed on GC B 
cells (Good-Jacobson et al. 2010). Haynes and colleagues have shown that within 
CXCR5
high 
CCR7
low
 (TFH cells) the PD-1 expression levels and the abundance of IL-
4 were the highest (Haynes et al. 2007).  
 
In our study, TFH cells was shown to express very low levels of CCR7 compared to 
CXCR5
low/-
 ICOS
low/- 
cells that express high levels of CCR7. Down-regulation of 
CCR7 expression is crucial for TFH cells follicular homing (Gómez-Martín et al. 
2010; Laurent, Fazilleau & Brousset 2010). By down-regulation of CCR7, activated 
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TH cells become less reactive to both CCL19 and CCL21, which are main T-zone 
chemokines, leading TFH cells to move inside GC (Haynes 2008).   
 
The TFH cells identified in this study expressed high level of BCL-6 detected by 
flowcytometry. This is consistent with previous studies (Kroenke et al. 2012; Ma et 
al. 2009; Nurieva et al. 2009). BCL-6 has been considered the master regulatory 
transcription factor that controls TFH cell differentiation (Crotty, Johnston & 
Schoenberger 2010; Johnston et al. 2009; Nurieva et al. 2009; Yu et al. 2009b). 
Over-expression of BCL-6 in activated T helper cells has been reported to stimulate 
IL-6 receptor and IL-21 receptor expression and they are both necessary for TFH cells 
differentiation (Laurent, Fazilleau & Brousset 2010). Recent studies have shown that 
TFH differentiation does not occur in vivo in the absence of BCL-6 (Bcl6
-
/
-
). 
However, the differentiation of other CD4 T cell subsets is relatively unaffected by 
the lack of BCL-6 (Johnston et al. 2009; Nurieva et al. 2009; Yu et al. 2009b). 
 
Several cytokines are produced by TFH cells that have major roles in B cell function 
and antibody production, and these include IL-4, IL-10 and IL-21 (Kim et al. 2001; 
King 2009). Here we showed that TFH cells (CD4
+
 CXCR5
hi
 ICOS
hi
) in human 
NALT expressed highest levels of IL-4, IL-10 and IL-21 as compared to CXCR5
Int
 
ICOS
Int 
and CXCR5
low/-
 ICOS
low/-
 cell populations. These findings are consistent 
with the previous report that CD4
+
 CXCR5
hi
 cells express higher amounts of IL-4, 
IL-10 and IL-21 compared to CD4
+
 CXCR5
low
 T cells (Ma et al. 2009). It was 
previously reported that with the acquisition of CXCR5, the production of IL-4 and 
IL-21 increases (Ma et al. 2009). Kim et al. reported in human tonsillar tissues that 
TFH cells were more efficient in production of IL-4 and IL-10 as evidenced by 
intracellular staining and ELISA compared to non-TFH cells (Kim et al. 2001).  
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Using an IL-21 reporter mouse, Luthje and co-workers reported that the expression 
of  IL-10 mRNA was restricted to IL-21
+
 TFH cells (Luthje et al. 2012). Chevalier et 
al. reported that CXCR5
+
 T cells expressed significantly higher levels of IL-10 as 
compared with CXCR5
-
 T cells in human blood. (Chevalier et al. 2011). A study by 
Yusuf et al demonstrated that IL-4 production was observed by TFH cells but not 
non-TFH cells. The majority of the IL-4 was produced by the highest CXCR5 
expressing cells and no IL-4 was made by non-TFH CD4 T cells (Yusuf et al. 2010).  
Our study also shows the importance of IL-21 in TFH cell-mediated B cell antibody 
production in adenotonsillar cells. Blocking the IL-21R by a recombinant 
neutralizing antibody significantly reduced the numbers of TFH cell and that was 
correlated with the reduction of specific antibody production by adneotonsillar B 
cells. Further details are described in detail separately in result chapters 4 and 5.  
Research from human subjects and animal models suggest that there may be 
differences in innate and adaptive immunity in different age populations.  However, 
it is unknown whether there is an age-associated change in TFH cell repertoire. In this 
study, we have found that there was an age-associated difference in TFH cell 
percentage in human NALT. A significant difference in the percentage of TFH cells 
between children and adults was seen, i.e. the mean TFH percentage was higher in 
children than in adults. Furthermore, in adults, there appeared to be a significant 
decrease in TFH percentage with age. However, when we further analysed the 
percentage of TFH cells in different age groups in children, no significant difference 
in the percentage was seen from age 1.5 to 13 years. The finding that the percentage 
of TFH cells in adenotonsillar tissues stayed at a relatively high level from the age 1.5 
to 13 in children that were higher than in adults suggests that TFH cells were primed 
fairly early and rapidly in young childhood. It is possible that immediately after 
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birth, the intensive exposure to foreign agents eg. microbes during infancy rapidly 
primed TFH cells during which GC in secondary lymphoid tissues form intensively.  
 
Studies in animal models suggest neonates are deficient in TFH priming.  In a mouse 
study following immunisation, numbers of TFH cells (CXCR5
high
 PD-1
high
 CD4
+
 
cells) in draining LN in neonates (1-week-old) were significantly lower than in adult 
mice (6-8 weeks old) (Mastelic et al. 2012).  Another study showed that the numbers 
of TFH cell in neonate mice were considerably lower than that in adults before 
immunization (baseline); and also neonates had significantly lower antibody 
production, affinity maturation, and GC reactions compared with adults following 
immunization (Debock et al. 2013).    
 
Although the results from mouse studies suggest neonates are deficient in TFH 
priming, repeated and/or frequent exposure of adenotonsillar tissue to various 
antigens during infancy in children may enable NALT to rapidly develop TFH 
numbers at later infancy.  It is known that young infants’ response to immunisation 
is generally low and needs booster immunisations. There are evidences to support 
that at the age of 12 months, children respond to immunisations more efficiently than 
younger infants (Demirjian & Levy 2009; Wood & Siegrist 2011). It is difficult for 
this study to determine the time during infancy that effective priming of TFH occurs, 
as no children <1 year were able to be recruited into this study. There may be 
differences between human and mouse studies in that children are exposed to natural 
infections intensively during infancy whereas mice do not. 
It is now known that TFH works closely together with GC B cells for optimal B cell 
response. Therefore, we expected there maybe a correlation between the numbers of 
GC B cell and TFH cell. Indeed, we show that there was a good correlation between 
the two. This finding is corroborated by several previous reports in mice and 
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humans. Baumjohann and colleagues using a mouse model showed that the 
proportions of both TFH cell (defined as CXCR5
+
 PD-1
+ 
or CXCR5
+ 
ICOS
+
) and GC 
B cell were positively correlated with increasing doses of antigens (Baumjohann et 
al. 2013). A more recent study using human tonsils and LN reported that numbers of 
GC B cell (CD19
+
 CD38
+
 IgD
-
) were correlated with numbers of TFH cell (Renand et 
al. 2013).  
TFH and GC B cell interactions are considered to be crucial in GC B cell response. In 
the GC, TFH cells interact with GC B cells via a range of molecular pairings 
including ICOS and ICOS ligand, PD-1 and PD-1 ligand, and IL-21 and its receptor 
(IL-21R). These interactions leads to the secretion of IL-4, IL-10 and IL-21 by TFH 
which are received by the GC B cells for optimal GC function in the form of high 
affinity memory B cells and long-lived plasma cells (Nutt & Tarlinton 2011). 
Recent studies suggest there may be TFH equivalent in the circulation i.e. peripheral 
blood (pTFH) that express CXCR5 and ICOS markers and have similar B cell-help 
functions (Bentebibel et al. 2013; Morita et al. 2011; Pallikkuth et al. 2012; Simpson 
et al. 2010; Vinuesa & Cook 2011). Using these markers, we demonstrated the 
presence of such pTFH cells by flowcytometry. Similar to percentages of TFH in 
NALT, there appeared to be an age-associated difference in the percentage of pTFH 
cells. A lower percentage of pTFH cells were observed in 14-18 years group 
compared to children less than 13 years. There was a further reduction in pTFH cell 
percentage in older individuals. The similar correlation of these TFH percentages with 
age may suggest that these pTFH cells in the circulation are related to TFH cells found 
in secondary lymphoid tissues. It is plausible that these circulating pTFH cells may be 
originated from the same cellular precursors with the typical TFH in secondary 
lymphoid tissues.  
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A number of reports offer support to the hypothesis that these peripheral blood CD4
+ 
CXCR5
+
 T cells are related to TFH cells found in NALT. These circulating CXCR5
+
 
CD4 T cells are absent from the peripheral blood of human ICOS-deficient patients 
which coincide with a disturbed GC formation in secondary lymphoid tissue 
(Bossaller et al. 2006). Recently, Morita et al. report that pTFH cells (CXCR5
+
 CD4
+
 
T cells) from human peripheral blood provide better help to B cells than CXCR5
-
 
CD4 T cells. Circulating CXCR5
+
 T cells are shown to be more effective in 
providing help to naïve B cells to differentiate toward plasmablasts at least in the 
presence of the superantigen SEB (Morita et al. 2011). Similar to tonsillar TFH cells, 
a recent study reported that blood CXCR5
+ 
CD4 T cells secreted IL-21 upon contact 
with naïve B cells, whereas CXCR5
- 
CD4 T cells barely secreted any IL-21 (Morita 
et al. 2011). B cells were able to produce IgG, IgM and IgA only when co-cultured 
with CXCR5
+
 cells in an IL-21- and ICOS-dependent manner. In contrast, CXCR5
- 
CD4 T cells were unable to induce any switched immunoglobulin and only small 
amounts of IgM were produced (Morita et al. 2011).  
In summary, we have shown the presence of a prominent number of TFH cells in 
NALT of children which were higher than adults. The fact that young children at 
1.5-2 years already appeared to have developed a high number of TFH suggests that 
TFH priming by antigens during infancy (<1 year) is fairly efficient. TFH in 
adenotonsillar MNC expressed high levels of IL-4, IL-10 and IL-21 which are 
important for B cell antibody production. We also shown a correlation between the 
numbers of GC B cell and TFH cell in human NALT. Since TFH provides crucial help 
for B cell immune response, novel vaccine adjuvants to boost TFH number or 
function may be an attractive vaccination strategy to enhance vaccine efficacy in 
young children.   
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Chapter 4 
 
 
CpG-DNA promotes TFH cells 
in human NALT and PBMC 
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4.1 Introduction 
It is known that T cell help to B cells is an essential process for T cell-dependent 
antibody response. In the last decade, TFH cells have been identified as a new T 
helper subset. Within secondary lymphoid organs, including tonsils, TFH cells are 
considered to be specialized to regulate the development of effector and memory B 
cells and long-lived plasma cells. The interaction between TFH and B cells leads to B 
cell differentiation and GC formation (Choi et al. 2011). 
For better future vaccine design, there has been an increasing interest in 
understanding the mechanisms that controls the differentiation and maturation of TFH 
cells. It has been reported that some vaccine adjuvants were able to promote antigen-
specific TFH cells. These antigen-specific TFH cells were shown to help B cells to 
produce higher affinity antibodies (Fazilleau et al. 2009). Other studies using 
nanoparticle vaccines to malaria have shown enhanced humoral responses with 
robust GC formation in parallel with an expansion of antigen-specific TFH cells 
(Moon et al. 2012).  
In recent years, a number of novel adjuvants and vaccine delivery systems aimed to 
enhance vaccine immunogenicity have been under investigation (Spensieri et al. 
2013). CpG-DNA is a TLR-9 ligand and has been suggested as a candidate vaccine 
adjuvant capable of enhancing antibody responses when combined to antigens 
(Klinman 2006; McCluskie & Davis 1999; Weeratna et al. 2000). However, it 
remains unclear whether CpG-DNA could act on TFH through which to mediate B 
cell function.  
CpG-DNA are short single-stranded synthetic oligonucleotides containing 
unmethylated Cytosine-Guanine (CpG, where the p indicates the phosphodiester 
bond) dinucleotides and also known as CpG motifs. CpG-DNA is recognized by 
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TLR-9 and activation of TLR-9 leads to strong immunostimulatory effects. Three 
types of stimulatory CpG-DNA have been suggested based on their 
immunostimulatory activities named as CpG-DNA type A, B and C (Klinman 2006; 
McCluskie & Davis 1999). In this study type B CpG-DNA was chosen to be 
examined as a candidate adjuvant. CpG-DNA class B was first identified in 1995 by 
Krieg and colleges (Krieg et al. 1995). Members of this class of CpG-DNA have 
been shown to induce B cell proliferation, differentiation and immunoglobulin and 
cytokine secretion. They induce pDC expression of costimulatory molecules, 
including CD86, CD54, MHC II and CD40 (Hartmann & Krieg 2000; Krieg & Yi 
2000; Krieg et al. 1995).  
DC are considered to be the most effective APCs and provide an important link 
between the innate and adaptive immunity (Stockwin et al. 2000).  DCs are usually 
found where pathogens are most likely to first be encountered. Upon antigen 
encounter, DCs migrates to the draining LN via lymphatic vessels where they 
interact with T cells. The common nominator of several agents with adjuvant 
activity, including, CpG-DNA, is that they stimulate immune responses by inducing 
the maturation of DCs (Ramírez-Pineda et al. 2004). Recently, it has been reported 
that antigen presentation by DC is necessary to initiate TFH cell development (Choi et 
al. 2011; Goenka et al. 2011). pDC represents a small subset of DC and have been 
previously described in the T-cell area of human mucosa, especially in tonsils (Polak 
et al. 2008; Rescigno 2013). In humans, pDC uniquely express both TLR-7 and 
TLR-9 which are not found on other DC types (Fuchsberger, Hochrein & O'Keeffe 
2005; Hornung et al. 2002).  
 
Influenza virus is an important cause of respiratory tract infection and responsible for 
3–5 million clinical infections and 250,000–500,000 fatal cases annually worldwide 
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(Stöhr 2002). Influenza virus infection induces host immune responses that help to 
reduce virus replication and prevent further virus spread. Protection against influenza 
virus infection has been shown to be mediated largely by anti-HA neutralizing 
antibodies, and their induction at high and sustained titres is essential for successful 
vaccination. The surface HA glycoprotein of influenza virus is a major target for 
antiviral activity as immune response to HA offer neutralizing antibodies following 
vaccination or natural infection (Wilks et al. 2012).   
CpG-DNA is known to have a strong stimulatory effect on B cells. This TLR-9 
ligand was also reported to enhance T cell–mediated help through DC maturation 
and differentiation (Krieg 2002). Accordingly, for working with TFH cells and B 
cells, CpG-DNA class B was chosen to be examined as a candidate adjuvant. 
Giving that we showed there is a significant number of TFH in human NALT and it 
seems to be primed early in childhood, in this study, we investigated whether a 
candidate adjuvant CpG-DNA has any effect on TFH in NALT and subsequently on B 
cell antibody production. 
4.2 Aims of Study 
More specifically, this study will investigate: 
 Whether CpG-DNA promotes TFH cell frequencies in human NALT and PBMC.  
 Whether CpG-DNA enhances B cell immunity to Influenza virus through TFH 
cells in human NALT. 
 The role of IL-21 in TFH cell-mediated B cell antibody production. 
 The role of pDC in the TFH cell mediated B cell antibody production.  
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4.3 Experimental Design 
Adenotonsillar MNC were stimulated with CpG-DNA, an influenza virus antigen (a 
partially purified seasonal H1N1 virus (A/H1N1Brisbane/2007)), or in combination 
of the two. The effects of these stimulations on TFH cells number were analysed by 
flowcytometry. HA-specific B cell responses were measured using ELISpot assay 
and cell culture supernatants were analysed for antibody production by ELISA. 
Additionally, the role of IL-21 in TFH cell-mediated B cell antibody production in 
adenotonsillar MNC was analysed by blocking IL-21 receptor. The role of pDC in 
the TFH cell mediated B cell antibody production was also analysed. 
4.3.1 Patients and Samples  
Surgically removed adenotonsillar tissues were obtained from both children and 
adults (1.5-36 years). Peripheral blood samples were also obtained. Patients who 
were previously vaccinated against influenza or who had any known 
immunodeficiency were excluded from the study. 
4.3.2 Mononuclear Cell Separation 
Mononuclear cells were isolated using Ficoll density centrifugation following 
methods described previously in the materials and methods chapter 2. Briefly, 
adenotonsillar tissues were minced by a scalpel to release cells into the medium. 
Then the cell suspension was filtered through a 70μm cell strainer. The 
adenotonsillar cells and peripheral blood were carefully layered onto 15 ml Ficoll-
Paque™ PREMIUM and spun at 400g for 30 min at room temperature. The cloudy 
layer of mononuclear cells was carefully harvested. MNC were washed with sterile 
PBS solution, then the pellet was re-suspended in 5 ml RPMI-1640 culture medium 
with HEPES (Sigma-Aldrich, UK) supplemented with 10% heat inactivated FBS 
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(Sigma), 1% L-glutamine (Sigma), streptomycin (50μg/ml) and penicillin (50U/ml) 
(Sigma-Aldrich). After counting, each cell suspension was adjusted to contain 4x10
6
 
cells/ml concentrations.  
4.3.3 Influenza Virus Antigens and CpG-DNA 
4.3.3.1 sH1N1 Virus Antigen 
The seasonal H1N1 influenza virus (sH1N1) antigen used in this study for cell 
stimulation experiments was derived from A/Brisbane/59/2007 strains. This 
Influenza antigen was β-propiolactone inactivated, partially purified 
A/Brisbane/59/2007 virus antigens from National Institute for Biological Standards 
and Control (NIBSC, UK).  
4.3.3.2 Recombinant HA 
The recombinant HA was derived from a seasonal H1N1 influenza virus 
(A/Brisbane/59/2007) (BEI Resources, ATCC, USA). This recombinant HA was 
used as the coating antigen in ELISA and ELISpot assays.    
4.3.3.3 CpG-DNA 
In this study, a type B CpG-DNA (CpG 2006, InvivoGen, USA) was chosen to be 
examined as a candidate adjuvant. CpG-DNA class B was first identified in 1995 by 
Krieg and colleges (Krieg et al. 1995).  
4.3.4 Stimulation by Influenza Virus Antigen and CpG-DNA for Antibody and 
IL-21 Production 
The cell suspension was adjusted to contain 4x10
6
 cells/ml concentrations in RPMI-
1640 medium. 500 μl/well of cells were cultured in 48-well flat bottom culture plates 
then stimulated with (1μg/ml) sH1N1 antigen alone or in combination with 
(0.1μg/ml) CpG-DNA, or CpG-DNA alone. Cells then were cultured for 24 hours for 
cytokine production and 14 days for antibody production at 37°C, 5% CO2. After 
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that, cell culture supernatants were collected from each well and stored at -80°C until 
further analysis by ELISA. 
4.3.5 Measurement of HA Specific IgG/IgM/IgA ELISA Assay 
ELISA assay in this study was designed and developed to detect influenza HA-
specific IgG, IgM and IgA antibodies found in cell culture supernatants using a 
procedure as previously described (Mahallawi et al. 2013). In brief, ELISA plates 
were coated with recombinant HA purified protein then incubated overnight at 4°C. 
The following day, plates were washed then blocked for 1 hour at room temperature. 
Samples were then added and incubated for 2 hours at room temperature. Plates were 
washed and followed by the addition of alkaline phosphatase-conjugated mouse anti-
human IgG or IgM or IgA. After 2 hours, plates were washed and PNPP substrate 
buffer were added then incubated at room temperature in dark. Finally, the OD at 
405nm was measured using a microtiter plate reader and data were analysed using 
DeltaSoft software. 
4.3.6 Measurement of B Cell Antibody Response by ELISpot Assay 
ELISpot assay was used to measure the frequencies of antibody-producing B cells 
specific to HA of sH1N1 (A/Brisbane/59/2007) using a protocol previously 
described. Briefly, ELISpot plates were coated overnight at 4°C with recombinant 
HA of sH1N1. Plates were washed and blocked by incubation with RPMI containing 
10% FBS at room temperature for 1 hour. Stimulated MNC were then added to the 
plates and incubated overnight at 37°C. Plates were washed and incubated with goat 
anti-human IgG biotin for 30 minutes at room temperature. After washing, 
Horseradish peroxidase Avidin D conjugate was added and incubated. Coloured 
spots were developed with the addition of substrate  and counted using an automated 
ELISpot reader.  
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4.3.7 CD45RO+ Cell Depletion From Adenotonsillar MNC  
To evaluate the CpG-DNA stimulation to induce TFH cells from naïve T (CD45RO
-
) 
cells, effector and memory (CD45RO
+
) cells were depleted from the adenotonsillar 
MNC. The cells to be depleted (CD45RO
+
) were labelled with the specific magnetic 
micro-beads binding with the target surface molecules (CD45RO). The cell 
suspension is then allowed to pass through a MACS LD column, placed within the 
magnetic field of a MACS separator. The magnetically labelled cells (CD45RO
+ 
cells) are retained within the column, and the unlabelled cells (CD45RO
- 
MNC) pass 
through the column and collected in a tube placed underneath it. The depletion of 
CD45RO
+
 cells in adenotonsillar MNC removed the majority of TFH cells.  
 
4.3.8 Flow Cytometric Analysis of Cells  
4.3.8.1 Cell Stimulation for Flowcytometry Analysis 
The cell suspension was adjusted to contain 4x10
6
 cells/ml concentrations in RPMI-
1640. 500 μl/well of cells were cultured in 48-well flat bottom culture plates and 
stimulated with (1μg/ml) sH1N1 antigen alone or in combination with (0.1μg/ml) 
CpG-DNA and CpG-DNA alone. For TFH cells analysis, PBMC and unfractionated 
adenotonsillar MNC were cultured for 3 days and CD45RO
+
 cell-depleted 
adenotonsillar MNC were cultured for 7 days at 37°C, 5% CO2. After that, cells were 
harvested for FACS staining.   
4.3.8.2 Cell Staining for Phenotyping for FACS Analysis 
For TFH cells identification, adenotonsillar MNC and PBMC were stained with anti-
human-CD3, -CD4, -CXCR5 and -ICOS antibodies. All cell staining was performed 
as described earlier. Immediately after staining, cells were acquired/analysed using a 
BD FACS Calibur or fixed and permeabilized if needed for intracellular staining. 
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4.3.8.3 Intracellular Staining for BCL-6, IL-21 and TLR-9 
For BCL-6 analysis, stimulated cells were incubated for 3 days. For IL-21 analysis, 
stimulated cells were incubated overnight, then 10µg/ml brefeldin A was added to 
each sample and further incubated for 4 hours at 37°C in 5% CO2. For TLR-9 
analysis, freshly isolated cells were used for staining. After that, cells were harvested 
and washed twice with FACS staining buffer followed by surface staining with 
fluorochrome-labelled anti-human antibodies depending on the phenotype (Table 
2.1) in the same procedure described earlier. Next, cells were fixed with intracellular 
fixation buffer. After incubation for 20 min, cells were washed twice with 
permeabilization buffer. Then the proper amount of either BCL-6, IL-21 or TLR-9 
anti-human antibodies was added and incubated for 30 min. Cells were then washed 
with permeabilization buffer then resuspended in FACS staining buffer; and 
immediately acquired/analysed by flow cytometery. 
 
4.3.9 T cell Proliferation Assay  
T cell proliferation was analysed by CFSE staining followed by flow cytometry. 
Briefly, adenotonsillar MNC were labelled with CFSE (at 37°C, for 8 min) and the 
reaction was quenched with ice-cold media. After washing, cells were resuspended 
in RPMI 1640 media and stimulated with (1μg/ml) sH1N1 antigen alone or in 
combination with (0.1μg/ml) CpG-DNA and CpG-DNA alone, and incubated (at 
37°C, in 5% CO2) for 5 days. Then cells were harvested, washed and resuspended in 
0.02% BSA in PBS and anti-CD4-PE-Cy7, -CXCR5-PE and -ICOS-APC were 
added to stain CD4
+
 CXCR5
hi
 ICOS
hi
 cells (TFH cells).  TFH cell proliferation index 
was examined by gating from TFH cells (CXCR5
hi
 ICOS
hi
 cells) then analysed by 
flow cytometry using BD FACS Calibur (BD bioscience).  
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4.3.10 Purification of TFH cells, B cells and pDC for Co‐culture Experiments 
For co-culture experiments, cells were isolated by magnetic cell sorting using 
EasySep™ magnetic technology (STEMCELL Technologies Inc.) as described in 
details in material and method chapter 2. Briefly, adenotonsillar B cells were 
negatively selected using EasySep™ human B cell enrichment kit (purity >99%). 
Adenotonsillar CD4
+
 T cells were also negatively selected using EasySep™ human 
CD4
+
 T cell enrichment kit (purity >98%). Followed by the isolation of CD4
+
 
CXCR5
hi
 (TFH cells) by positive selection using biotin anti-human CXCR5 antibody 
and EasySep™ biotin selection kit (purity >90%). Non-TFH cells (CD4
+
 CXCR5
-
) 
was negatively selected from CD4
+
 T cells gaining a purity of >99%.  Adenotonsillar 
pDC were also negatively selected using EasySep™ human plasmacytoid DC 
enrichment kit (purity 96%). 
4.3.11 B Cell Help by TFH Cells  
The ability of adenotonsillar TFH cells to induce antibody production by 
adenotonsillar B cells was studied using an autologous system as follows. In co-
culture experiments, B cells were cultured with an equal number of either TFH cells 
or non-TFH cells at a ratio of 1:1 using a cell concentration of 5x10
5
 cells/ml. 250 
μl/well of B:T co-culture cells were cultured in 96-well round bottom plate in the 
presence or absence of a combination of CpG-DNA and influenza virus antigen. 
Cells were then cultured at 37°C, 5% CO2,  for 10 days for antibody production.  
4.3.12 Assessment of Effect of pDC   
In co-culture experiments, B cells were cultured with an equal number of TFH cells at 
a ratio of 1:1 using a cell concentration of 5x10
5
 cells/ml with or without pDC. 
Purified pDC were then added to this mixture using a concentration of 5x10
4
 
cells/ml. 250 μl/well of B cells + TFH cells + pDC co-culture cells were cultured in 
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96-well round bottom plate in medium alone or in the presence or absence of a 
combination of CpG-DNA and influenza virus antigen. Cells were then cultured at 
37°C, 5% CO2, for 10 days for antibody production.  
 
4.3.13 Anti-IL-21R Blocking Experiments  
Adenotonsillar MNC suspension was adjusted to contain 4x10
5
 cells/ml 
concentrations in RPMI-1640 medium. Cells were cultured in 96-well round bottom 
plate in the presence or absence of different stimulants with or without the 
recombinant human anti-IL-21R Fc blocking antibody (α-IL-21R). Firstly, α-IL-21R 
was added to the designated wells and incubated for 1 hour at 37°C in a 5% CO2 
incubator.  These cells were then stimulated with (0.5μg/ml) sH1N1 antigen in 
combination with (0.05μg/ml) CpG-DNA. Cells were then cultured at 37°C, 5% 
CO2, for 3 days for TFH cell analysis by FACS and 10 days for antibody production. 
After 3 days, cells were harvested and stained for surface staining markers such as 
CD4, CXCR5 and ICOS in a same procedure described earlier. Furthermore, after 10 
days incubation, cell culture supernatants were collected from each well and stored 
at -80°C until further analysis by ELISA to measure the specific HA of H1N1 IgM 
and IgA. 
4.3.14 Statistical Analysis  
Statistical analysis was carried out using GraphPad Prism 5 software. Differences 
between stimulated and unstimulated samples in the same group of subjects were 
analysed by Student’s paired t test (parametric). Correlation between two factors was 
analysed by Pearson’s (parametric) correlation test. Throughout the thesis, * 
indicates a P-value between 0.01-0.05, ** indicates a P-value between 0.001-0.01 
and *** indicates a P-value <0.001. 
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4.4 Results 
4.4.1 CpG-DNA Promotes TFH Cells in Adenotonsillar Cells 
To determine whether CpG-DNA has any effect on TFH cells, both unfractionated 
adenotonsillar MNC (A) and CD45RO
+
 cell-depleted adenotonsillar MNC (B) were 
stimulated with different concentrations of CpG-DNA (0, 0.01, 0.1, 1, 2 and 4 
µg/ml), followed by staining CD4/CXCR5/ICOS and flowcytometric analysis for 
TFH percentage.  As shown in figure 4.1.A and B, CpG-DNA induced a significant 
increase in percentage of TFH cells in a dose dependent manner for both 
unfractionated MNC and CD45RO
+
 cell depleted MNC.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. CpG-DNA promotes TFH cells in adenotonsillar cells 
Effect of CpG-DNA on percentage of TFH cells in unfractionated adenotonsillar MNC (A) 
and CD45RO
+
 cell depleted MNC (B) following stimulation for 3 and 7 days respectively 
with different concentrations of CpG-DNA. The values represent the mean ± SEM from 
10 individual tonsils (p-value derived from Paired two-tailed t test, ***P < 0.001, **P < 
0.01, and *P < 0.05, NS: not significant).  
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Further analysis using CD4
+
 CXCR5
hi
 BCL-6
+
 as a TFH cell marker following 
stimulation of adenotonsillar MNC for 72 hours with different concentrations of 
CpG-DNA (0, 0.01, 0.1 and 1 µg/ml) showed similar results.  As shown in figure 
4.2, CpG-DNA induced a significant increase in percentage of CD4
+
 CXCR5
hi
 BCL-
6
+
 cells in a dose dependent manner.   
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Figure 4.2. CpG-DNA promotes CD4
+
 CXCR5
hi
 BCL-6
+
 cells in adenotonsillar cells   
Effect of CpG-DNA on percentage of CD4
+
 CXCR5
hi 
BCL6
+
 cells in MNC stimulated for 3 
days with different concentrations of CpG-DNA. The values represent the mean ± SEM 
from 7 individual tonsils (p-value derived from Paired two-tailed t test, **P < 0.01, and *P < 
0.05, NS: not significant).   
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4.4.2 Effect of CpG-DNA on IL-21 Production in Relation to TFH cells in 
NALT 
As TFH was shown to correlate with a high level of IL-21 expression (results chapter 
3), the effect of CpG-DNA on IL-21 production in cell culture supernatants were 
analysed following stimulation of unfractionated adenotonsillar MNC for 24 hours 
with CpG-DNA. As shown in figure 4.3.A, CpG-DNA induced a significant increase 
in IL-21 concentration. To ascertain the effect of CpG-DNA on TFH production of 
IL-21 purified CXCR5
hi
 CD4
+
 T cells (TFH) were co-cultured with purified B cells in 
the presence of CpG-DNA for 24 hours. IL-21 concentration was shown to increase 
significantly following CpG-DNA stimulation in the presence of TFH cells (Figure 
4.3.B) but not in the presence of CXCR5
- 
CD4
+
 T cells (non-TFH) (Figure 4.3.C).  
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Figure 4.3. IL-21 concentration increases in the presence of CXCR5
hi
, but not of 
CXCR5
-
 CD4
+
 T cells following stimulation with CpG-DNA 
Unfractionated adenotonsillar MNC were stimulated with CpG-DNA (A) and purified 
CXCR5
+
 CD4
+
 T cells (TFH) (B) or CXCR5
-
 CD4
+
 T cells (non-TFH) (C) were co-cultured 
with B cells in the presence of CpG-DNA. After 24 hours, cell culture supernatants were 
collected and analysed for IL-21 using ELISA. The value represents the mean ± SEM from 
22 (Unfractionated adenotonsillar MNC) and 17 (Purified cells) individual tonsils (p-value 
derived from Paired two-tailed t test, ***P < 0.001, NS: not significant).  
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4.4.3 Effect of CpG-DNA as an Adjuvant on B cell Antibody Production in 
Relation to TFH Cells 
To investigate the adjuvanting effect of CpG-DNA on B cell antibody production in 
association with TFH cells, influenza HA-specific antibody response was studied 
following influenza virus antigen stimulation. Adenotonsillar MNC were stimulated 
with sH1N1 virus antigen with or without CpG-DNA for 14 days. Cell culture 
supernatants were collected and analysed for anti-sH1N1 HA IgG, IgM and IgA 
antibody production using ELISA. As shown in figure 4.4, the addition of CpG-
DNA significantly enhanced the production of HA-specific IgG (Figure 4.4.A), IgM 
(Figure 4.4.B) and IgA (Figure 4.4.C) antibodies compared to sH1N1 virus antigen 
alone.     
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Figure 4.4. Anti-sH1N1 HA-specific antibody production in adenotonsillar MNC 
following CpG-DNA and influenza antigen stimulations 
Adenotonsillar MNC were stimulated with sH1N1 virus antigen with or without CpG-DNA. 
After 14 days, cell culture supernatants were collected and analysed for anti-sH1N1 HA IgG 
(A), IgM (B) and IgA (C) antibody production using ELISA. Results are expressed as mean 
antibody titre (OD) ± SEM from 34 individual tonsils. The OD was chosen to be used 
because no proper standard for IgM and IgA was found for anti-sH1N1 HA (p-value derived 
from Paired two-tailed t test, ***P < 0.001 and **P < 0.01, NS: not significant). 
A B C 
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To ascertain whether TFH are required for the antibody induction induced by sH1N1 
virus antigen and CpG-DNA, TFH (CD4
+
 CXCR5
hi
) cells were purified and co-
cultured with purified B cells in the presence of CpG-DNA and sH1N1 antigen. As 
shown in figure 4.5, the co-cultured cells stimulated by CpG-DNA and sH1N1 
antigen induced significant antibody production only in the presence of CD4
+ 
CXCR5
hi
 (TFH) cells, but not in the presence of CD4
+ 
CXCR5
-
 (non-TFH) cells; i.e. 
TFH but not non-TFH cells were able to help B cells for the production of HA-specific 
IgG (Figure 4.5.A), IgM (Figure 4.5.B) and IgA (Figure 4.5.C) antibodies. 
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Figure 4.5. HA-specific sH1N1 IgG, IgM and IgA titre are produced from B cells co-
cultured with purified TFH cells but not with non-TFH cells 
Purified B cells were co-cultured with either purified TFH cells or non-TFH cells (at a ratio of 
1:1). These cells were stimulated with sH1N1 virus antigen with or without CpG-DNA and 
CpG-DNA alone.  After 10 days, cell culture supernatants were collected and analysed for 
anti-sH1N1 HA IgG (A), IgM (B) and IgA (C) antibody production using ELISA. The 
value represents the mean ± SEM from 22 individual tonsils (p-value derived from Paired 
two-tailed t test, ***P < 0.001, and NS: not significant). 
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To find out whether the antibody production by adenotonsillar MNC following 
stimulation by CpG-DNA and sH1N1 virus antigen is correlated with changes in 
TFH, percentage of TFH were analysed. As shown in figure 4.6.A CpG-DNA alone, at 
a concentration of 0.1µg/ml, induced a small increase in percentage of TFH cells. The 
sH1N1 virus antigen was also shown to increase the percentage of TFH cells 
compared to unstimulated medium control (25.3% versus 20.1%). The addition of 
CpG-DNA to sH1N1 virus antigen significantly enhanced the percentage of TFH cells 
elicited by sH1N1 antigen (29.6%).   
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Figure 4.6. Effect of CpG-DNA on TFH percentage in adenotonsillar MNC in the 
presence of an influenza virus antigen 
(A) A representative density plot of flowcytometric analysis of MNC adenotonsillar 
stimulated for 72 hours with a sH1N1 antigen with or without CpG-DNA. The value 
shown is the percentage of TFH cells in CD4
+
 T cells.  (B) Mean percentage of TFH cells in 
adenotonsillar MNC stimulated with sH1N1virus antigen with or without CpG-DNA. The 
values represent the mean ± SEM from 37 individual tonsils (p-value derived from Paired 
two-tailed t test, ***P < 0.001 and *P < 0.05). 
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To investigate the induction of TFH cells from naïve CD4
+
 T cells, adenotonsillar 
MNC samples were analysed after magnetic depletion of effector and memory 
(CD45RO
+
) T cell population. Further analysis using CD45RO
+
 cell depleted 
adenotonsillar MNC showed similar results following stimulation with sH1N1 
antigen with or without CpG-DNA.  As shown in figure 4.7.A, CpG-DNA together 
with the sH1N1 virus antigen induced a marked increase in the percentage of TFH 
(mean, 8.8%), higher than CpG-DNA or sH1N1 antigen stimulation alone (means 
4.6% and 6.2% respectively).   
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Figure 4.7. Effect of CpG-DNA on TFH percentage in CD45RO
+
 cell depleted MNC in 
the presence of an influenza virus antigen 
(A) A representative density plot showing effect of CpG-DNA and sH1N1 antigen on TFH 
percentage in CD45RO
+
 cell depleted MNC following stimulation for 7 days. The value 
shown is the percentage of TFH cells in CD45RO
+
 cell depleted MNC.  (B) Mean percentage 
of TFH cells from CD45RO
+
 cell depleted MNC stimulated with sH1N1virus antigen and 
CpG-DNA. The values represents the mean ± SEM from 16 individual tonsils (p-value 
derived from Paired two-tailed t test, ***P < 0.001, **P < 0.01, and *P < 0.05). 
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When CD4
+
 CXCR5
hi
 BCL-6
+
 was used as a marker for TFH cells, the effect of CpG-
DNA and influenza antigen on TFH cells was similar to above (Figure 4.8). 
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Figure 4.8. CpG-DNA promotes CD4
+
 CXCR5
hi
 BCL-6
+
 cells in adenotonsillar cells  
(A) A representative density plot flowcytometry analysis of MNC stimulated for 3 days with 
sH1N1 virus antigen with or without CpG-DNA and CpG-DNA alone. The value shown is 
the percentage of CD4
+
 CXCR5
hi 
BCL6
+
 cells. (B) Summary percentage of CD4
+
 CXCR5
hi 
BCL6
+
 cells from MNC stimulated with sH1N1 virus antigen with or without CpG-DNA and 
CpG-DNA alone. The values represent the mean ± SEM from seven individual tonsils (p-
value derived from Paired two-tailed t test, ***P < 0.001, **P < 0.01, and *P < 0.05).  
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To determine whether there is a correlation between the enhanced antibody 
production induced by CpG-DNA and TFH, percentage of TFH cells were analysed in 
association with HA-specific sH1N1 IgG, IgM and IgA production. As shown in 
figure 4.9, the percentage of TFH cells were correlated well with HA-specific sH1N1 
IgG (Figure 4.9.A) (r = 0.72, P< 0.001), IgM (Figure 4.9.B) (r = 0.82, P< 0.001) and 
IgA levels (Figure 4.9.C) (r = 0.78, P< 0.001).  
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Figure 4.9. Correlation between HA-specific sH1N1 antibody levels and percentage of 
TFH cell in adenotonsillar MNC 
A regression linear plot showing the correlation between percentage of TFH cell to the HA-
specific sH1N1 IgG (A) (r = 0.72, P< 0.001, n=17), HA-specific sH1N1 IgM (B) (r = 0.82, 
P< 0.001, n=17) and HA-specific sH1N1 IgA levels (C) (r = 0.78, P< 0.001, n=17). 
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4.4.4 Effect of CpG-DNA and Influenza Antigen on TFH Cell Proliferation in 
Adenotonsillar MNC 
To study whether TFH proliferate upon stimulation by CpG-DNA and influenza 
antigen, adenotonsillar MNC were stained with CFSE followed by stimulation with 
CpG-DNA and sH1N1 virus antigen for 5 days before flowcytometry. As shown in 
figure 4.10.A, CpG-DNA together with sH1N1 antigen induced marked TFH cell 
proliferation, with a mean TFH cell proliferation index of 16.3%, significantly higher 
than CpG-DNA alone and sH1N1 virus antigen alone (means 8.4% and 11.6% 
respectively).     
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Figure 4.10. Analysis of TFH cell proliferation in the presence of an influenza virus 
antigen and CpG-DNA 
(A) A representative CFSE staining analysis of MNC stimulated for 5 days with sH1N1 
virus antigen with or without CpG-DNA, the value shown is the percentage of TFH cells 
proliferation in CD4
+
 T cells. (B) Summary percentage of TFH cell proliferation from MNC 
stimulated with sH1N1 virus antigen with or without CpG-DNA. The values represent the 
mean ± SEM of TFH cell proliferation index gated from CXCR5
hi
 ICOS
hi
 cells from 10 
individual tonsils (p-value derived from Paired two-tailed t test, ***P < 0.001, **P < 0.01, 
and *P < 0.05). 
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4.4.5 Effect of Plasmacytoid DC on TFH-mediated Help for B cell Antibody 
Production  
Having shown that TFH cells contribute to the B cell antibody production, efforts 
were made to identify the mechanisms for this action. As TFH did not show 
significant expression of TLR-9 (shown later in figure. 4.14), whereas pDC is known 
to express high levels of TLR-9, and also a significant number of pDC exists in 
tonsillar tissue, possible effect of pDC was studied. Purified B cells were co-cultured 
with purified TFH cells with or without purified pDC cells. These cells were 
stimulated with sH1N1 virus antigen combined with CpG-DNA.  As shown in figure 
4.11, the presence of pDC in the co-culture significantly enhances anti-sH1N1 HA-
specific IgM (Figure 4.11.B) and IgA antibody production (Figure 4.11.C), although 
no difference was shown for IgG antibody (Figure 4.11.A).  
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Figure 4.11. pDC enhances the antibody production when added to purified TFH cells 
co-cultured with purified B cells 
 Purified B cells were co-cultured with purified TFH cells (at a ratio of 1:1) with or without 
purified pDC cells. These cells were stimulated with sH1N1 virus antigen combined with 
CpG-DNA. After 10 days, cell culture supernatants were collected and analysed for anti-
sH1N1 HA IgG (A), IgM (B) and IgA (C) antibody production using ELISA. The value 
represents the mean ± SEM from 10 individual tonsils (p-value derived from Paired two-
tailed t test, **P < 0.01, and *P < 0.05, NS: not significant). XR
+
: CXCR5
hi
 cells, BC: B 
cells, pDC: plasmacytoid DC.  
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4.4.6 Detection of Antibody Secreting Cells (ASC) Following Stimulation by 
CpG-DNA and Influenza Virus Antigen in Adenotonsillar cells  
 
To confirm antibody production measured by ELISA, ELISpot assay was performed 
to enumerate the numbers of anti-sH1N1 HA B cell responses following stimulation 
by sH1N1 virus antigen with or without CpG-DNA. As shown in figure 4.12.A that 
CpG-DNA alone induced a small increase in numbers of HA-specific sH1N1 IgG 
ASC compared to unstimulated medium control (mean ± SEM, 7.8 ± 1.1 and 3.2 ± 
0.35 respectively). sH1N1 virus antigen was also shown to induce numbers of HA-
specific sH1N1 IgG ASC (mean ± SEM, 23.8 ± 3.7). The addition of CpG-DNA to 
sH1N1 virus antigen significantly enhanced the numbers of HA-specific sH1N1 IgG 
ASC (mean ± SEM, 38.8 ± 4.3) in human adenotonsillar tissues (Figure 4.12.A and 
B).  
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Figure 4.12. ELISpot assay to enumerate antibody secreting B cell response showing 
number of HA-specific ASC 
Adenotonsillar MNC were stimulated with sH1N1 virus antigen with or without CpG-DNA 
and CpG-DNA alone. (A) Representative sample showing the number of HA-specific ASC.  
(B) Summary of the number of HA-specific ASC from MNC stimulated with sH1N1virus 
antigen with or without CpG-DNA and CpG-DNA alone.  The value represents the mean ± 
SEM from 10 individual tonsils (p-value derived from Paired two-tailed t test, ***P < 0.001, 
**P < 0.01, and *P < 0.05). 
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4.4.7 IL-21 is Important in TFH cell-mediated B cell Antibody Production in 
Adenotonsillar cells 
In order to study the importance of IL-21 in TFH cell-mediated B cell antibody 
production, anti-IL-21R blocking antibody (α-IL-21 R) was added to adenotonsillar 
MNC and incubated for 1 hour at 37 ⁰C, then stimulated with CpG-DNA and sH1N1 
antigen for 3 days (for TFH analysis) and 10 days (for antibody production).  As 
shown in figure 4.13.A blocking IL-21 receptor reduced the percentage of TFH cells 
compared to un-blocked controls. Further, the antibody level (sH1N1 IgM and 
sH1N1 IgA) was also significantly reduced when IL-21 receptor was blocked as 
shown in figures 4.13.B and C respectively. 
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Figure 4.13. Blocking IL-21R leads to a significant reduction in percentage of TFH cells 
and antibody production in human adenotonsillar tissue 
Anti-IL-21R blocking antibody (α-IL-21R) was added to adenotonsillar MNC and incubated 
for 1 hour/37 ⁰C, then stimulated with CpG-DNA and sH1N1 virus antigen.  (A) Shows the 
percentage of TFH cells with and without α-IL-21R. The specific sH1N1 IgM (B) and IgA 
(C) OD level from adenotonsillar MNC stimulated with sH1N1 virus antigen + CpG-DNA 
with and without α-IL-21R after 10 days measured by ELISA. The values represent the 
mean ± SEM from eight individual tonsils (p-value derived from Paired two-tailed t test, 
***P < 0.001 and **P < 0.01).  
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4.4.8 TLR-9 Expression on Purified TFH cells, non-TFH cells, B cells and pDC   
Purified TFH cells, non-TFH cells, B cells and pDC were analysed for the expression 
of TLR-9 by staining them with intracellular anti-TLR-9-PE. TFH cells show a higher 
number of TLR-9
+
 cells compared to non-TFH cells (Figure 4.14.A). B cells show a 
high TLR-9 expression compared to isotype control (Figure 4.14.B). Further, a high 
TLR-9 MF1 was also seen in purified pDC (Figure 4.14.C).  
  
Figure 4.14. TLR-9 expression in TFH, non-TFH, B cells and pDC 
(A) Representative density plot analysis of purified TFH cells and non-TFH cells compared to 
an isotype control. The values represented in (A) are the mean percentage of CD4
+
 TLR-9
+
 
cells from five individual tonsils.  
Representative histogram analysis of purified B cells (black line) (B) and purified pDC 
(black line) (C) compared to an isotype control (gray shade), showing the difference in 
TLR-9 expression from five individual tonsils.  
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4.4.9 Effect of CpG-DNA on pTFH cells in PBMC  
In order to study the effect of CpG-DNA on pTFH cells, freshly isolated PBMC were 
stimulated for 72 hours with CpG-DNA with or without sH1N1 antigen.  As shown 
in figure 4.15.A, CpG-DNA alone induced a small increase in pTFH percentage 
(0.6%). In combination with sH1N1 antigen, CpG-DNA induced a marked increase 
in the percentage of pTFH (1.8%).  
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Figure 4.15. CpG-DNA can promote pTFH cells in PBMC 
(A) Representative density plot flowcytometry analysis of PBMC stimulated for 72 hours 
with sH1N1 virus antigen with or without CpG-DNA and CpG-DNA alone. The value shown 
is the percentage of pTFH cells in CD4
+
 T cells.  (B) Summary percentage of pTFH cells from 
PBMC stimulated with sH1N1 virus antigen with or without CpG-DNA. The values represent 
the mean ± SEM from 12 individual samples (p-value derived from Paired two-tailed t test, 
***P < 0.001, **P < 0.01, and *P < 0.05).  
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4.4.10 Induction of IL-21 in PBMC with Influenza virus antigen and CpG-DNA 
Induction of IL-21 was analysed in PBMC culture supernatants, 24 hours after 
stimulation with sH1N1 virus antigen with or without CpG-DNA and CpG-DNA 
alone. Production of IL-21 was shown to be higher with CpG-DNA combined with 
sH1N1 virus antigen stimulation (mean ± SEM, 108.4 ± 20.1) than that induced by 
either CpG-DNA (mean ± SEM, 45.1 ± 4.9) or sH1N1 virus antigen alone (mean ± 
SEM, 42.9 ± 5.9) (Figure 4.16).  
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Figure 4.16. IL-21 Levels increases after stimulation with CpG-DNA in PBMC 
PBMC were stimulated with sH1N1 virus antigen with or without CpG-DNA and CpG-
DNA alone.   After 24 hours, cell culture supernatants were collected and analysed for IL-
21 levels using ELISA. CpG-DNA combined with sH1N1 virus antigen induced high levels 
of IL-21 compared to sH1N1 virus antigen alone. The value represents the mean ± SEM 
from 11 individual samples (p-value derived from Paired two-tailed t test, **P < 0.01).  
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4.5 Discussion  
It is recognised now that TFH cells are important in GC B cell differentiation and 
antibody responses, therefore promoting TFH frequency and function may be a good 
vaccination strategy. Recently, it has been reported that certain adjuvants were able 
to enhance the generation and development of TFH (Moon et al. 2012; Su et al. 
2013). As CpG-DNA has been identified as a vaccine adjuvant capable of enhancing 
B cell responses when combined to different antigens (Cooper et al. 2004; Halperin 
et al. 2003; Rynkiewicz et al. 2011; Sagara et al. 2009; Siegrist et al. 2004), we 
asked whether CpG-DNA has an effect on  TFH and thereby enhance specific 
antibody production. 
In this study, we found that the percentage of tonsillar TFH cells (Figure 4.1) was 
increased by CpG-DNA stimulation in a dose dependent manner in both 
unfractionated and CD45RO
+
 cell-depleted adenotonsillar MNC. This suggests that 
CpG-DNA may activate and/or promote the induction of TFH cells.  
 
We also showed that co-incubation of CpG-DNA with influenza virus antigen 
induced a much enhanced increase in the percentage of TFH cells. The addition of 
CpG-DNA to sH1N1 virus antigen also significantly enhanced the HA-specific IgG, 
IgM and IgA antibody production compared to the influenza virus antigen alone. 
This enhancement of TFH cells percentage strongly correlated with the levels of the 
influenza HA-specific IgG, IgM and IgA antibodies. To ascertain whether TFH were 
required for this antibody induction, TFH cells and non-TFH cells were purified and 
co-cultured with purified B cells in the presence of CpG-DNA and sH1N1 antigen. 
We reported that the co-cultured cells induced significant antibody production only 
in the presence of CD4
+ 
CXCR5
hi
 (TFH) cells, but not in the presence of CD4
+ 
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CXCR5
-
 (non-TFH) cells; i.e. TFH but not non-TFH cells were able to help B cells for 
the production of HA-specific antibodies. These results suggest that the enhanced 
antibody production by CpG-DNA may be mediated, at least in part, by TFH cells, 
and our results are also corroborated by several recent studies. 
Using a murine model Mastelic et. al reported that adjuvantation with CpG-DNA 
increased TFH and GC B cell neonatal responses, up to adult levels. These mice were 
immunized with tetanus toxoid adsorbed to aluminium hydroxide with or without a 
class B CpG-DNA. The addition of CpG-DNA significantly enhanced the numbers 
of TFH cells especially in neonatal mice (Mastelic et al. 2012). The study also 
reported that the increase in tetanus toxoid-specific IgG antibody production was 
associated with an increase in the numbers of neonatal GC B cells (Mastelic et al. 
2012).  More recently, Chakarov and Fazilleau reported that mice vaccinated with a 
peptide in incomplete Freund’s adjuvant (IFA) combined with CpG-DNA induced a 
significant increase in antigen-specific TFH cells compared to mice vaccinated with 
IFA only. This CpG-DNA effect on TFH cells was dose dependent and was seen only 
in CpG-DNA type B and not type A or C (Chakarov & Fazilleau 2014). 
Furthermore, adjuvantation of IFA with CpG-DNA type B increased both the 
antigen specific GC B cells and plasma cells in correlation with a raise in serum 
antigen-specific IgG (Chakarov & Fazilleau 2014).  
 
In line with these findings, Rookhuizen and DeFranco reported a robust expansion of 
total and antigen-specific GC B cells and high titre of antigen specific IgG antibodies 
in mice vaccinated with an antigen adjuvanted with CpG-DNA (Rookhuizen & 
DeFranco 2014). CpG-DNA enhanced the total number of TFH cells per LN and also 
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increased the proportion of TFH in activated CD4
+
 T cells (Rookhuizen & DeFranco 
2014).  
 
Using an ELISpot assay, we also detected significant numbers of IgG ASC upon 
stimulation by the sH1N1 virus antigen and CpG-DNA. Co-incubation of CpG-DNA 
with sH1N1 antigen significantly augmented the antigen-specific IgG ASC to 
influenza HA in adenotonsillar cells compared to the antigen stimulation alone. It is 
likely that influenza HA- specific memory B cells are abundant in NALT, which 
respond to the antigen stimulation and CpG-DNA. Our results also demonstrated the 
predominance of IgG ASC that is concordant with previous studies showing memory 
B cell responses to protein antigens in human NALT (Boyaka et al. 2000; Nadal et 
al. 1992).  
 
A significant increase in CD4
+
 CXCR5
hi
 BCL-6
+
 was seen after CpG-DNA 
stimulation in a dose dependent manner and this was correlated with the increase in 
numbers of TFH cells. BCL-6 is the master regulatory transcription factor that 
controls TFH cell differentiation (Johnston et al. 2009; Nurieva et al. 2009; Yu et al. 
2009b). In this study BCL-6 expression was assessed by flowcytometry. The BCL-6 
expression in CD4
+
 T cells was shown to be increased consistently by stimulation 
with CpG-DNA and sH1N1 antigen.  
A rise in number of TFH-IL-21
+
 cells after stimulation with CpG-DNA (data not 
shown), that was correlated with an enhanced IL-21 production in cell culture 
supernatant.  We further showed that mainly TFH cells but not non-TFH cells 
produced IL-21 following stimulation with CpG-DNA. It is known that IL-21 plays 
an important role in TFH cell differentiation and B cell immunity in vivo (Eto et al. 
2011).  
 134 | P a g e  
 
We showed in this study that tonsillar TFH cells were able to proliferate following 
stimulation with CpG-DNA and sH1N1 virus antigen. This may suggest that there 
are antigen-specific TFH (eg. Influenza antigen-specific TFH) which proliferate upon 
antigenic stimulation. The fact CpG-DNA enhances TFH proliferation would indicate 
that it is possible to use CpG-DNA to modulate TFH function to enhance B cell 
response. Studies by Morita et al. showed the induction of blood CXCR5
+
 CD4
+
 T 
cells to proliferate after stimulation with CMV or an inactivated influenza virus 
(Morita et al. 2011). A study by Rasheed and colleagues reported that a polyclonal 
stimulation of tonsillar CD4
+
 T cells with anti-CD3/CD28 antibodies induced TFH 
cell proliferation (Rasheed et al. 2006). Bendigs et al. showed that the addition of 
CpG-DNA to anti-CD3-stimulated T cells induced a proliferative responses in the 
absence of APC and suggested that CpG-DNA could directly co-stimulate T cells 
(Bendigs et al. 1999). Lacroix-Lamandé et al. reported in mouse model, CpG-DNA 
administered orally induced a significantly increased numbers of CD4
+
 T cell 
observed in the intestinal mucosa and the draining lymph nodes (Lacroix-Lamandé 
et al. 2009). 
 
TLR-9 expression was examined by intracellular staining followed by 
flowcytometry, and we found that TLR-9 was detectable only at a low level on TFH 
cells. TLR expression in T cells remains inconclusive, however, several studies have 
reported the expression of TLR-9 on CD4
+
 T cells and the direct co-stimulatory 
effects of CpG-DNA on primary T cell activation (Kabelitz 2007). A previous study 
by Bendigs et al. showed that TLR-9 ligand (CpG-DNA) was able to co-stimulate T 
cell proliferation and cytokine production in the absence of APCs (Bendigs et al. 
1999). Another study demonstrated in murine purified CD4
+
 T cells that CpG-DNA 
directly enhances CD4
+
 T cell proliferation and IL-2 production. They also reported 
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that MyD88 expression particularly in CD4
+
 T cells was required for the CpG-DNA-
mediated antibody response to a T cell dependent antigen in vivo (Gelman et al. 
2006). Treatment of highly purified activated mouse CD4
+
 T cells with dsRNA 
synthetic analog poly (I:C) and CpG-DNA upregulated the expression of TLR-3 and 
TLR-9 respectively, although peptidoglycan and LPS (respective ligands for TLR-2 
and TLR-4) showed no effect (Gelman et al. 2004). 
 
As expected, TLR-9 was expressed in tonsillar B cells. The TLR-9 expression by B 
cells is well documented (Bourke et al. 2003; Jiang et al. 2007). pDC was also found 
to express TLR-9. In humans, the expression of TLR-9 by pDC is unique in the DC 
system and other DC types including conventional DC were not found to express 
TLR-9 (Fuchsberger, Hochrein & O'Keeffe 2005; Hornung et al. 2002).  
 
We have shown that TFH express high levels of IL-21 and that were important for B 
cell antibody production. TFH cells also express IL-21 receptor (IL-21R), and this 
coexpression reflects an autocrine loop (Nurieva et al. 2008; Silver & Hunter 2008). 
Recently it has been reported that IL-21 acts as growth factor and it is required for 
the generation and/or maintenance of TFH cells (Vogelzang et al. 2008). Our study 
showed the importance of IL-21 in TFH cell-mediated B cell antibody production in 
adenotonsillar cells. Blocking the IL-21R by a neutralizing antibody significantly 
reduced the numbers of TFH cells. The reduction of TFH cells was correlated with a 
significant reduction of HA-specific IgM and IgA production. Because the Fc 
portion of IL-21R-Fc protein was from human IgG, the control for these experiments 
was human IgG. Consequently, specific-HA IgG secretion could not be analyzed in 
these cultures because of the cross-reactivity of the Fc portion of IL-21R-Fc in the 
IgG ELISA.  
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In agreement with these findings, Vogelzang and colleagues reported that IL-21 
deficient mice exhibited a marked reduction in GC B cells and GC formation 
compared with wild type mice 7 days after immunization. Further, major defects in 
IgG1 production was reported in these IL-21 deficient mice (Vogelzang et al. 2008). 
Analyses of TFH cells 7 days after immunization shown a defect in the generation of 
TFH cells, defined as CD4
+
 CXCR5
+ 
ICOS
+
 T cells, in IL-21 deficient mice 
(Vogelzang et al. 2008). Nurieva et al. reported that the numbers of both TFH cells 
and GC B cells were significantly lower in IL-21 deficient mice immunized with 
keyhole limpet hemocyanin (KLH) compared with wild type mice (Nurieva et al. 
2008).  
 
Using purified TFH cells and B cells from human tonsillar tissues, Berglund et al. 
have reported a major reduction in IgM production when IL-21 was blocked by 
neutralizing antibody (IL-21R-Fc) compared to unblocked controls (Berglund et al. 
2013). Rodríguez-Bayona et al. studied purified tonsillar TFH cells and plasma cells 
co-cultured in the presence or absence of neutralizing antibody (IL-21R-Fc). This 
study showed that secretion of IgA by plasma cells was significantly reduced when 
IL-21R was neutralized as a result of blocking TFH cell-derived IL-21. Further, 
blocking IL-10 did not reduce the TFH cell effect on plasma cell antibody production, 
indicating that TFH cell-derived IL-21 was the active factor (Rodríguez-Bayona et al. 
2012). Therapies aimed at blocking the IL-21/IL-21R signalling, either directly on 
IL-21/IL-21R or indirectly targeting TFH cells to control the differentiation of 
autoreactive B cells into plasma cells, was suggested as a potential strategy for 
treatment of autoimmune diseases (Moens & Tangye 2014). 
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To determine whether pDC cells contribute to the adjuvant effect of CpG-DNA in 
the TFH cell mediated B cell antibody response, purified pDC were added to TFH cells 
and co-cultured with B cells. We found that the addition of pDC to TFH-B cell co-
culture significantly enhanced the influenza HA-specific antibody response. This 
suggests that pDC may contribute significantly to CpG-DNA-mediated TFH help to B 
cell antibody response. There has been no data available on any potential effect of 
pDC on TFH in the published literature. However, it has been shown that antigen 
presentation by myeloid DC is necessary to initiate TFH cell development (Choi et al. 
2011; Goenka et al. 2011), despite that in most cases, antigen presentation by B cells 
is responsible for promoting the full differentiation program of TFH cells 
(Ballesteros-Tato & Randall 2014; Johnston et al. 2009; Nurieva et al. 2009). As it is 
known that pDC express high levels of TLR-9, and we showed there is a prominent 
number of pDC in adenotonsillar tissue, pDC may play an important part in the TFH-
mediated B cell help for antibody response in human NALT. Recently, Chakarov 
and Fazilleau reported a significant increase in TFH cell development upon the 
addition of CpG-DNA to other vaccine adjuvant and that was depended on TLR-9 
signalling in CD11c
+
 DC. They also demonstrated an important role played by 
monocyte-derived DCs on the TFH cell response after CpG-DNA vaccination 
(Chakarov & Fazilleau 2014).  
 
CpG-DNA has strong immunostimulatory effects on pDC through TLR-9 
recognition and signalling (Krug et al. 2001a; Krug et al. 2001b; Rothenfusser et al. 
2002). Moseman et al. reported that CpG-DNA type B promoted pDC to prime 
allogeneic naïve CD4
+
 T cells (Moseman et al. 2004). Recently, Deal et al. reported 
that rotavirus-specific serum and mucosal antibody responses were enhanced upon 
the addition of purified pDC (Deal et al. 2013). Another study showed that the 
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depletion of pDC impaired the specific influenza antibody response (Jego et al. 
2003). Knowing that NALT are enriched with pDC (Polak et al. 2008; Rescigno 
2013), this important role played by pDC in the TFH cell mediated B cell antibody 
response might be an important strategy in modulating the immune response against 
respiratory pathogens.  
 
In summary, we show that CpG-DNA enhanced B cell antibody response that was 
correlated with induction of TFH cells in human NALT, suggesting that CpG-DNA 
may be able to enhance vaccine immunogenicity through modulating TFH function. 
IL-21 is crucial in TFH cell-mediated B cell antibody production in adenotonsillar 
cells. We also show an important role of pDC in enhancing the antibody levels in our 
tonsillar TFH - B cells co-cultures. Enhancing vaccine immunogenicity through 
modulation of TFH function in human NALT using immunological adjuvants such as 
CpG-DNA may be an effective vaccination strategy against respiratory pathogens. 
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Chapter 5 
 
 
Effect of TFH on Live 
Attenuated Influenza Vaccine 
(LAIV)-induced antibody 
response in NALT 
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5.1 Introduction 
Influenza virus is highly contagious and it is transmitted through airborne droplets 
and via the nasal mucosa. The virus infects by binding their surface glycoprotein HA 
to sialic acid receptors on the host epithelia cell surface (Barbey-Martin et al. 2002). 
Intranasal vaccination has been proposed for a more effective and biologically 
relevant way of immunization against influenza. Intranasal vaccination most likely 
relies on the local mucosal immune tissue for both local and systemic immune 
responses. Mucosal immunity in the upper respiratory tract is considered the first 
line of defence against a number of pathogens of both bacterial and viral origin. 
Human adenoids and tonsils are major components of NALT and known to be main 
induction sites for both mucosal and systemic immunity against upper respiratory 
tract pathogens including influenza infection (Kiyono & Fukuyama 2004; Tamura & 
Kurata 2004; Wu & Russell 1997; Zuercher et al. 2002).  
 
In the 1940s, inactivated influenza vaccines were first presented and they are still 
considered the main formulation of influenza vaccines. The aim of influenza 
vaccination is to induce an immunological protection against influenza infection. 
Protection following natural infection with influenza is primarily mediated by anti 
HA-specific antibodies in serum and mucosa, and T-cell responses associated with 
reduced disease severity (Brokstad et al. 2001).  Influenza vaccination is the main 
preventative method against influenza infection and its associated complications 
(Brokstad et al. 2001; Cox & Subbarao 1999).  
 
Live Attenuated Influenza Vaccine (LAIV) is a live, trivalent intranasal spray 
vaccine that produces the HA and NA surface antigens from a number of influenza 
viruses including one influenza A (H1N1) virus, one influenza A virus (H3N2), and 
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one influenza B virus (WHO). Studies have reported LAIV vaccines delivered 
intranasally were able to induce strong immune responses including induction of 
mucosal IgA and IgG, and serum IgG and enhanced local cytokine responses, which 
may provide better protection than intramuscular injection of inactivated influenza 
vaccines. LAIV vaccines were also shown to stimulate stronger cellular immune 
response by inducing influenza specific memory T cells and B cells (De Filette et al. 
2006; Vajdy et al. 2007). Intranasal vaccination with LAIV has been used 
successfully in several countries including USA and Canada (under the commercial 
name FluMist
®
) with good efficacy (Belshe 2004). Most recently, LAIV Intranasal 
vaccination has also been licensed in Europe including the UK (under the 
commercial name Fluenz
™
).  Both live attenuated vaccine and inactivated vaccines 
are currently in use. At present, seasonal influenza vaccination are recommended to 
be taken every year using TIV for all individuals in particular, children aged 6 
months or older, those with a diversity of chronic illnesses and health care workers.  
In addition, LAIV is also recommended for healthy non-pregnant people aged 2-49 
years (Osterholm et al. 2012).  
 
Intramuscular vaccinations with TIV mainly induce serum HAI antibody responses, 
in older children and adults who have significant immunological memory to 
influenza virus. In contrast, intranasal administration of LAIV induces both serum 
and mucosal antibody responses, particularly in young, non-immune children 
(Belshe 2004; Cox & Subbarao 1999; De Filette et al. 2006). Recent studies reported 
that LAIV intranasal influenza vaccine consistently showed higher efficacy in young 
children when compared to TIV delivered intramuscularly (Osterholm et al. 2012). 
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Although it has been shown to be safe and effective in humans, not much research 
has been done to evaluate the local mucosal immunity induced by these LAIV 
intranasal vaccines. As these vaccines contain live attenuated viruses and 
administered through the nasal mucosa mimicking natural infection, it may induce an 
immune response resembling natural immunity. NALT components, including 
adenotonsillar tissues are local mucosal immune organs in the upper respiratory 
tract; therefore, intranasal vaccines are likely to depend on these immune tissues to 
induce specific immune responses. 
 
Within secondary lymphoid organs, TFH cells have been identified as a new T helper 
subset specialized to regulate the development of effector and memory B cells and 
long-lived plasma cells. The interaction between TFH cells and B cells leads to B 
cells differentiation and GC formation within the follicle (Choi et al. 2011). 
Immunological events that lead to the development of protective immunity after 
vaccinations remain largely unknown. For better future vaccine design, there has 
been an increasing interest in understanding the mechanisms that controls the 
differentiation and maturation of TFH cells. 
 
In this study, an in vitro cell culture model was used to study the effect of TFH 
mediated B cell immune responses induced by a LAIV intranasal vaccine, which 
contains live attenuated influenza viruses including A/Brisbane/59/2007 (H1N1), 
A/Brisbane/10/2007 (H3N2) and B influenza strains.  
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5.2 Aims of Study 
To investigate: 
 Whether LAIV intranasal vaccine promotes TFH cells in human NALT.  
 Whether LAIV enhances B cell immunity to Influenza virus through TFH cells in 
human NALT. 
 The role of IL-21 in TFH cell-mediated B cell antibody production in NALT. 
5.3 Experimental Design 
Adenotonsillar MNC were stimulated with a LAIV intranasal vaccine. The effect of 
LAIV stimulation on TFH cell numbers were analysed by flow cytometry. HA-
specific memory B cell responses were measured using ELISpot and cell culture 
supernatants were analysed for antibody production by ELISA. Additionally, the role 
of IL-21 in TFH cell-mediated B cell antibody production in NALT was analysed by 
blocking IL-21 receptor. 
5.3.1 Patients and Samples  
Surgically removed adenotonsillar tissues were obtained from children and adults 
(1.5–36 years). Peripheral blood samples were also obtained from each patient on the 
same day of operation. Patients who were previously vaccinated against influenza or 
who had any known immunodeficiency were excluded from the study. 
5.3.2 Mononuclear Cell Separation 
Mononuclear cells were isolated using Ficoll density centrifugation following 
methods described previously in the materials and methods chapter 2. Briefly, 
adenotonsillar tissue samples were minced by a scalpel to release cells into the 
medium. Then the cell suspension was filtered through a 70μm cell strainer. The 
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adenotonsillar cells and peripheral blood were carefully layered onto 15 ml Ficoll-
Paque™ PREMIUM and spun at 400g for 30 min at room temperature. The interface 
layer of mononuclear cells was carefully harvested. MNC were washed twice with 
sterile PBS solution, then the pellet was re-suspended in 5 ml RPMI-1640 culture 
medium with HEPES supplemented 10% heat inactivated FBS, 1% L-glutamine, 
streptomycin (50μg/ml) and penicillin (50U/ml). After counting, each cell 
suspension was adjusted to contain 4x10
6
 cells/ml concentrations. 
5.3.3 Influenza Virus Antigen and LAIV 
5.3.3.1 Intranasal Live Attenuated Influenza Vaccine (LAIV)  
Intranasal LAIV (FluMist formula 2009-10) is a live, trivalent intranasal spray 
vaccine that produces the HA and NA surface antigens from a number of influenza 
viruses including A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2) and B 
influenza strains. These three viruses are characterized as being temperature 
sensitive, cold adapted and attenuated viruses (FluMist, BEI resources ATCC).  
 
5.3.3.2 Recombinant HA 
The recombinant HA was derived from a seasonal H1N1 influenza virus 
(A/Brisbane/59/2007) (BEI Resources, ATCC, USA). This recombinant HA was 
used as the coating antigen in ELISA and ELISpot assays.   
  
5.3.4 Stimulation by LAIV for Antibody and IL-21 Production 
Adenotonsillar MNC were isolated from adenotonsillar tissues as described earlier. 
The cell suspension was adjusted to contain 4x10
6
 cells/ml concentrations in RPMI-
1640 medium. 500 μl/well of cells were cultured in 48-well flat bottom culture plates 
then stimulated with 2μl/well LAIV (FluMist, BEI resources, ATCC). An 
unstimulated medium control was included in each experiment. Cells then were 
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cultured for 24 hours for cytokine production and 14 days for antibody production at 
37°C, 5% CO2.  Cell culture supernatants were collected from each well and stored 
at -80°C until further analysis by ELISA. 
 
5.3.5 Measurement of HA Specific IgG/IgM/IgA ELISA Assay 
ELISA assay was used to detect influenza HA -specific IgG, IgM and IgA antibodies 
found in cell culture supernatants using a procedure as previously described 
(Mahallawi et al. 2013). In brief, ELISA plates were coated with purified 
recombinant HA and incubated overnight at 4°C. The following day, plates were 
washed then blocked for 1 hour at room temperature. Samples were then added and 
incubated for 2 hours at room temperature. Plates were washed and followed by the 
addition of alkaline phosphatase-conjugated mouse anti-human IgG or IgM or IgA. 
After 2 hours, plates were washed and PNPP substrate buffer were added then 
incubated at room temperature and in dark. Finally, the OD at 405nm was measured 
using a microtiter plate reader and data were analysed using DeltaSoft software. 
 
5.3.6 Measurement of B cell Antibody Response by ELISpot Assay 
ELISpot assay was used to measure the frequencies of antibody-producing B cells 
specific to HA of sH1N1 (A/Brisbane/59/2007) using a protocol previously 
described. Briefly, ELISpot plates were coated overnight at 4°C with recombinant 
HA of sH1N1. Plates were washed and blocked by incubation with RPMI containing 
10% FBS at room temperature for 1 hour. LAIV stimulated MNC were then added to 
the plates and incubated overnight at 37°C. Plates were washed and incubated with 
goat anti-human IgG biotin for 30 min at room temperature. After washing, 
Horseradish peroxidase Avidin D conjugate was added and incubated. Coloured 
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spots were developed with the addition of substrate  and counted using an automated 
ELISpot reader.  
 
5.3.7 CD45RO+ Cell Depletion from Adenotonsillar MNC  
To evaluate the LAIV stimulation on CD45RO
-
 cells, effector memory (CD45RO
+
) 
cells were depleted from the adenotonsillar MNC. The cells to be depleted 
(CD45RO
+
) were labelled with the specific magnetic micro-beads binding with the 
target surface molecules (CD45RO). The cell suspension is then allowed to pass 
through a MACS LD column, placed within the magnetic field of a MACS separator. 
The magnetically labelled cells (CD45RO
+ 
cells) are retained within the column, and 
the unlabelled cells (CD45RO
- 
MNC) pass through the column and collected in a 
tube placed underneath it. The depletion of CD45RO
+
 cells in adenotonsillar MNC 
removed the majority of TFH cells. 
 
5.3.8 Flow Cytometric Analysis  
5.3.8.1 Cell Stimulation for Flowcytometry Analysis 
Adenotonsillar MNC were adjusted to contain 4x10
6
 cells/ml concentrations in 
RPMI-1640. 500 μl/well of cells were cultured in 48-well flat bottom culture plates 
and stimulated with 2μl/well LAIV. An unstimulated control was included in each 
experiment. For TFH cells analysis, unfractionated adenotonsillar MNC were cultured 
for 3 days and CD45RO
+
 cell-depleted adenotonsillar MNC were cultured for 7 days 
at 37°C, 5% CO2. After that, cells were harvested for FACS staining.   
 
5.3.8.2 Cell Staining for Phenotyping for FACS Analysis 
For TFH cells identification, adenotonsillar MNC and PBMC were stained with anti-
human-CD3, -CD4, -CXCR5 and -ICOS antibodies. For GC B cells identification, 
adenotonsillar MNC were stained with anti-human CD19, -CD38 and -IgD 
 147 | P a g e  
 
antibodies. All cell staining was performed as described earlier. Immediately after 
staining, cells were acquired/analysed using a BD FACS Calibur or fixed and 
permeabilized if needed for intracellular staining. 
 
5.3.8.3 Intracellular Staining for BCL-6 and IL-21  
For BCL-6 analysis, stimulated CD45RO
+
 cell-depleted adenotonsillar MNC were 
incubated for 7 days. For IL-21 analysis, stimulated cells were incubated overnight, 
and then 10µg/ml brefeldin A was added to each sample and further incubated for 4 
hours at 37°C in 5% CO2. After that, cells were harvested and washed twice with 
FACS staining buffer followed by surface staining with fluorochrome-labelled anti-
human antibodies depending on the phenotype (Table 2.1) in a same procedure 
described earlier. Next, cells were fixed with intracellular fixation buffer. After 
incubation for 20 min, cells were washed twice with permeabilization buffer. Then 
the proper amount of BCL-6 or IL-21 anti-human antibodies  was added and 
incubated for 30 min. Cells were then washed with permeabilization buffer then 
resuspended in FACS staining buffer; and immediately acquired/analysed by flow 
cytometery. 
 
5.3.9 T cell Proliferation Assay  
T cell proliferative response was analysed by CFSE staining followed by flow 
cytometry. Briefly, adenotonsillar MNC were labelled with CFSE (at 37°C, for 8 
min) and the reaction was quenched with ice-cold media. After washing, cells were 
resuspended in RPMI 1640 media and stimulated with 2μl/well LAIV, and incubated 
(at 37°C, in 5% CO2) for 5 days. Then cells were harvested, washed and resuspended 
in 0.02% BSA in PBS and anti-CD4-PE-Cy7, -CXCR5-PE and -ICOS-APC were 
added to stain CD4
+
 CXCR5
hi
 ICOS
hi
 cells (TFH cells). TFH cell proliferation was 
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then examined by analysis of CFSE dilution and by gating from TFH cells (CXCR5
hi
 
ICOS
hi
 cells) followed by flow cytometry using BD FACS Calibur.  
 
5.3.10 Purification of TFH cells and B cells for Co‐culture Experiments 
For co-culture experiments, cells were isolated by magnetic cell sorting using 
EasySep™ magnetic technology (STEMCELL Technologies Inc.) as described in 
details in material and method chapter 2. Briefly, adenotonsillar B cells were 
negatively selected using EasySep™ human B cell enrichment kit (purity >99%). 
Adenotonsillar CD4
+
 T cells were negatively selected using EasySep™ human CD4+ 
T cell enrichment kit (purity >98%). CD4
+
 CXCR5
hi
 (TFH cells) were isolated by 
positive selection using biotin anti-human CXCR5 antibody and EasySep™ biotin 
selection kit (purity >90%). Non-TFH cells (CD4
+
 CXCR5
-
) was negatively selected 
from CD4
+
 T cells gaining a purity of >99%.  Details described previously in the 
materials and methods chapter 2. 
 
5.3.11 B cell Help by TFH Cells  
The ability of adenotonsillar TFH cells to help B cell antibody production was studied 
using an autologous system as follows. In co-culture experiments, B cells were 
cultured with an equal number of either TFH cells or non-TFH cells at a ratio of 1:1 
using a cell concentration of 5x10
5
 cells/ml. 250 μl/well of B:T cells were co-
cultured in 96-well round bottom plate in the presence or absence of LAIV 
(0.5μl/ml). Cells were then cultured at 37°C, 5% CO2, for 10 days followed by 
analysis for antibodies by ELISA.  
 
5.3.12 Anti-IL-21R Blocking Experiments  
Adenotonsillar MNC suspension was adjusted to contain 4x10
5
 cells/ml 
concentrations in RPMI-1640 medium. Cells were cultured in 96-well round bottom 
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plate in the presence or absence of LAIV with or without the recombinant human α-
IL-21R. Firstly, recombinant human α-IL-21R was added to the designated wells and 
incubated for 1 hour at 37°C in a 5% CO2 incubator.  These cells were then 
stimulated with LAIV (0.5μl/ml). Cells were then cultured in a CO2 incubator at 
37°C, 5% CO2, for 3 days for TFH cell analysis and 10 days for antibody production. 
After 3 days, cells were harvested and stained for surface staining markers such as 
CD4, CXCR5 and ICOS in a same procedure described earlier. Furthermore, after 10 
days incubation, cell culture supernatants were collected from each well and stored 
at -80°C until further analysis by ELISA to measure the HA-specific H1N1 IgM and 
IgA antibodies. 
 
5.3.13 Statistical Analysis  
Statistical analysis was carried out using GraphPad Prism 5 software (GraphPad 
Software, San Diego, CA, USA). Differences between stimulated and unstimulated 
samples in the same group of subjects were analysed by Student’s paired t test 
(parametric). Throughout the thesis, * indicates a P-value between 0.01-0.05, ** 
indicates a P-value between 0.001-0.01 and *** indicates a P-value <0.001. 
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5.4 Results 
5.4.1 Optimisation of LAIV concentration for TFH cell stimulation in 
adenotonsillar MNC 
The optimal concentration of LAIV required for induction of TFH cells in CD45RO
+
 
cell-depleted adenotonsillar MNC was determined by stimulation of 5 samples with 
different concentrations (0, 0.5, 1.0, 1.5, 2 and 4 μl/ml) of LAIV. As shown in figure 
5.1, 2μl/ml of LAIV showed to give the highest stimulatory effect compared to the 
unstimulated (0 μl/ml) controls. This concentration (2 μl/ml) was used to stimulate 
adenotonsillar MNC in subsequent experiments. Similar findings were also seen in 
unfractionated adenotonsillar MNC (See appendix-I). 
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Figure 5.1. Dose-response curve for TFH cell induction by stimulation with LAIV 
(A) A representative density plot flowcytometry analysis of CD45RO
+
 cell-depleted 
adenotonsillar MNC stimulated for 7 days with different concentrations of LAIV. The value 
shown is the percentage of TFH cells in CD4
+
 T cells.  (B) Summary percentage of TFH cells 
from CD45RO
+
 cell-depleted adenotonsillar MNC stimulated with LAIV. The values 
represent the mean ± SEM from five individual tonsils.  
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5.4.2 LAIV can promote TFH cells in adenotonsillar cells 
In order to study the effect of LAIV on TFH cells, freshly isolated adenotonsillar 
MNC were stimulated for 72 hours with LAIV (2µl/ml).  It is shown in figure 5.2.A 
that LAIV elicited a significant increase in the percentage of TFH cells compared to 
unstimulated medium control (25.5% versus 19.8%).  
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Figure 5.2. LAIV can promote TFH cells in adenotonsillar cells 
(A) Representative density plot flowcytometry analysis of MNC stimulated for 72 hours 
with LAIV. The value shown is the percentage of TFH cells in CD4
+
 T cells.  (B) Summary 
percentage of TFH cells from MNC stimulated with LAIV (2µl/ml). The values represent 
the mean ± SEM from 15 individual tonsils (p-value derived from Paired two-tailed t test, 
***P < 0.001).  
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In order to study the effect of LAIV on TFH induction from naive CD4
+
 T cells, 
adenotonsillar MNC depleted of activated and memory (CD45RO
+
) T cells were 
stimulated for 7 days with LAIV (2µl/ml).  As shown in figure 5.3.A, LAIV induced 
a marked increase in the percentage of TFH cells (mean, 12.4%) higher than 
unstimulated medium control (mean 3.3%).   
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Figure 5.3. LAIV induced TFH cells in CD45RO
+
 depleted adenotonsillar MNC 
(A) A representative density plot showing induction TFH following cell stimulation for 7 
days with LAIV. The value shown is the percentage of TFH cells in CD4
+
 CD45RO
- 
T cells.  
(B) Summary percentage of TFH cells from MNC stimulated with 2µl/ml LAIV. The values 
represent the mean ± SEM from 12 individual tonsils (p-value derived from Paired two-
tailed t test, ***P < 0.001).  
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5.4.3 Induction of CD4+ BCL-6+ cells in adenotonsillar cells by LAIV  
Effect of LAIV on TFH induction was also analysed by staining for CD4
+
 BCL-6
+
 
TFH cells, adenotonsillar MNC depleted of activated and memory (CD45RO
+
) T cells 
were stimulated with LAIV (2µl/ml). These cells were then harvested and stained for 
BCL-6 intracellular staining following a protocol described earlier. It is shown in 
figure 5.4.A that LAIV induced a significant increase in the number of CD4
+
 BCL-
6
+
 cells (12.2%) compared to unstimulated medium control (2.1%) within TFH cells 
in human adenotonsillar tissues.    
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Figure 5.4. CD4
+
 BCL-6
+
 cells induction by LAIV 
 (A) A representative density plot flowcytometry analysis of MNC (CD45RO
+
) depleted cells 
stimulated for 7 days with LAIV. The value shown is the percentage of CD4
+
 BCL-6
+
 gated 
from TFH cells.  (B) Summary of CD4
+
 BCL-6
+
 cells from MNC stimulated with LAIV. The 
values represent the mean ± SEM from eight individual tonsils (p-value derived from Paired 
two-tailed t test, **P < 0.01).  
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5.4.4 Effect of LAIV on TFH cell proliferation in adenotonsillar MNC 
To determine whether TFH cells proliferate upon stimulation by LAIV, adenotonsillar 
MNC were stained with CFSE followed by stimulation with LAIV for 5 days before 
flowcytometry. As shown in figure 5.5.A, LAIV induced a marked TFH cell 
proliferation, with a mean TFH cell proliferation index of 15.2%, significantly higher 
than unstimulated medium control (mean 6.5%).   
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Figure 5.5. TFH cell proliferative response in adenotonsillar MNC after stimulation 
with LAIV 
 (A) Representative CFSE staining analysis of MNC stimulated for 5 days with LAIV, the 
value shown is the mean TFH cell proliferation index in CD4
+
 T cells.  (B) Summary 
analysis of TFH cell proliferation from MNC stimulated with LAIV. The value represents 
the mean ± SEM of TFH cell proliferation index gated from CXCR5
hi
 ICOS
hi
 cells from 10 
individual tonsils (p-value derived from Paired two-tailed t test, **P < 0.01).  
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5.4.5 Induction of anti-sH1N1 HA antibodies in adenotonsillar cells by LAIV 
 Induction of HA-specific antibody production to sH1N1 in adenotonsillar MNC 
culture was analysed following LAIV stimulation with different doses (0, 0.5, 1.0, 
1.5, 2 and 4 μl/ml) of LAIV.  As seen in figure 5.6, HA-specific sH1N1 antibody 
production (IgG, IgM and IgA) was highest when stimulated with LAIV at 2μl/ml, 
the same as the optimal concentration shown earlier for TFH induction. This 
concentration was therefore used to stimulate adenotonsillar MNC in subsequent 
experiments. 
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Figure 5.6. Optimisation of LAIV concentration for in vitro stimulation of 
adenotonsillar MNC for specific antibody response 
Dose response of LAIV in the induction of anti-sH1N1 HA IgG (A), IgM (B) and IgA 
(C) production in adenotonsillar MNC cultures. The values represent anti-sH1N1 HA 
IgG, IgM and IgA titre mean ± SEM from five individual tonsils.  
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To investigate the effect of intranasal vaccine on B cell antibody production in 
association with TFH cells, influenza HA-specific antibody response was studied 
following LAIV stimulation. Adenotonsillar MNC were stimulated with LAIV for 
14 days. Cell culture supernatants were collected and analyzed by ELISA assay for 
the detection of specific sH1N1 HA antibodies. As shown in figure 5.7.A, significant 
influenza HA-specific IgG titres were detected in the MNC culture supernatants after 
stimulation (mean ± SEM: 0.75 ± 0.13) compared with unstimulated medium 
control, (p < 0.001). LAIV stimulation also induced HA-specific IgM production 
(mean ± SEM: 0.31 ± 0.10) compared with unstimulated medium control (p<0.001) 
(Figure 5.7.B). HA-specific IgA antibodies were also induced in cell culture 
supernatants (mean ± SEM: 0.22 ± 0.02) compared with unstimulated medium 
control (p< 0.001) (Figure 5.7.C).  
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Figure 5.7. LAIV induces HA-specific anti-sH1N1 IgG, IgM and IgA in adenotonsillar 
MNC 
Adenotonsillar MNC were stimulated with LAIV. After 14 days, Cell culture supernatants 
were collected and analysed for anti-sH1N1 HA IgG (A), IgM (B) and IgA (C) antibody 
using ELISA. The values represent the mean ± SEM from 16 individual tonsils (p-value 
derived from Paired two-tailed t test, ***P < 0.001). 
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To ascertain whether TFH are required for the antibody induction induced by LAIV, 
TFH (CD4
+
 CXCR5
hi
) cells were purified, co-cultured with purified B cells in the 
presence of LAIV. As shown in figure 5.8, the co-cultured cells stimulated by LAIV 
induced significant antibody production only in the presence of CD4
+ 
CXCR5
hi
 (TFH) 
cells, but not in the presence of CD4
+ 
CXCR5
-
 (non-TFH) cells; i.e. TFH but not non-
TFH cells were able to help B cells for the production of HA-specific IgG 
(Figure.5.8.A), IgM (Figure.5.8.B) and IgA (Figure.5.8.C) antibodies. 
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Figure 5.8. LAIV induces HA-specific sH1N1 IgG, IgM and IgA from B cells co-
cultured with purified TFH cells but not with non-TFH cells 
 Purified B cells were co-cultured with either purified TFH cells (Red bar) or non-TFH cells 
(open bar) (at a ratio of 1:1) and stimulated with LAIV.  After 10 days, cell culture 
supernatants were collected and analysed for anti-sH1N1 HA IgG (A) IgM (B) and IgA (C) 
antibody production using ELISA. The value represents the mean ± SEM from 16 
individual tonsils (p-value derived from Paired two-tailed t test, NS: Not Significant, ***P 
< 0.001).  
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5.4.6 Detection of ASC following stimulation by LAIV in adenotonsillar cells  
To confirm antibody production measured by ELISA, ELISpot assay was performed 
to enumerate the numbers of anti-sH1N1 HA B cell responses following stimulation 
by LAIV. It is shown in figure 5.9 that LAIV induced significant numbers of HA-
specific sH1N1 IgG ASC compared to unstimulated medium control (mean ± SEM, 
27.8 ± 2.7 versus 4.0 ± 0.65) in human adenotonsillar tissues. 
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Figure 5.9. ELISpot assay to enumerate IgG ASC to sH1N1-HA 
Adenotonsillar MNC were stimulated with LAIV for 5 days. (A) A representative sample 
showing the number of HA-specific ASC induced by LAIV.  (B) Summary of the number of 
HA-specific ASC from MNC stimulated with LAIV.  The values represent the mean ± SEM 
from 8 samples (paired two-tailed t test, ***P < 0.001). 
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5.4.7 Effect of LAIV on Human adenotonsillar GC B cells 
B cell subsets in adenotonsillar MNC was analysed with a combination of CD19, 
CD38 and IgD fluorescence-labelled anti-human antibodies. After gating on CD19
+
 
B cells, GC B cells were identified as (CD19
+
 CD38
hi 
IgD
-
) (R1, Red). In order to 
study the effect of LAIV on GC B cells in vitro, freshly isolated adenotonsillar MNC 
were stimulated for 72 hours with LAIV intranasal vaccine. As shown in figure 
5.10.A, LAIV significantly increased the number of GC B cells compared to 
unstimulated medium control (mean, 15.3% versus 9.2%).  
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Figure 5.10. Effect of LAIV on adenotonsillar GC B cells 
(A) Representative flowcytometry dotplot showing B cell subsets including GC B cells 
(CD19
+
 CD38
hi 
IgD
-
) in adenotonsillar MNC after stimulation with LAIV. The values 
represent the mean percentage of GC B cells. (B) Summary of GC B cells from 
adenotonsillar MNC stimulated with LAIV. The values represent the mean ± SEM from 
13 individual tonsils (Paired two-tailed t test, ***P < 0.001).  
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5.4.8 Induction of CD4+ IL-21+ cells in adenotonsillar cells by LAIV 
In order to study the effect of LAIV on IL-21 producing cells, freshly isolated 
adenotonsillar MNC were stimulated for 24 hours with LAIV (2µl/ml). These cells 
were then harvested and stained for IL-21 following a protocol described earlier. 
Compared to unstimulated medium control, figure 5.11 shows that LAIV induced a 
significant increase in the number of IL-21 producing cells (9.0% versus 14.1%) 
within TFH cells in human adenotonsillar tissues.    
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Figure 5.11. Induction of CD4
+
 IL-21
+
 cells in adenotonsillar cells by LAIV 
 (A) Representative density plot flowcytometry analysis of MNC stimulated for 24 hours 
with LAIV. The value shown is the percentage of CD4
+
 IL-21
+
 gated from TFH cells.  (B) 
Summary percentage of CD4
+
 IL-21
+
 cells (gated from TFH cells) from MNC stimulated with 
LAIV. The values represent the mean ± SEM from 12 individual tonsils (p-value derived 
from Paired two-tailed t test, **P < 0.01).  
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Further, the induction of IL-21 was also analysed in unfractionated adenotonsillar 
MNC culture supernatants 24 hours after stimulation with LAIV. Production of IL-
21 was shown to be significantly higher with LAIV stimulation compared to 
unstimulated medium control (mean ± SEM, 846.5 ± 89.2 versus 389.7 ± 48.2) 
(Figure.5.12.A). To ascertain the effect of LAIV intranasal vaccine on TFH 
production of IL-21, purified CXCR5
hi
 CD4
+
 T cells (TFH) were co-cultured with 
purified B cells in the presence of LAIV for 24 hours. IL-21 concentration was 
shown to increase significantly following LAIV stimulation in the presence of TFH 
cells (Figure.5.12.B) but not in the presence of CXCR5
- 
CD4
+
 T cells (non-TFH) 
(Figure.5.12.C).  
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Figure 5.12. IL-21 concentration increases in the presence of TFH cells, but not with 
non-TFH cells following stimulation with LAIV    
Unfractionated adenotonsillar MNC were stimulated with LAIV (A) and purified TFH cells 
(B) or non-TFH cells (C) were co-cultured with B cells in the presence of LAIV intranasal 
vaccine. After 24 hours, cell culture supernatants were collected and analysed for IL-21 
using ELISA. The value represents the mean ± SEM (A, n=22; B, n=17; C, n=17) (Paired 
two-tailed t test, **P < 0.01, ***P < 0.001, NS: not significant).  
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5.4.9 IL-21 is important in TFH cell-mediated B cell antibody production in 
adenotonsillar cells 
In order to study the importance of IL-21 in TFH cell-mediated B cell antibody 
production, anti-IL-21R blocking antibody (α-IL-21 R) was added to adenotonsillar 
MNC and incubated for 1 hour at 37 ⁰C, then stimulated with LAIV for 3 days (for 
TFH cells analysis) and 10 days (for antibody production).  As shown in figure 5.13.A 
blocking IL-21 receptor significantly reduced the percentage of TFH cells compared 
to un-blocked samples, (mean, 20.1% versus 15.9%). Further, the antibody level 
(sH1N1 IgM and sH1N1 IgA) was also significantly reduced when IL-21 receptor 
was blocked as shown in figures 5.13.B and 5.13.C respectively.   
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Figure 5.13. Blocking IL-21R leads to a significant reduction in percentage of TFH cells 
and antibody production in human adenotonsillar tissue 
α-IL-21R was added to MNC and incubated for 1 hour/37 ⁰C, then stimulated with LAIV.  
(A) Shows the percentage of TFH cells with and without α-IL-21R. The specific sH1N1 IgM 
(B) and IgA (C) OD levels from MNC stimulated with LAIV with and without α-IL-21R 
after 10 days measured by ELISA. The values represent the mean ± SEM from eight 
individual tonsils (p-value derived from Paired two-tailed t test, ***P < 0.001).  
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5.4.10 LAIV can promote pTFH cells, anti-sH1N1-HA antibodies and IL-21 in 
PBMC 
In order to study the effect of LAIV on pTFH cells in vitro, freshly isolated PBMC 
were stimulated for 72 hours with LAIV (2µl/ml).  As was shown in figure 5.14.A 
that LAIV induced a significant increase in pTFH cells compared to unstimulated 
medium control (mean, 1.3% versus 0.4%) in human PBMC. 
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Figure 5.14. LAIV can promote pTFH cells in PBMC 
(A) Representative density plot flowcytometry analysis of PBMC stimulated for 72 hours 
with LAIV. The value shown is the mean percentage of pTFH cells in CD4
+
 T cells.  (B) 
Summary percentage of pTFH cells from PBMC stimulated with LAIV (2µl/ml). The values 
represent the mean ± SEM from 10 individual patients (p-value derived from Paired two-
tailed t test, **P < 0.01).  
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Further, PBMC were isolated and co-cultured with LAIV for 14 days. Cell culture 
supernatants were collected and analyzed by ELISA assay for the detection of 
specific sH1N1 HA antibodies. As seen in figure 5.15.A, significant specific 
influenza HA-IgG antibody titres were detected in the PBMC culture supernatants 
after stimulation with LAIV (mean ± SEM: 0.44 ± 0.08 compared with unstimulated 
medium control, p<0.001). (Figure 5.15.B) LAIV stimulation also induced specific 
influenza HA-IgM antibody production in PBMC, (mean ± SEM: 0.18 ± 0.03) 
compared with unstimulated medium control, p<0.001. IgA antibodies to sH1N1 HA 
were also induced in PBMC culture supernatants (Figure 5.15.C), (mean ± SEM: 
0.18 ± 0.01) compared with unstimulated medium control, p < 0.001. 
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Figure 5.15. LAIV induces HA-specific anti-sH1N1 IgG, IgM and IgA in PBMC 
PBMC stimulated with LAIV. After 14 days, cell culture supernatants were collected and 
analysed for anti-sH1N1 HA IgG (A), IgM (B) and IgA (C) antibody using ELISA. The 
values represent the mean ± SEM from 10 individual donors (p-value derived from Paired 
two-tailed t test, **P < 0.01).  
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Induction of IL-21 was also analysed in PBMC culture supernatants, 24 hours after 
stimulation with LAIV. Production of IL-21 was shown to be significantly higher 
with LAIV stimulation compared to unstimulated medium control (mean ± SEM, 
138.8 ± 19.3 versus 39.9 ± 3.8) (Figure 5.16).  
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Figure 5. 16. IL-21 Levels increases after stimulation with LAIV in PBMC 
Human PBMC were stimulated with LAIV. After 24 hours, cell culture supernatants were 
collected and analysed for IL-21 levels using ELISA. LAIV induced high levels of IL-21 
compared to unstimulated medium control.   The value represents the mean ± SEM from 
seven individual samples (p-value derived from Paired two-tailed t test, **P < 0.01).  
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5.5 Discussion 
As LAIV intranasal vaccines were previously shown to induce strong immune 
response including mucosal IgA and IgG, and serum IgG and enhanced local 
cytokine responses (De Filette et al. 2006; Vajdy et al. 2007), we asked whether TFH 
cells contribute to the potent induction of antibodies in NALT B cells by LAIV.  In 
this study, numbers of TFH cells and GC B cells and antibody responses in NALT to 
HA-specific sH1N1 were investigated following stimulation of adenotonsillar MNC 
with LAIV vaccine which contains an A/Brisbane/59/2007 (H1N1), 
A/Brisbane/10/2007 (H3N2) and B influenza strains. 
 
We found that the percentage of TFH cells was increased significantly following 
stimulation by LAIV in a dose dependent manner. Galli et al.  previously reported 
that an early post-vaccination increase in the number of vaccine-specific CD4
+
 T 
cells is correlated with the rise and long-term maintenance of protective antibody 
titres to avian influenza (Galli et al. 2009). More recently, Spensieri and colleagues 
showed in a clinical trial that blood-derived influenza-specific ICOS
+
 IL-21
+
 CD4
+
 T 
cells help the in vitro differentiation of autologous B cells into cells secreting 
influenza-specific antibody in an antigen, IL-21 and ICOS dependent manner 
(Spensieri et al. 2013).  In line with these findings, Bentebibel et al. reported, using a 
non-adjuvanted trivalent split seasonal influenza vaccine, a significant induction of 
ICOS
+ 
CXCR5
+ 
CD4
+
 T cells representing a crucial immunological response 
associated with highly protective antibody levels after seasonal influenza 
vaccination. These ICOS
+ 
CXCR5
+ 
CD4
+
 T cells were seen in blood 7 days after 
vaccination and correlated with the increase of antibody responses (Bentebibel et al. 
2013). Furthermore, an in vitro induction of ICOS
+ 
CXCR5
+ 
CD4
+
 T cells by split 
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influenza vaccines was found to support B cells to differentiate into plasma cells 
(Bentebibel et al. 2013).  
 
In this study, significant increases in CD4
+
 BCL-6
+
 cells were also seen after LAIV 
stimulation. Consistently, the BCL-6 expression was significantly increased by 
LAIV, and that was correlated with the increase in number of TFH cells.  BCL-6 is 
highly expressed by TFH cells and is required for the TFH cell differentiation 
program (Johnston et al. 2009; Nurieva et al. 2009; Yu et al. 2009b).  
 
We also showed the LAIV intranasal vaccine induces the TFH cell proliferation in 
NALT.  Similar finding was seen by Morita et al. showing the induction of blood 
CXCR5
+
 CD4
+
 T cells to proliferate after stimulation with CMV or an inactivated 
influenza virus (Morita et al. 2011). A study by Rasheed and colleagues reported that 
a polyclonal stimulation of human tonsillar CD4
+
 T cells with anti-CD3/CD28 
antibodies induced the TFH cell proliferation (Rasheed et al. 2006).  
  
As expected, a significant increase in CD19
+
 CD38
hi
 IgD
-
 (GC B cells) was seen 
after LAIV stimulation. As shown in chapter 3, numbers of TFH cells strongly 
correlates with numbers of GC B cells. This is consistent with previous studies in 
both mice and humans (Baumjohann et al. 2013; Renand et al. 2013). A strong 
enhancement in number of GC B cells which was also shown to be correlated with 
the appearance of TFH cells after an influenza virus infection (Elsner, Ernst & 
Baumgarth 2012).  Fernandez and colleagues using an intranasal vaccination with a 
recombinant SEB vaccine in a mouse model, reported that elevated GC B cells 
within NALT were accompanied by high levels of IgA
+
 and IgG
+
 B cells (Fernandez 
et al. 2011). A study by Bessa et al. reported a strong specific IgG and IgA responses 
in serum and lungs using an intranasal virus-like particles vaccine.  Also An efficient 
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induction of B cell responses was also seen characterized by the presence of large 
numbers of GC B cells as well as plasma cells in the bone marrow and memory B 
cells in the spleen (Bessa et al. 2008).  
 
Significant antibody responses of all three isotypes (IgG, IgM and IgA) to the HA of 
seasonal H1N1 virus were observed in adenotonsillar MNC following LAIV 
stimulation. As we showed in this study (Figure 5.8), co-culture of purified TFH cells, 
but not non-TFH cells, with purified B cells was able to induce antigen specific IgG, 
IgM and IgA antibodies. This finding supports the assumption that TFH help to B 
cells is needed for the production of these antibodies in NALT compartments. Using 
a similar in vitro system, Bryant and colleagues co-cultured tonsillar CD4
+ 
CXCR5
+
 
cells (TFH cells) and CD4
+ 
CXCR5
-
 (non-TFH cells) with autologous B cells and 
showed similar results following stimulation by PHA and IL-2. (Bryant et al. 2007). 
Similar finding was also shown by Rasheed et al. reporting that CXCR5
- 
ICOS
- 
CD4
+
 
T cells (non-TFH cells) did not influence B cell production of IgG, and in contrast, 
CXCR5
hi 
ICOS
hi
 CD4
+
 T cells (TFH cells) promoted B cell secretion of IgG (Rasheed 
et al. 2006). In addition, Rodríguez-Bayona et al. reported similar finding by co-
culturing either the whole fraction of tonsil total CD4
+
 T cells or purified TFH cells 
with purified tonsil plasma cells. The purified TFH cell co-culture showed an increase 
of tonsillar plasma cell antibody production but not total CD4
+
 T cells co-cultures 
(Rodríguez-Bayona et al. 2012). Using an ELISpot assay, we also detected 
significant numbers of IgG ASC upon stimulation by the LAIV intranasal vaccine. 
This confirms the results of antibody induction measured by ELISA. 
 
IL-21 plays an important role in TFH cell differentiation and the development of B 
cell immunity (Eto et al. 2011). Our results showed that stimulation with the LAIV 
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intranasal vaccine significantly enhances IL-21 production. Mainly TFH cells but not 
non-TFH cells stimulated with LAIV produced IL-21. In line with this finding, a 
significant increase in CD4
+
 IL-21
+
 cells was seen after LAIV stimulation. Other 
groups also showed elevated IL-21 levels after Influenza vaccination. Pallikkuth and 
colleagues reported an increased level of serum IL-21 in individuals vaccinated with 
an inactivated monovalent A/California/07/2009 H1N1 vaccine (Pallikkuth et al. 
2011). An elevated IL-21 in plasma samples was also seen in individuals vaccinated 
with the 2011-2012 recommended influenza vaccine, containing the following 
strains: A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/ 
Brisbane/60/2008 (Parmigiani et al. 2013). A recent study using a trivalent split 
seasonal influenza vaccine, reported that circulating CXCR5
+
 ICOS
+
 CD4
+
 T cells 
were found to co-express several cytokines, including IL-21. In contrast, very few 
CXCR5
+
 ICOS
-
 CD4
+
 T cells expressed IL-21 (Bentebibel et al. 2013). 
 
As shown in chapters 3 and 4, TFH express high levels of IL-21 and that were 
important in TFH cell-mediated B cell antibody production in adenotonsillar cells. 
Here we show that blocking the IL-21R by a recombinant neutralizing antibody 
significantly reduced the numbers of TFH cells. The reduction of TFH cells was 
correlated with the reduction of specific-HA IgM and IgA. Similar to other groups 
finding, the specific-HA IgG could not be evaluated in these cultures because of the 
cross-reactivity of the Fc portion of IL-21R-Fc in the IgG ELISA (Bryant et al. 2007; 
Rodríguez-Bayona et al. 2012). The importance of IL-21/IL-21R was discussed in 
more details in results chapter 4. 
 
In accordance with these findings, several studies reported that IL-21 deficient mice 
exhibited a marked reduction in TFH cells, GC formation and antibody production 
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compared with wild type mice after immunization (Nurieva et al. 2008; Vogelzang et 
al. 2008). Using purified TFH cells and B cells from human tosillar tissues, Berglund 
et al. have reported a major reduction in IgM production when IL-21 was blocked by 
neutralizing antibody (IL-21R-Fc) compared to unblocked controls (Berglund et al. 
2013). Rodríguez-Bayona et al. reported purified tonsillar TFH cells and plasma cells 
co cultured in the presence or absence of neutralizing antibody (IL-21R-Fc). This 
study showed that secretion of IgA by plasma cells was significantly reduced when 
IL-21R was neutralized as a result of blocking TFH cell-derived IL-21 (Rodríguez-
Bayona et al. 2012).  
 
Our results support that human NALT are likely to be a major induction site of 
immune response against influenza following LAIV immunization. It is also 
suggested that the in vitro model of human NALT using adenotonsillar cell culture 
could be used to study the LAIV-induced immune responses which may predict the 
immunogenicity and efficacy of candidate LAIV vaccines in humans. It has been 
shown previously that LAIV intranasal vaccination induces an immune response that 
more closely resembles natural immunity than that elicited by inactivated vaccine by 
injection and more likely to induce broader immunity (Cox & Subbarao 1999). 
 
In summary, stimulation with LAIV induced potent HA-specific antibody production 
against influenza virus in NALT that was correlated with the significant increase in 
the number of TFH cells.  The findings that co-culture of TFH cells, but not of non-TFH 
cells with B cells induced significant antibody production together with IL-21 
production support that TFH cells provide critical support to B cell-mediated humoral 
immunity following LAIV intranasal vaccination.  
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Chapter 6 
 
 
 
General Discussion and 
Conclusion 
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6.1 Discussion 
TFH cells have been identified as a new T helper subset specialized to regulate the 
development of antigen-specific B cells and long-lived plasma cells. As they play a 
critical role in mediating B cell antibody response, promoting TFH cell number and 
function may be a good vaccination strategy. Research into intranasal vaccination 
strategy against respiratory infection has attracted a great interest in recent years, 
especially following the successful use of live-attenuated influenza vaccines. 
Intranasal vaccination relies on local mucosal immune tissue, ie. NALT, to mount a 
local as well as a systemic immune responses. Considering the crucial role of TFH 
help for B cell immunity, it is valuable to determine whether TFH plays a role in 
intranasal vaccine-induced immunity. In this study, we have characterised TFH cells 
in NALT in children and adults and investigated the possible effect of candidate 
adjuvant CpG-DNA on TFH cells in NALT and in mediating the B cell antibody 
response to influenza antigens. 
6.1.1 Characterisation of TFH cells in human NALT 
Firstly, TFH cells were characterised using a combination of surface markers and 
CD4
+
 CXCR5
high
 ICOS
high
 were identified as TFH cells as reported previously 
(Bentebibel et al. 2011; Rasheed et al. 2006; Yu & Vinuesa 2010a). The frequencies 
of TFH expressed as a proportion in CD4
+
 T cells range from 12% to 36% (in 
children) and from 5% to 20% (in adults). These are in general consistent with 
previous reports (Bentebibel et al. 2011; Rasheed et al. 2006; Yu & Vinuesa 2010a).  
In addition to the use of CXCR5 and ICOS markers, additional markers for TFH cells 
including PD-1, BCL-6 and
 
CCR7 
 
were also used to confirm the identification of 
TFH in this study (Ma et al. 2009). Several cytokines are expressed by TFH cells that 
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have major roles in B cell function and antibody production, including IL-4, IL-10 
and IL-21 (Kim et al. 2001; King 2009). We showed that TFH cells in human NALT 
expressed higher levels of IL-4, IL-10 and IL-21 as compared to non-TFH cell 
populations. These findings are consistent with the previous report that CD4
+
 
CXCR5
hi
 cells express higher amounts of IL-4, IL-10 and IL-21 compared to CD4
+
 
CXCR5
low
 T cells (Kim et al. 2001; Ma et al. 2009).  
There was a prominent percentage of TFH cells in adenotonsillar tissues from both 
children and adults, especially the former. The mean TFH percentage in 
adenotonsillar MNC was shown to be significantly higher in children than in adults. 
In general, there appeared to be an age-associated decrease in TFH percentage. The 
finding that the percentage of TFH cells in NALT was already at a relatively high 
level in young children at the age 1.5-2 years suggests that TFH cells were primed 
fairly early and rapidly in young childhood. It is possible that immediately after 
birth, the intensive exposure to foreign agents (eg. microbial infection) during 
infancy rapidly primed TFH cells during which GC in secondary lymphoid tissues 
form intensively.  
6.1.2 CpG-DNA promotes TFH cells in human NALT 
Secondly, to study whether TFH could be promoted by immunological adjuvant, 
CpG-DNA was used with or without an influenza antigen to stimulate adenotonsillar 
MNC, followed by analysis of antigen-specific B cell antibody response. We found 
that the number of TFH cells, defined as CXCR5
hi
 ICOS
hi
 cells (Figure 4.1) or as 
CXCR5
hi
 BCL-6
+
 cells (Figure 4.2) was increased by CpG-DNA stimulation in a 
dose dependent manner. We also showed that co-incubation of CpG-DNA with an 
influenza virus antigen induced a marked increase in the number of TFH cells (Figure 
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4.6) and that was correlated with the enhancement in HA-specific antibody 
production (Figure 4.4). Further analysis using co-culture of purified CD4
+
 CXCR5
hi
 
(TFH) cells, but not non-TFH cells, with B cells in the presence of CpG-DNA and 
influenza antigen, induced an enhanced antigen-specific antibody response. These 
results suggest that the enhanced antibody production by CpG-DNA is mediated, at 
least in part, by TFH cells.  
 
These results are also corroborated by several recent studies. Using a murine model 
Mastelic et al reported that CpG-DNA increased the TFH and GC B cell responses 
which was also correlated with an increase in antigen-specific antibody production 
(Mastelic et al. 2012). More recently, Chakarov and Fazilleau reported that mice 
vaccinated with a peptide in IFA combined with CpG-DNA induced a significant 
increase in antigen-specific TFH cells and GC B cells compared to mice vaccinated 
with IFA only. This CpG-DNA effect on TFH cells was dose dependent and was seen 
only in CpG-DNA type B and not type A or C. The increment of antigen specific GC 
B cells and plasma cells due to CpG-DNA was correlated with a rise in serum 
antigen-specific IgG antibody (Chakarov & Fazilleau 2014). An expansion of 
antigen-specific TFH cells, GC B cells and high titre of antigen specific antibodies in 
mice vaccinated with an antigen adjuvanted with CpG-DNA was also reported by 
Rookhuizen and DeFranco (Rookhuizen & DeFranco 2014).  
6.1.3 LAIV promotes TFH cells in human NALT 
Thirdly, we found that the number of tonsillar TFH cells increased significantly 
following stimulation by LAIV in a dose dependent manner. Galli et al reported that 
an early post-vaccination increase in the number of vaccine-specific CD4
+
 T cells is 
correlated with the rise and long-term maintenance of protective antibody titres to 
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avian influenza (Galli et al. 2009). More recently, Spensieri and colleagues showed 
in a clinical trial that blood-derived influenza-specific ICOS
+
 IL-21
+
 CD4
+
 T cells 
help the in vitro differentiation of autologous B cells into cells secreting influenza-
specific antibody in an antigen, IL-21 and ICOS dependent manner (Spensieri et al. 
2013).  In line with these findings, Bentebibel et al. reported, using a non-adjuvanted 
trivalent split seasonal influenza vaccine, a significant induction of ICOS
+ 
CXCR5
+ 
CD4
+
 T cells representing a crucial immunological response associated with highly 
protective antibody levels after seasonal influenza vaccination. These ICOS
+ 
CXCR5
+ 
CD4
+
 T cells were seen in blood 7 days after vaccination and correlated 
with the increase of antibody responses (Bentebibel et al. 2013). Furthermore, an in 
vitro induction of ICOS
+ 
CXCR5
+ 
CD4
+
 T cells by split influenza vaccines was 
found to support B cells to differentiate into plasma cells (Bentebibel et al. 2013).  
6.1.4 Effect of CpG-DNA and LAIV on TFH cell proliferation in human NALT 
We showed in this study that tonsillar TFH cells were able to proliferate following 
stimulation with LAIV or with CpG-DNA combined to sH1N1 virus antigen. This 
may suggest that there are antigen-specific TFH (eg. influenza antigen-specific TFH) 
which proliferate upon antigenic stimulation. The fact CpG-DNA enhances TFH 
proliferation would indicate that it is possible to use CpG-DNA to modulate TFH 
function to enhance B cell response. Studies by Morita et al. showed the induction of 
blood CXCR5
+
 CD4
+
 T cells to proliferate after stimulation with CMV or an 
inactivated influenza virus (Morita et al. 2011). A study by Rasheed and colleagues 
reported that a polyclonal stimulation of tonsillar CD4
+
 T cells with anti-CD3/CD28 
antibodies induced TFH cell proliferation (Rasheed et al. 2006). Bendigs et al. 
showed that the addition of CpG-DNA to anti-CD3-stimulated T cells induced a 
proliferative responses in the absence of APC and suggested that CpG-DNA could 
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directly co-stimulate T cells (Bendigs et al. 1999). Lacroix-Lamandé et al. reported 
in a mouse model, CpG-DNA administered orally induced a significant increase in 
numbers of CD4
+
 T cell observed in the intestinal mucosa and the draining LN 
(Lacroix-Lamandé et al. 2009). 
6.1.5 GC B cells strongly correlate with TFH cells  
In this study, we reported a significant increase in CD19
+
 CD38
hi
 IgD
-
 (GC B cells) 
after LAIV stimulation. It is now known that TFH cell works closely together with 
GC B cells for optimal B cell response.  As shown in chapter 3 (Figure 3.11), 
numbers of TFH cell strongly correlates with numbers of GC B cell. This is consistent 
with previous studies in both mice and humans (Baumjohann et al. 2013; Renand et 
al. 2013). A strong enhancement in number of GC B cells was shown to be 
correlated with the appearance of TFH cells after an influenza virus infection (Elsner, 
Ernst & Baumgarth 2012).   
6.1.6 Effect of CpG-DNA and LAIV on B cell antibody production in relation 
to TFH cells  
Significant antibody responses of IgG, IgM and IgA to HA of seasonal H1N1 virus 
were observed in adenotonsillar MNC following CpG-DNA combined with sH1N1 
virus antigen or LAIV stimulation. As we showed in this study (Figures 4.5 and 
5.10), co-culture of purified TFH cells, but not non-TFH cells, with purified B cells 
was able to induce antigen specific IgG, IgM and IgA antibodies. This finding 
supports the assumption that TFH help to B cells is needed for the production of these 
antibodies in NALT. Using a similar in vitro system, Bryant and colleagues co-
cultured tonsillar CD4
+ 
CXCR5
+
 cells (TFH cells) and CD4
+ 
CXCR5
-
 (non-TFH cells) 
with autologous B cells and showed similar results following stimulation by PHA 
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and IL-2. (Bryant et al. 2007). Similar finding was also shown by Rasheed et al. 
reporting that CXCR5
- 
ICOS
- 
CD4
+
 T cells (non-TFH cells) did not influence B cell 
production of IgG, and in contrast, CXCR5
hi 
ICOS
hi
 CD4
+
 T cells (TFH cells) 
promoted B cell secretion of IgG (Rasheed et al. 2006). In addition, Rodríguez-
Bayona et al. reported similar finding by co-culturing either tonsillar CD4
+
 T cells or 
purified TFH cells with purified tonsil plasma cells. The purified TFH cell co-culture 
showed a increase of tonsillar plasma cell antibody production but not non-TFH cells 
co-cultures (Rodríguez-Bayona et al. 2012).  Using an ELISpot assay, we also 
detected significant numbers of IgG ASC upon stimulation by CpG-DNA combined 
with sH1N1 virus antigen or the LAIV intranasal vaccine. This confirms the results 
of antibody induction measured by ELISA. 
6.1.7 Effect of pDC on TFH-mediated help for B cell antibody production  
To determine whether pDC cells contribute to the adjuvant effect of CpG-DNA to 
antigen-specific T cell-dependent B cell response, purified pDC were added to TFH 
cells co-cultured with B cells. We found that the addition of pDC to TFH-B cell co-
culture significantly enhances influenza HA-specific antibody response. This 
suggests that pDC may contribute significantly to CpG-DNA-mediated TFH help to B 
cell antibody response. There has been no data available on any potential effect of 
pDC on TFH in the published literature. However, it has been shown that antigen 
presentation by myeloid DC is necessary to initiate TFH cell development (Choi et al. 
2011; Goenka et al. 2011), despite that in most cases, antigen presentation by B cells 
is responsible for promoting the full differentiation program of TFH cells 
(Ballesteros-Tato & Randall 2014; Johnston et al. 2009; Nurieva et al. 2009).  
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As it is known that pDC express high levels of TLR-9, and we showed there is a 
prominent number of pDC in adenotonsillar tissue, pDC may play an important part 
in the TFH-mediated B cell help for antibody response in human NALT. Recently, 
Chakarov and Fazilleau reported a significant increase in TFH cell development upon 
the addition of CpG-DNA to other vaccine adjuvant and that was depended on TLR-
9 signalling in CD11c
+
 DC. They also demonstrated an important role played by 
monocyte-derived DCs in the TFH cell response after CpG-DNA vaccination 
(Chakarov & Fazilleau 2014).  
6.1.8 TLR-9 expression in TFH, non-TFH, B cells and pDC   
In this study, we found that TLR-9 was detectable only at a low level on TFH cells. 
Although it may be possible that CpG-DNA promotes TFH cells through a direct 
effect on TFH cells via TLR-9, it is likely that CpG-DNA may also work through B 
cells and or pDC, as it is known that these latter two cell types express higher levels 
of TLR-9. TLR expression in T cells remains inconclusive, despite several studies 
have reported the expression of TLR-9 on CD4
+
 T cells and the direct co-stimulatory 
effects of CpG-DNA on primary T cell activation (Kabelitz 2007). A previous study 
by Bendigs et al. showed that CpG-DNA was able to co-stimulate T cell proliferation 
and cytokine production in the absence of APCs (Bendigs et al. 1999). Another study 
demonstrated in murine purified CD4
+
 T cells that CpG-DNA directly enhances 
CD4
+
 T cell proliferation and IL-2 production (Gelman et al. 2006). Treatment of 
highly purified activated mouse CD4
+
 T cells with CpG-DNA upregulated the 
expression of TLR-9 (Gelman et al. 2004). TLR-9 was also expressed in tonsillar B 
cells. The TLR-9 expression by B cells is well documented (Bourke et al. 2003; 
Jiang et al. 2007). pDC was also found to express TLR-9. In humans, the expression 
of TLR-9 by pDC is unique in the DC system and other DC types including 
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conventional DC were not found to express TLR-9 (Fuchsberger, Hochrein & 
O'Keeffe 2005; Hornung et al. 2002).  
6.1.9 IL-21 is important in TFH-mediated B cell antibody production in NALT  
It is known that IL-21 plays an important role in TFH cell differentiation and B cell 
immunity (Eto et al. 2011). In this study, we found a rise in number of TFH-IL-21
+
 
cells after stimulation with CpG-DNA or LAIV that was correlated with an enhanced 
IL-21 production in cell culture supernatant. We further showed that mainly TFH 
cells but not non-TFH cells produced IL-21. Elevated IL-21 levels after influenza 
vaccination was reported by other groups (Pallikkuth et al. 2011; Parmigiani et al. 
2013). A recent study using a trivalent split seasonal influenza vaccine, reported that 
circulating CXCR5
+
 ICOS
+
 CD4
+
 T cells were found to co-express several cytokines, 
including IL-21. In contrast, very few CXCR5
+
 ICOS
-
 CD4
+
 T cells expressed IL-21 
(Bentebibel et al. 2013). 
As shown in chapters 3 and 4 and 5, TFH express high levels of IL-21 that were 
important in TFH cell-mediated B cell antibody production in adenotonsillar cells. 
TFH cells also express IL-21 receptor (IL-21R), and this coexpression reflects an 
autocrine loop (Nurieva et al. 2008; Silver & Hunter 2008). Here we show that 
blocking the IL-21R by a recombinant neutralizing antibody significantly reduced 
the numbers of TFH cells. The reduction of TFH cells was correlated with the 
reduction of specific-HA IgM and IgA. These results support the importance of IL-
21 in TFH cell-mediated B cell antibody production in adenotonsillar cells. 
 
In accordance with these findings, several studies reported that IL-21 deficient mice 
exhibited a marked reduction in TFH cells, GC formation and antibody production 
compared with wild type mice after immunization (Nurieva et al. 2008; Vogelzang et 
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al. 2008). Using purified TFH cells and B cells from human tonsillar tissues, 
Berglund et al. have reported a major reduction in IgM production when IL-21 was 
blocked by neutralizing antibody (IL-21R-Fc) compared to unblocked controls 
(Berglund et al. 2013). Rodríguez-Bayona et al. reported purified tonsillar TFH cells 
and plasma cells co cultured in the presence or absence of neutralizing antibody (IL-
21R-Fc). This study showed that secretion of IgA by plasma cells was significantly 
reduced when IL-21R was neutralized as a result of blocking TFH cell-derived IL-21 
(Rodríguez-Bayona et al. 2012).  
6.1.10 pTFH found in PBMC 
Recent studies suggest there may be TFH equivalent in the circulation i.e. peripheral 
blood (pTFH) that express CXCR5 and ICOS markers and have similar B cell-help 
functions (Bentebibel et al. 2013; Morita et al. 2011; Pallikkuth et al. 2012; Simpson 
et al. 2010; Vinuesa & Cook 2011). Using these markers, we demonstrated the 
presence of such pTFH cells in PBMC. Like NALT TFH cells, an age-associated 
difference in the number of pTFH cells was also seen and numbers of pTFH cell were 
much lower in adults than in children PBMC. The similar correlation of these TFH 
cell numbers found in NALT and PBMC with age may suggest that these pTFH cells 
in the circulation are related to TFH cells found in secondary lymphoid tissues. In 
addition, the increment of IL-21 found in PBMC culture supernatant after 
stimulation with CpG-DNA combined with sH1N1 influenza virus or with LAIV and 
its correlation with elevated numbers of pTFH cells may also suggest that these pTFH 
cells have a same origin with TFH cells found in secondary lymphoid tissues. 
A number of reports offer support to the hypothesis that these peripheral blood CD4
+ 
CXCR5
+
 T cells are related to TFH cells found in NALT (Bossaller et al. 2006). 
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Recently, Morita et al. report that pTFH cells (CXCR5
+
 CD4
+
 T cells) from human 
peripheral blood provide better help to B cells than CXCR5
-
 CD4 T cells (Morita et 
al. 2011). Similar to tonsillar TFH cells, a recent study reported that blood CXCR5
+ 
CD4
+
 T cells secreted IL-21 upon contact with B cells, whereas CXCR5
- 
CD4 T cells 
barely secreted any IL-21 (Morita et al. 2011). B cells were able to produce IgG, 
IgM and IgA only when co-cultured with CXCR5
+
 cells in an IL-21- and ICOS-
dependent manner. In contrast, CXCR5
- 
CD4 T cells were unable to induce any 
switched immunoglobulin and only small amounts of IgM were produced (Morita et 
al. 2011).  
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6.2 Conclusion  
In summary, we have shown the presence of a prominent percentage of TFH in 
human NALT and the percentages in children were higher than in adults, which may 
correlate with the enhanced exposure to microbial colonisation in children especially 
in early childhood. The fact that young children at 1.5-2 years already developed a 
high percentage of TFH suggests that TFH cell priming by antigens during early 
childhood is fairly efficient. Since TFH provides crucial help for B cell immune 
response, novel vaccine adjuvants or intranasal vaccines to boost TFH number or 
function may be an attractive vaccination strategy to enhance vaccine efficacy in 
young children. The use of CpG-DNA as an adjuvant enhanced B cell antibody 
response that was correlated with induction of TFH cells in human NALT, suggesting 
that CpG-DNA may be able to enhance vaccine immunogenicity through modulating 
TFH function. Stimulation with LAIV induced potent HA-specific antibody 
production against influenza virus in NALT that was correlated with the significant 
increase in the number of TFH cells.  The findings that co-culture of TFH cells, but not 
non-TFH cells with B cells induced significant antibody production together with IL-
21 production support that TFH cells provide critical support to B cell-mediated 
humoral immunity following stimulation with CpG-DNA and LAIV intranasal 
vaccine. IL-21 is crucial in TFH cell-mediated B cell antibody production in 
adenotonsillar cells. We also showed an important role of pDC in enhancing the 
antibody levels in our tonsillar TFH - B cells co-cultures. Enhancing vaccine 
immunogenicity through modulation of TFH cells function in human NALT using 
immunological adjuvants such as CpG-DNA or intranasal vaccines may be an 
effective vaccination strategy against respiratory pathogens. 
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6.3 Future directions 
Although the present findings show novel insights of the role of TFH cells, more 
research is required before any definitive conclusions can be drawn on the exact role 
and contribution of human TFH cells in humoral immune responses.  
Finding the percentage of TFH cell and their B cell helper functional capabilities from 
other secondary lymphoid tissue such as LN will be interesting to look at in 
comparison to TFH cells found in adenotonsillar tissues. This may not only support 
current data but also help provide a better insight into the role of TFH cells in 
humoral immune response.  
Showing the significant age-dependent decrease in percentage of TFH cells in this 
study, investigating the colonization status for several pathogens in different age 
groups will be interesting to study to see if there may have any correlation with 
percentage of TFH cells.   
Future studies would also involve investigation of other TLR ligands as mucosal 
adjuvants, including, flagellin (TLR-5 ligand), LPS (TLR-4 ligands) and other 
mucosal adjuvants to study their effect on TFH cell percentage and function. Other 
mucosal vaccines such as Rotavirus vaccines and oral Polio vaccines could be 
studied to investigate the role of TFH cells in promoting B cell antibody production.  
Ideas for future in vitro co-culture experimental work would include blocking of 
other TFH main markers including CXCR5 and ICOS to reveal their importance in 
TFH cells for enhancing B cell helper capability. This would also involve 
investigating crosstalk between TFH cells and B cells in regulating cytokine 
production and B cell responses (i.e. antibody production and isotype switching), 
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which would be carried out under several different culture conditions. 
Purification of pTFH cells found in PBMC and studying their role in promoting B 
cells for better antibody production and the adhesion molecules involved will be an 
important future study to support the hypothesis that pTFH found in PBMC and TFH 
found in NALT share the same origin.  
Finally, in vivo studies using pDC deficient mice will be able to show more details in 
the importance of pDC in TFH cell-mediated B cell antibody production.  
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Appendix-I 
Optimisation of LAIV for TFH cell stimulation in adenotonsillar MNC 
The optimal concentration of LAIV required for TFH cells stimulation in 
unfractionated adenotonsillar MNC was determined by stimulation of 5 samples with 
different concentrations (0, 0.5, 1.0, 1.5, 2 and 4 μl/ml) of LAIV. As shown in figure 
8.1, 2μl/ml of LAIV showed to give the highest stimulatory effect compared to the 
unstimulated controls.  
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Figure 8.1. Dose-response curve for TFH cell induction by stimulation with LAIV 
Summary percentage of TFH cells from unfractionated adenotonsillar MNC stimulated with 
different concentrations of LAIV. The values represent the mean ± SEM from five 
individual tonsils.  
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Appendix-II 
Preparation of different media and buffers 
 10x Phosphate Buffered Saline (PBS) pH 7.4  
1. One litre of 10x PBS was prepared in a sterile 1 litre glass bottle, using following 
recipe: 
 
Na2HPO4                                            14.4 gm  
KH2PO4                                              2.4 gm  
NaCl                                                    80 gm  
KCl                                                      2 gm  
Deionized H2O                                    900 ml  
 
2. Then pH was adjusted to 7.4 by adding concentrated HCl drop by drop, with 
gentle shaking of the bottle and simultaneous measurement with a pH meter. 
When the pH is adjusted then the bottle was topped-up to 1 litre by adding 
deionized water.  
 
 ELISA/ELISpot Washing Buffer (PBS- Tween-20)  
1. One litre of ELISA/ELISpot washing buffer (1xPBS with 0.05% Tween 20) was 
prepared in a sterile glass bottle, using following recipe:  
 
10x PBS                                                100 ml  
Deionized H2O                                      900 ml  
Tween-20                                               0.5 ml 
 
 P-Nitrophenyl Phosphate (PNPP) Substrate for ELISA  
1. One litre of p-nitrophenyl phosphate (PNPP) substrate (1M diethanolamine) buffer 
(pH 9.8) was prepared in a sterile glass bottle, using following recipe: 
Diethanolamine                                      97 ml  
Deionized H2O                                      800 ml  
MgCl2                                                    100mg  
2. Then the bottle was placed on a magnetic stirrer with a magnetic flea inside. 
Whilst stirring the pH was measured and adjusted to 9.8 by adding 10M 
hydrochloric acid.  
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3. Once the pH is correctly adjusted, the buffer was transferred to a measuring 
cylinder and distilled water was added to give a final volume of 1000 ml.  
4. Thereafter, the buffer was transferred back to the bottle and stored at 4˚C.  
5. Finally, the substrate was prepared by dissolving p-nitrophenyl phosphate 
disodium salt (5mg) tablet into 5 ml of substrate buffer to give a PNPP concentration 
of 1 mg/ml.  
 
 Acetate buffer for AEC Substrate  
1. One litre of 50 mM acetate buffer (pH 5.0) was prepared in a sterile glass bottle, 
using following recipe: 
2. 0.2M Acetic acid solution was prepared by adding 1.16 ml glacial acetic acid into 
100 ml deionized H2O.  
3. 0.2M Sodium acetate solution was prepared by adding 6.8 gm sodium acetate into 
250 ml deionized H2O.  
4. Then, the acetate buffer was prepared by adding 74 ml of 0.2M acetic acid 
solution, 176 ml of 0.2M sodium acetate solution and 700 ml of deionized H2O.  
5. Thereafter, the bottle was placed on a magnetic stirrer with a magnetic flea inside. 
Whilst stirring the pH was measured and adjusted to 5.0 by adding glacial acetic 
acid.  
6. Once the pH is correctly adjusted, the buffer was transferred to a measuring 
cylinder and distilled water was added to give a final volume of 1000 ml.  
7. Finally, the buffer was transferred back to the bottle and stored at 4˚C.  
 
 3-Amino-9-ethylcarbazole (AEC) Substrate for ELISpot  
1. AEC Substrate was prepared using following recipe: 
2. 2.5 gm of 3-Amino-9-ethylcarbazole was added into 250 ml of dimethyl 
formamide (DMF) solution and kept in dark at 4°C (refrigerator).  
3. Finally, the working substrate solution for the ELISpot assay was prepared by 
adding 0.5 ml of AEC substrate into 9.5 ml of acetate buffer; and 25 μl of H2O2 
immediately before dispensing into the plate.  
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